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Abstract 
There are approximately 5.5 Million individuals in South Africa infected with HIV-1, 
predominantly subtype C (HIV-1C). The emergence of drug resistance to the current 
Antiretroviral (ARV) regimes is of great concern, thus development of novel, effective 
drugs/vaccines is vital. Certain conserved and thus vulnerable epitopes within the viral 
envelope (Env) involved in coreceptor binding are usually protected from the immune 
system in peripheral blood by the variable loops. However, in immune-privileged sites 
the Env of CD4-independent viruses may exist in a pre-triggered state where these 
coreceptor binding epitopes are exposed. Targeting the conserved sites could effectively 
neutralize HIV-1. This study aimed to adapt an HIV-1C primary isolate towards CD4-
independence in the Cf2Th cell line through serial in vitro passage. Primary viruses 
from 20 drug-naïve HIV-1 AIDS patients were isolated and genotypically and 
phenotypically characterized. The highest percentage (30%) of CXCR4-usage amongst 
primary isolates from HIV-1C (and CD recombinant) infected AIDS patients worldwide 
was detected. These data may illustrate the increasing frequency of HIV-1C CXCR4-
utilizing (X4) viruses with time and may support the theory that env is capable of 
evolving. The emergence/evolution of HIV-1C X4 viruses may have profound 
implications for viral pathogenesis, disease progression and future use of CCR5 
antagonists as ARVs. Longitudinal follow-up studies on larger cohorts may confirm this 
finding. The CXCR4-utilizing isolate 05ZAFV03 was successfully adapted and serially 
passaged 12 times through Cf2Th cells, whilst gradually decreasing amounts of CD4 
expressing cells numbers over time. Viral growth was detected with 10% CD4 
expressing cells however, 100% CD4-independence was not reached. Proviral DNA 
from each stage of the adaptation process was sequenced and analyzed for mutations 
acquired within env. The only amino acid change noted was an E152K mutation within 
the V1 region at passage 4. Overall, the extent of env diversity appears to be a complex 
relationship between isolate-specific and cell-type specific factors. Future attempts to 
obtain and characterize an HIV-1C CD4-independent isolate will provide potential sites 
for therapeutic intervention by compounds such as small molecule inhibitors and/or 
neutralizing antibodies against the most globally prevalent HIV-1 subtype.  
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1.1 The Global HIV/AIDS pandemic 
Acquired Immunodeficiency Syndrome (AIDS) was first detected in May 1981 
among four homosexual men in Los Angeles, United States of America who 
presented with infections such as Pneumocystis carinii pneumonia (PCP), Kaposi’s 
sarcoma, prolonged fever and Candida infections [1, 2]. The apparent sexually 
transmitted immune deficiency in these patients was thought to be due to 
cytomegalovirus (CMV) infections in homosexual men, and called Gay-Related 
Immune Deficiency Syndrome (GRIDS) [1-5]. However, this disease was not only 
seen in homosexual men, by 1983 groups of intravenous drug abusers, individuals 
receiving blood and blood products and heterosexual Haitians in America, 
presented with AIDS [6, 7]. 
The causative agent of AIDS is a retrovirus that was first isolated from patients and 
demonstrated cytopathic effects on CD4+ T cells [8]. This virus was initially 
referred to as Human T-cell leukaemia virus (HTLV-III) [8-10] and is now called 
Human Immunodeficiency Virus (HIV), the etiologic agent of AIDS. HIV-1 
crossed the species barrier from chimpanzees to humans during the early twentieth 
century and has since infected millions of humans. Origins of HIV have thus been 
linked to the simian immunodeficiency virus (SIV) from the genus Lentiviruses of 
the family Retroviridae [11-14]. Currently, one percent of the world’s population 
is infected with the worlds’ fastest evolving pathogen, HIV [15].  
AIDS is characterized by the progressive depletion of CD4+ T lymphocytes which 
play an important role in establishing and enhancing the cell-mediated and the 
humoral immune response [2, 5]. When an individual suffers severe damage to 
their immune system, their vulnerability to opportunistic infections (OIs) and 
malignancies are heightened due to the loss of the individuals’ ability to mount an 
effective immune response. Ultimately death results after many years of untreated 
infection [9].   
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There was an estimated 39.5 million people worldwide living with HIV at the end 
of 2006. An estimated 4.3 million became newly infected with HIV and an 
estimated 2.9 million lost their lives to AIDS that year. These figures are almost 
equivalent to 11,780 new infections and 7,945 deaths per day due to AIDS [16]. 
The emergence of this pandemic has arguably been the most catastrophic event in 
medicine in the last 25 years.  
Africa remains the global epicentre of the AIDS pandemic and the major burden of 
HIV/AIDS is currently borne by sub-Saharan Africa. Almost two-thirds (24.7 
million) of all individuals infected with HIV globally, live in sub-Saharan Africa 
(Figure 1.1). By the end of 2006, 34% of all AIDS deaths globally were occurring 
in Southern Africa [16]. About fourteen percent (5,5 million) of the current global 
HIV-1 infected population is living in South Africa [16]. Antenatal surveillance 
suggests that the prevalence of HIV in South Africa among pregnant women (15-
24 years) is 22.5%. Furthermore women bear a disproportionately large part of 
South Africa’s HIV/AIDS burden. It is one of the worst in the world and shows 
neither evidence of a decline, nor a decrease/plateau in HIV-1 prevalence [16]. 
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Figure 1.1 Diagrammatic representation of the global number of HIV infected adults and 
children living with HIV at the end of 2006. The total number of people living with HIV/AIDS 
continues to grow and is currently 39.5 Million (34.1 Million- 47.1 Million). Figure adapted from 
[16].    
1.2 Consequences of the HIV replication strategy 
Genetic diversity of HIV-1 exists along the entire length of the genome between 
viral isolates from different individuals and between viral quasispecies within the 
same individual. The most unique and precarious characteristics of HIV-1 is its 
inherent variability and capability of generating quasispecies as a direct result of 
two features; lack of a proof-reading mechanism by the viral reverse transcriptase 
(RT) enzyme during replication [17] and its rapid replication rate [18, 19]. The 
error prone RT has an estimated misincorporation (insertions/deletions) rate of 1 x 
10-4 - 3.4 x 10-5 per base pair per replication cycle [17, 20-24]. This equates to 
about one nucleotide being miss-incorporated per replication cycle of 9.7 kb. This 
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process is exacerbated by the high production of approximately 1 x 1010 viral 
particles daily and in the absence of proof-reading mechanisms, this results in 
extensive viral heterogeneity [18, 19, 22, 25-27].  
Recombination between two RNA genomes also results in major gene-
rearrangements and generation of diversity within the subpopulations within the 
host [28-30]. Together, these features allow HIV to rapidly mutate its genome 
enabling the virus to constantly evolve and increase genetic variability. This 
impacts on factors such as the genotypic viral diversity amongst different isolates, 
immune escape and emergence of Antiretroviral (ARV) drug resistance [20]. 
1.2.1 Subtypes 
To date, two main types of HIV have been identified with origins as zoonotic 
lentiviruses; HIV-1 is believed to have originated from a SIVCPZ from the 
chimpanzee (Pan troglodytes) population [13, 31] and HIV-2 is believed to have 
originated from the SIVSM sooty mangabey (Cercocebus atys); SIV originated 
from macaques (SIVMAC) [32, 33].  
HIV-1 and 2 are transmitted in the same fashion (section 1.5.1), yet HIV-2 has a 
lower rate of transmission, longer asymptomatic period, lower viral load and hence 
it is less pathogenic [34, 35]. HIV-2 is endemic in West Africa and to a lesser 
extent elsewhere in the world such as Europe and the West coast of India [36, 37]. 
However, HIV-1 predominates worldwide and has a three times higher mortality 
rate compared to HIV-2 [38].  
In addition to the two main types of HIV, further classification systems have been 
constructed from the copious phylogenetic data analyses of the many strains of 
HIV-1 and HIV-2 isolated and analyzed worldwide. There are four sub-
classifications for HIV-1; groups, subtypes, sub-subtypes and circulating 
recombinant forms (CRFs). Of the groups; the Major group (Group M) is 
responsible for the current global pandemic and the Outlier Group (Group O) and 
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New group (Group N; consisting of non-O and non-M viruses) are less globally 
distributed. Group O and N are both highly genetically divergent from group M 
and sparsely distributed in Cameroon and West Central Africa [39-42].  
Group M is further subdivided up into 9 distinct subtypes, namely A, B, C, D, F, 
G, H, J, K wherein there are two sets of sub-subtypes A1, A2 and F1, F2 
respectively [43, 44]. The emergence of CRFs has resulted from many 
recombination events between different HIV-1 viruses and already 34 CRFs  have 
been described [45-47]. These viruses share an identical mosaic structure in their 
genomes as they have descended from the same recombination events [48]. The 
following criteria should be fulfilled in order for an isolate to be considered a CRF; 
firstly, there must be full-length genome sequences for at least two isolates, 
secondly they should only resemble each other and no other existing CRF in their 
subtype structure and finally they should have been found in at least two 
epidemiologically unlinked individuals [48-51]. 
HIV-1 subtype C is the most prevalent subtype as well as the most rapidly 
spreading HIV-1 subtype worldwide, according to the latest WHO/UNAIDS 
statistics [52, 53]. Subtype C infections mainly occur in developing countries 
where viral transmission routes are mostly heterosexual and perinatal, however, 
this subtype has only recently been studied in depth. HIV-1 subtype C now causes 
the vast majority of new HIV-1 infections worldwide (55%) [52] and has thus 
become a major focus of drug development and vaccine efforts [16]. 
1.3 Structure of the HIV-1 Virion and Genome  
An intact, mature T-lymphotropic HIV-1 retrovirus is spherical in shape, with a 
diameter of approximately 80 to 120 nm [8]. As in all retroviruses, HIV-1 has two 
copies (diploid) of identical plus-strand genomic RNA. The viral regulatory, 
structural and accessory proteins and enzymes are encoded by 9 genes spanning 
approximately 9.7 kb of genetic material. These 9 open reading frames code for at 
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least 16 distinct proteins. Three of these genes encode structural proteins (Gag, Pol 
and Env), 2 genes encode regulatory proteins (Tat and Rev) and 4 genes encode 
accessory proteins (Vif, Vpr, Vpu and Nef) (Figure 1.2) [54, 55]. The viral 
envelope (Env), encoded by env, encases a matrix protein membrane (p17/MA), 
which provides further structure to the virion as well as encompasses the single 
layer of structural capsid/core proteins (p24/CA), encoded by gag. The capsid 
contains the viral RNA, the protease (PR), RT heterodimer (comprised of two 
subunits; the RNAse H (p66) subunit and the reverse transcriptase (p51) subunit), 
and integrase (IN), encoded by pol. 
* (~9.7 kb)
Gag
Pol
Vif
Vpr
Vpu
Env
NefTat1 Tat2
Rev2Rev1
p17 p24 p9 p6
Prot RT RH INT5’ LTR
3’ LTR
gp120 gp41
The HIV-1 Virion and Genome Map
* Viral RNA
HIV-1 Virion
 
Figure 1.2 Schematic illustration of the HIV-1 virion structure and genome organization. The 
HIV-1 genome is approximately 9.7 kb in length and complex in its organization. It is comprised of 
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9 genes, which encode open reading frames for at least 16 structural, regulatory, accessory and 
enzymatic proteins. 
1.4 The HIV Life Cycle  
HIV-1 predominantly infects T Lymphocytes and/or primary 
monocytes/macrophages that express CD4 glycoproteins on their surfaces [56, 57]. 
This commonly results in progressive loss of CD4+ T lymphocytes and a decline in 
their function within the host. An in-depth understanding of the HIV-1 life cycle is 
paramount to designing potential therapeutic drugs for treatment of this disease as 
well as developing preventative approaches such as microbicides and vaccines.  
1.4.1 Entry 
The env is initially translated into a 160 kDa envelope glycoprotein (gp160/Env) 
precursor. This polypeptide precursor becomes N-linked glycosylated in the rough 
endoplasmic reticulum and is then cleaved by host cellular proteases in the Golgi 
apparatus to yield two functional glycoproteins [58]. The cleavage site is an 
arginine-rich hydrophobic region between the surface glycoprotein subunit (gp120) 
and the transmembrane glycoprotein subunit (gp41) [59-61]. Clusters of three 
protruding gp120 proteins associate non-covalently with three gp41 subunits on the 
viral surface and assemble as trimers [62-64]. The HIV-1 Env/gp160 plays a 
pivotal role in the viral life cycle, and is responsible for viral transmission, host 
cell entry, tropism and influences replication kinetics. 
HIV and SIV entry into a host cell is a dynamic and complex, multi-step, cascade 
process. Viral entry is initiated with the binding of the viral gp120 to the primary 
CD4+ receptor on a CD4+ T cell which is followed by the sequential binding of a 
chemokine coreceptor [56, 57, 62, 65, 66]. Once the glycoprotein has bound CD4, 
conformational molecular rearrangements within the viral gp120 are triggered, 
exposing specific CD4 induced (CD4i) conserved coreceptor binding epitopes [66-
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68]. This structural intermediate is responsible for the exposure and/or formation 
of a chemokine coreceptor binding site. Among the variety of coreceptors, either 
the β-chemokine receptor 5 (CCR5) and/or α-chemokine receptor 4 (CXCR4) are 
most commonly used [69-71]. Generally, HIV-1 viral isolates that are transmitted 
and those that predominate during the early stages of infection/asymptomatic 
phase, utilize the CCR5 coreceptor [72]. However, CXCR4 utilizing viruses appear 
to emerge in the later stages of the disease progression in about 60% of HIV-1 
subtype B infected patients [73-76]. Viral tropism of HIV-1 can largely be linked 
to these two coreceptors [66, 69-71, 77-81].  
Once the coreceptor is bound, the gp120 protein may dissociate from the gp41 
protein which is stably anchored/inserted within the viral membrane [82]. This 
induces further conformational rearrangements within the gp41, involving the 
antiparallel association of the two coiled heptad repeats (HR-1 and HR-2), forming 
a fusion active six-stranded helix bundle/hairpin structure. This fusion peptide 
brings the viral and host cell membranes into close proximity. Finally the 
hydrophobic gp41 amino terminus is harpooned into the host cell membrane, 
leading to the fusion of viral and host outer lipid membranes [63, 83-87]. 
1.4.2 Reverse Transcription of Viral RNA 
Once the two membranes of the virus and target cell have fused, the viral 
capsid/core is injected into the cytoplasm of the host cell, rapidly uncoats and 
releases the viral RNA and other viral enzymes required for viral replication [88-
90]. The viral reverse transcriptase enzyme then transcribes the single stranded 
RNA molecules into double stranded complementary DNA molecules (cDNA) 
(Figure 1.3) [91-93]. 
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Figure 1.3 Schematic representation of the HIV-1 life cycle within a CD4+ T lymphocyte. The 
initial attachment to a primary CD4 receptor and a chemokine coreceptor is shown, thereafter 
penetration of the virus through the host membrane. Reverse transcription of the viral RNA into 
cDNA ensures compatibility of the transcripts for integration. The viral proteins are synthesized by 
means of hijacked host replication machinery and finally the virus assembles in the cytoplasm and 
proceeds to bud from the cell membrane. Maturation of the virion occurs post budding.   
1.4.3 Integration and Transcription of Proviral DNA 
The reverse transcription complex or pre-integration complex (PIC) forms, 
consisting of an aggregateion of the nascent cDNA, integrase, and other viral 
proteins. Unique nuclear localization signals (NLS) on karyophiles associated with 
the cell’s microtubule network direct the PIC through the host cell nuclear pores to 
its destination within the host nucleus [94-96]. The newly synthesized viral cDNA 
is then irreversibly integrated into an actively transcribed region within the cleaved 
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host genomic DNA, via integrase [97, 98]. The proviral DNA remains integrated 
within the host genetic material indefinitely.  
Host machinery is subsequently hijacked by viral proteins to transcribe and 
translate the newly inserted HIV genome [99, 100]. Transcriptional control is 
exerted by the Long Terminal Repeat (LTRs) regions, which contain enhancer and 
promoter sequences to up-regulate viral protein production. Viral transcription may 
occur in two separate stages [101, 102]; firstly, transcription is mediated by RNA-
Polymerase II directly interacting with host transcription factors and cis-acting 
elements, found on the LTRs of the HIV genome. The second phase of 
transcription is also activated from the LTR regions, only once the viral Tat protein 
has been synthesized [103, 104]. Some infected cells remain dormant and 
contribute to the organization of immune privileged latent viral reservoirs within 
lymphoid tissues, e.g. spleen, lymph nodes [105, 106]. 
1.4.4 Translation, Assembly and Budding 
Viral proteins are subsequently translated, from the 5’ to 3’ direction of mRNA, 
into polypeptide sequences that are then intracellularly cleaved into functional 
shorter proteins by the viral and/or host proteases within the host’s cytoplasm. 
Once all the viral proteins have been translated and cleaved into their correct 
functional sizes, certain viral proteins undergo specialized post-translational 
modifications whereby glycosylation, phosphorylation and myristoylation occurs 
[107-109].  
Structural and enzymatic proteins collect and assemble into immature HIV virions 
at the inner surface of the host cell membrane in cholesterol rich lipid rafts [110, 
111]. During the process of assembly and budding from a host cell, HIV 
incorporates host lipids and glycoproteins in the viral Env [112, 113]. Generally, 
HIV assembles at, and buds from the plasma membrane of T cells and epithelial 
cells [114]. However, in macrophages HIV assembles at, and buds into internal 
  
 
12 
late endosomal and multivesicular body (MVB) membranes which are then 
transported to the cell surface and exocytosed [115-117]. The outer Env of each 
virion consists of a lipid layer that was derived from the previous infected host 
CD4+ T lymphocyte or macrophage, post virion budding. This allows HIV to 
remain similar in phenotype to the host cell, contributing to the viral strategy of 
avoiding recognition by the hosts’ immune system. 
As the virion matures via the Gag polypeptide processing cascade [118], an 
infectious, post-budding particle forms that can then infect further host cells. Many 
CD4+ T lymphocytes become infected and can produce between 10.3 x 109 and 10 
x 1010 new virions per day [18, 19, 27]. Mathematical models have shown that the 
life span for productively infected lymphocytes is between one and two days until 
ultimate latent viral reservoir stabilization within the host cell or death [18, 19, 25-
27, 119]. 
1.5 Disease Pathogenesis and Progression  
The clinical course of disease progression is well characterized and can be 
separated into three distinct phases; the acute phase (primary infection), the 
asymptomatic phase (clinical latency) and finally AIDS. Figure 1.4 shows the 
typical disease progression depicting primary infection, clinical latency and final 
stage AIDS showing the relative viral phenotype associated with each stage. 
  
 
13 
 
Figure 1.4 Schematic diagram showing the three classic stages of disease progression in an HIV-
1 infected individual over several years. HIV-1 systematically depletes CD4+ T cells until the 
immune system is severely compromised and AIDS results. The viral load peaks shortly after 
infection during the acute phase, whereupon the CD4+ T cell numbers rapidly decline. After a few 
weeks, the immune system partially recovers in response to the nascent infection and the CD4+ T 
cell count improves slightly. The chronic/asymptomatic phase of infection can persist for a few 
years, with steadily increasing viral load and declining CD4+ T cell count. In the final AIDS phase, 
viral loads increase significantly and the immune system is depleted to low levels. Figure adapted 
from [120].  
1.5.1 Transmission 
HIV-1 is most commonly transmitted through infected bodily fluids during 
homosexual or heterosexual intercourse. There are however other means of 
transmitting the virus through non-sexual channels, such as transfusion of infected 
blood samples and/or products, sharing of infected needles among infected 
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intravenous drug users and vertical transmission; mother to child transmission 
(MTCT). Transmission from mother to child can occur in-utero, through the 
natural birth process, puerperal and/or through delivery of breast milk. During 
sexual transmission of HIV-1, the virus crosses the mucosal barrier and attaches to 
host cells expressing the necessary primary receptor and coreceptors for infection. 
The virus attaches to Langerhans cells (LC), which are defined as dendritic cells 
(DC), present at the vaginal/anal mucosa (stratified squamous epithelia) where 
virions are passed onto CD4+ T cells in systemic circulation [56, 57, 121, 122].  
Having attached and gained entry into the target cells, the virus is rapidly 
transported via the blood stream to the lymph node reservoirs where it replicates 
uncontrollably and disseminates throughout the body, rapidly depleting the CD4+ 
T cell pool [123, 124]. HIV-1 transmission is generally associated with the transfer 
of relatively homogenous viral populations to the host [125-127], upon where viral 
tropism may influence the selection of specific sub-population variants.  
1.5.2 Acute/Primary infection 
This phase lasts between 2 and 12 weeks and is associated with relatively high 
levels of viral titer and a decrease in total CD4+ T cell count [128-130]. 
Unfortunately, many HIV-1 positive patients are not diagnosed correctly within 
this phase. The acute stage of infection is referred to as the “window period”; a 
period when the patient is HIV-1 positive, but no patient antibodies have yet been 
made against the viral antigens. 
Within days after primary infection, cytotoxic T-lymphocyte (CTL) production is 
the first host immune response against HIV-1 [131]. Binding antibodies appear 
within weeks after infection and their presence is detected by p24 Enzyme Linked 
Immunosorbent Assays (ELISA). The CTL response is followed by neutralizing 
antibodies that partially block HIV-1 entry into host cells [132, 133], however 
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these antibodies may take months to develop. Due to the host cellular immune 
response, the viral load is partially curtailed [131, 132]. 
This acute clinical phase/primary infection (Figure 1.4) usually presents in patients 
with a flu-like illness, referred to as seroconversion illness, which may also affect 
the central nervous system (CNS) [134] and is the most infectious stage of disease 
[135]. Most individuals may develop headache, myalgia, fever, malaise, 
lymphadenopathy and pharyngitis during primary infection. During this phase, 
large amounts of virus collect in the follicular dendritic cells (FDC) within the 
lymphoid organs and the Cerebrospinal Fluid (CSF), these regions are referred to 
as viral reservoirs [136-140]. Generally, CCR5 utilizing, Non-Syncytium Inducing 
(NSI) isolates are transmitted and predominate during the acute stages of infection 
(Figure 1.4) [141, 142].  
1.5.3 Clinical Latency/Asymptomatic Infection 
During this stage, HIV-1 is actively replicating within the body without causing 
noticeable symptoms (Figure 1.4). Patients are infectious during this period for up 
to 10 years, however, the duration of clinical latency may vary between individuals 
and the relative pathogenicity of the particular strain of HIV-1. Previous studies 
have shown that HIV-1 replication in lymph nodes is particularly high during this 
stage [143]. However, the immune system gradually deteriorates as CD4+ T cells 
are progressively depleted during later stages and this correlates with an 
exponential increase in viral load in the peripheral blood (Figure 1.4). 
1.5.4 Progression towards AIDS 
AIDS is the most severe manifestation of HIV infection within the host. AIDS is 
the end stage of the disease progression and is associated with CD4 counts below 
200 cells/mm3, and the onset of OIs [144]. The rate at which the initial infection 
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within an individual is controlled by the immune system, is a good indicator of 
how quickly the individual progresses to AIDS [145]. The higher the viral load set 
point of the individual, the higher the probability they will develop AIDS at a 
faster rate [145]. Prognosis in treatment-naïve patients in South Africa is rarely 
over two years from presentation of AIDS and the life expectancy (at birth) for 
men and women in Zimbabwe is now 37 and 34 years of age, respectively [146]. 
Symptomatic HIV-1 infection is primarily caused by the acquisition of OIs and 
diseases that a healthy immune system could usually overcome. Some of the more 
common OIs that are seen in AIDS patients are, Tuberculosis, Mycobacterium 
avium complex, Cryptococcus meningitis, Pneumocystis carinii pneumonia (PCP), 
diarrhoea, candidiasis, CMV retinitis, histoplasmosis, progressive multifocal 
leukoencephalopathy (PML), Kaposi’s sarcoma and Non-Hodgkin’s lymphoma 
[147-151]. Generally, CXCR4 utilizing, Syncytium Inducing (SI) isolates are 
detected during the late stages of disease as an individual progresses towards AIDS 
(Figure 1.4) [141, 142]. 
The current global definition of AIDS includes a positive test result for HIV as 
well as one or more of the 26 recorded OIs or a CD4+ lymphocyte count less than 
200 cells/mm3 or less than 14% of the total lymphocyte count [152]. In South 
Africa, AIDS is identified by the clinical diagnosis of a CD4+ T cell count of less 
than 200 cell/mm3 blood and the presentation of one or more OIs [153].  
The clinical criteria for patients to receive treatment, subsidized by the South 
African government, is to present with a CD4+ T cell count less than 200 
cells/mm3 irrespective of WHO stage disease or present with WHO stage IV 
disease irrespective of CD4 count [154, 155]. The National Government 
Antiretroviral Rollout in South Africa was initiated in April 2004 and at the end of 
September 2006, 235 000 HIV-1 infected individuals were on the roll-out of 
Highly Active Anti-Retroviral Therapy (HAART); this is a 2-fold increase since 
2004 [154]. However, less than 5% of 5.5 million HIV-1 infected people in South 
Africa in need of treatment are receiving it [16].  
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The HIV/AIDS epidemic has devastating effects on all aspects of the population 
from national development, social and economic consequences, to health, transport 
and education. Despite cases where HAART has been successful, there is an 
overwhelming rate of emergence of drug resistant strains of HIV-1 and incomplete 
suppression of HIV-1 replication in infected patients [156]. Patients endure 
adverse side effects from the therapy, toxicities from its long-term use [157] and 
adherence and affordability are part of the multitude of the urgent reasons for 
alternative treatment options.  This is why the search for a novel effective therapy 
and/or a vaccine is so essential. 
1.6 Envelope Glycoprotein  
1.6.1 Structure and Function 
The gp120 protein structure consists of three distinct domains, the inner domain, 
outer domain and bridging sheet (Figure 1.5) [66]. The bridging sheet is 
responsible for the connectivity of the inner and outer domains and all three 
domains are conformationally rearranged in such a way as to form a docking 
pocket within gp120 where the CD4 molecule binds. Post-CD4 binding, the four 
antiparallel β-pleated strands of the bridging sheet electrostatically interact/bind 
with either the CCR5 and/or CXCR4 chemokine receptor [66]. 
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Figure 1.5 Graphical representation of the three-dimensional structure of the gp120 protein. The 
inner domain (red) variable loops V1-V5 and outer domain (yellow) and bridging sheet (blue) are 
shown and participate in gp120 binding to the chemokine coreceptor. Figure adapted from [158]. 
The crystal structure of the unliganded SIV gp120 core [82, 159] shows that there 
are significant structural re-arrangements compared to the CD4-bound gp120 [66, 
160], confirming the conformational flexibility of gp120. Previous studies on 
trimer models based on gp120, suggest that the V3 region is conformationally 
flexible and adjusts its position relative to the V1-V2 domains post CD4 binding 
[82] (discussed in further detail later). The V1 and V2 loops partially mask the 
conserved CD4 and chemokine coreceptor binding sites and upon CD4-gp120 
binding, then the V2 loop is displaced, exposing the previously concealed V3 loop, 
CD4i epitopes and stabilizing the bridging sheet [68, 161]. These CD4-induced 
conformational changes have been shown to contribute significantly to the 
specificity and binding of the coreceptors [162-167]. 
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The inner domain of gp120 contains the N and C termini and is believed to interact 
with the transmembrane gp41 [168]. The outer domain includes the variable 
regions 3, 4 and 5 (V3 - V5) which are anchored at their bases by disulphide 
bonds. All the cystiene residues within gp120 are completely conserved [169, 170]. 
Many insertions, deletions and substitutions in these regions contribute to the high 
degree of sequence variability and amino acid diversity, allowing flexibility within 
these loops [168].  
The five conserved regions (C1 - C5) are interspersed between the five variable 
regions and fold into the gp120 core [66, 171]. These five constant regions within 
env have far less sequence variability and therefore harbour the more conserved 
function of chemokine coreceptor binding [171, 172]. The first and fifth conserved 
regions (C1 and C5) are implicated in the interaction between gp120 and the fusion 
peptide transmembrane glycoprotein gp41 [66, 173]. The conserved regions of 
gp120 are masked by the variable regions and are thus protected from attack by the 
hosts’ immune response. The host immune response may be evaded by the variable 
outer domain of gp120 which is exposed to the hosts’ immune system concealing 
the conserved regions. The outer domain thus avoids the humoral immune 
response and is referred to as the “silent face” [64]. 
Kwong et al., [66] elucidated the specific contact residues involved in the CD4-
gp120 interaction. Structure analysis elucidated 26 conserved gp120 amino acid 
residues that interact with 22 CD4 amino acid residues [66]. In culmination, this 
interaction buries 802 Å2 surface area of  gp120 and 742 Å2 from CD4 [66, 67, 82, 
174]. However, the surface areas that are actually in contact are much smaller, 
leading to the exposure of the gp120 core which is then readily able to bind to the 
chemokine coreceptor [62, 77, 164]. The chemokine binding residues are 
conformationally masked and not fully elucidated, however these sites are believed 
to be highly sensitive to antibody neutralization [175, 176].  
Genetic, immunological and structural studies of the HIV-1 Env have revealed its 
incredibly diversity in the form of immunodominant loops, and its cunning 
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mechanisms of humoral and cellular immune system evasion. Immune evasion is 
achieved by the conformational masking of conserved coreceptor binding regions 
by the highly variable loops and “self-masquerading glycan shield” [61, 64, 176-
178]. 
1.6.2 Glycosylation of gp120  
The gp120 envelope protein undergoes post-translational modifications by 
enzymatic attachment of asparagine (N)-linked polysaccharide chains. The N-
linked glycosylation targets any peptide sequence motif that is defined by 
NX1(S/T)X2, where X represents any amino acid, except Proline [179]. The gp120 
is highly glycosylated harbouring approximately 24 potential complex glycans 
within the variable regions and high mannose/hybrid glycans within the conserved 
regions of gp120 (Figure 1.6) [169, 180]. Over half of the molecular mass of 
gp120 is due to the significant N-linked glycosylation addition onto the protein 
[181]. Glycosylation of the gp120 molecule is essential for the correct folding and 
processing of the three dimensional envelope protein [182] and thus the correct 
structural conformation is assumed for CD4 binding.  
The heavy carbohydrate moieties form a “glycan shield” that sterically 
masks/protects the vulnerable surfaces on the viral envelope from host neutralizing 
antibody attack [171, 177, 183]. The position and amount of glycosylation sites 
and variation thereof, differ over time and thus provide an indication of the degree 
of escape of an isolate from the hosts’ immune system [184]. 
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Figure 1.6 Schematic representation of the HIV-1 envelope protein. Epitopes that are capable of 
inducing neutralizing antibodies are coloured and the variable loops are designated in boxes (V1 – 
V5). Mannose-type or hybrid type glycosylation sites are indicated by the branched black 
structures, complex-type oligosaccharides are shown by the U-shaped black structures. Some 
epitopes that are capable of eliciting neutralizing antibodies are coloured in orange (V2 loop) and 
blue (V3 loop). The numbering of the amino acid residues in this figure was not used in the text and 
the figure was adapted from [185].  
1.6.3 Envelope Heterogeneity and Disease Progression 
Many studies have investigated the correlation between disease progression and 
viral heterogeneity. The variable regions of the envelope glycoprotein (particularly 
focusing on the V3 region) are major determinants in host cell tropism and elicit 
humoral and cellular immune responses against specific recognition sites [186, 
187].  
  
 
22 
When the host is initially infected with HIV-1, the virus is transmitted as a 
homogeneous population of quasispecies with relatively low sequence diversity 
[125-127]. After primary infection in a treatment naïve individuals, the viral 
sequence diversity rapidly increases with disease progression and then decreases in 
viral diversity in the late stages of disease when the immune system ultimately 
deteriorates [188]. The HIV-1 populations within an individual are constantly 
evolving and sequences may differ as much as 10% from one-another at the end 
stages of disease [76].  
Viral escape may be a function of host immune pressure or it may be purely a 
chance event due to the highly error-prone, poor proof-reading capabilities of the 
HIV-1 reverse transcriptase coupled with the high viral replication rate (see section 
1.2). These changes may result in changes in length and overall charge of the 
variable loops (and other regions within gp120) as well as changes in number and 
position of glycosylation sites within the envelope [177]. Whatever the cause of 
immune evasion, the virus undergoes extensive viral heterogeneity and this is a 
determining factor for disease progression [189, 190].  
The classical early stages of HIV-1 infection are characterized by predominating 
NSI, macrophage (M)-tropic, slow/low replicating, CCR5 utilizing (R5) variants 
(Figure 1.4) [191-195]. The R5 variants predominate during the acute and 
asymptomatic phases of infection [72] and play an important role in transmission 
and the infection of macrophages at the site of infection [126, 195-198]. R5 
variants have been found to dominate even after vertical and sexual transmission 
[198] even when the dominant cell type during early and late infection is CD4+ T 
cells.  
However, T-cell (T)-tropic, SI, rapid/high replicating CXCR4 utilizing (X4) 
variants may emerge during the later phases of disease pathogenesis leading to 
accelerated loss of naïve and resting CD4+ T cells, broadening of the coreceptor 
usage profile of HIV-1 isolates and rapid progression to AIDS (Figure 1.4). This is 
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observed in at least 50%-60% of HIV-1 subtype B patients [73, 193, 194, 196, 
199-207]. 
Dual tropic viruses, capable of gaining entry into a host cells via the CXCR4 
and/or the CCR5 coreceptor are termed R5X4 strains [141, 208]. CCR5 is 
expressed on activated lymphocytes, macrophages, dendritic cells and microglial 
and neuronal cells, however CXCR4 is ubiquitously expressed on all somatic cells 
[209]. Dual tropic variants may be an important structural intermediate during the 
switching process between R5 utilizing and X4 utilizing HIV-1 isolates [210, 211]. 
CXCR4 utilizing viruses have shown increased cytopathicity in vitro, which may 
be a fundamental link between coreceptor switching and the increased 
pathogenicity in late stage AIDS patients [212, 213]. 
1.6.4 Determinants of Coreceptor Usage and Switching 
1.6.4.1 Structure of CCR5 and CXCR4 
Both chemokine receptors CCR5 (previously named LESTR/fusin) and CXCR4 
contain 352 amino acids, and are G-Protein Coupled receptors (GPCRs) that 
transverse the cellular membrane seven times [192]. These heptahelical large 
protein receptors transduce extracellular signals into intracellular signals via the 
activation of a G protein, bound to Guanosine triphosphate (GTP) [192]. The three 
extracellular domains of the receptor are glycosylated and contain four highly 
conserved cysteine moieties, which form disulphide bonds that stabilize the 
receptor within the membrane (Figure 1.7 A and B). Moore and Stevenson have 
elucidated the subtle differences in charge between the surfaces of the two 
coreceptors, CCR5 has a neutral charge, as opposed to the negatively charged 
CXCR4 [214]. Despite this low homogeneity between the two major coreceptors, 
dual tropic viruses can use both CXCR4 and CCR5 relatively efficiently [80, 215].  
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Figure 1.7 (A) Schematic representation of the CCR5 chemokine coreceptor, a 7-transmembrane 
major coreceptor for HIV-1 gp120 with amino terminus (NH2) on the outside and the carboxyl 
terminus (COOH) on the inside of the cytoplasmic domain of the cell. The cysteine residues are 
indicated in red and the three extracellular loops (ECL) are depicted [80]. (B) Schematic 
representation of the 7-transmembrane chemokine CXCR4 coreceptor. The amino terminus (NH2) 
is on the outside and the carboxyl terminus (COOH) on the inside of the cytoplasmic domain of the 
cell. The cysteine residues are indicated in red and the three extracellular domains are depicted 
ECL1, ECL2, ECL3, respectively. Figure adapted from [216]. 
Further analysis of CCR5 and CXCR4 has shown that negatively charged amino 
acids, including tyrosine, in the amino termini of the coreceptors are critical for 
binding of the viral envelope [217]. The second extracellular loop of CXCR4 is 
implicated in expanded host cell tropism and yields a more negative charge, which 
may lead to the greater attraction to the more positive CXCR4 tropic envelope 
[217-219]. The association between gp120 and the coreceptor is likely one based 
on charge, indicating that the higher the positive charge of the envelope, the higher 
the likelihood of the isolate using CXCR4 to gain entry.  
The Env of a R5 utilizing HIV-1 may evolve to use CXCR4 over time and this 
may be intimately associated with the common structural features of the two 
coreceptors and the ability of gp120 to adapt/mutate to influence this interaction as 
disease progresses.  
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1.6.4.2 V3 Loop and coreceptor Usage 
The V3 loop plays a critical role in coreceptor binding of HIV-1 and host cell 
tropism [220-222]. Coreceptor usage has been extensively studied in HIV-1 
subtype B and certain characteristics that influence coreceptor binding have been 
elucidated. The intact crystal structure of HIV-1 V3-containing gp120 core in 
complex with CD4 and an antigen-binding fragment of the R5 antibody, has been 
elucidated [174]. This crystal structure elegantly depicts how the V3 loop extends 
outwards and downwards away from the gp120 glycoprotein towards the host cell 
membrane (Figure 1.8).  
This V3 loop was described as a “molecular hook” that engages the N-terminus of 
the CCR5 coreceptor [174]. The conserved Proline (P) - Glycine (G) motif on the 
tip of the V3 loop projects 30 Å towards to host cell membrane from the gp120 
core (Figure 1.8). This allows interaction of the V3 loop with the N-terminus of the 
CCR5 coreceptor; as the tip binds to the ECL2 of CCR5 and the conserved base 
interacts with the sulphated CCR5 N-terminus (Figure 1.8) [174]. 
 
Figure 1.8 (A) Crystal structure of a CD4-triggered gp120 in complex with the V3 loop (in red) 
at the host cell surface, superimposed onto a structure of the four-domain CD4 receptor. The highly 
conserved P-G tip of the V3 loop is projected 30 Å towards the host membrane. (B) Schematic 
representation of the CCR5 coreceptor interaction (green) with its tyrosine-sulphated N-terminus 
and extracellular loops (ECLs) and V3 (red). Figure adapted from [174].   
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The V3 loop amino acid charge, amino acid length variation, glycosylation 
patterns, tetrapeptide motif and its secondary structure have all been found to 
influence viral coreceptor usage [223, 224].  
The V3 region is hypervariable and induces both highly specific as well as broadly 
cross reactive antibodies (e.g. 447-52D and 2219) due to its high degree of 
antigenicity [225, 226]. Previous studies have shown more specifically, that it is 
the overall amino acid charge of the V3 loop which determines coreceptor 
phenotype [167, 175]. A higher positive charge will correlate with CXCR4 usage 
(X4 using virus) and SI phenotype, similarly a lower positive charge associates 
with the NSI CCR5 coreceptor usage (R5 using virus) [69-71, 77, 80, 164, 201, 
227-229].  
An accurate prediction of CCR5 coreceptor usage/NSI phenotype, may also be 
determined by the presence of a neutral amino acid (i.e. serine (S)) at position 11 
in the V3 loop as well as a negatively charged amino acid (either aspartic acid (D) 
or glutamic acid (E)) at position 25 [201, 202, 229-232]. Conversely, if a 
basic/positive amino acid is found at position 11 and/or 25 (i.e. arginine (R), lysine 
(K) and Histidine (H)), this overall positive charge will strongly correlate with the 
SI phenotype (Figure 1.9) [201, 202, 229, 233-235]. The higher the net charge of 
the V3 loop, the higher the correlation is of the positive V3 loop interacting with 
the negatively charged CXCR4 coreceptor [203]. 
The V3 region is usually 35 amino acids in length and located between amino 
acids 296 and 331 of gp120, forming a distinctive “finger-like” loop (in subsequent 
discussions, amino acid positions 1 through 35 correspond to 296 through 332 in 
the standard reference HXBc2) (Figure 1.9). Generally CXCR4 utilizing V3 loop 
sequences are slightly longer in length, due to the increased amino acid insertions 
[236, 237]. 
There are two potential N-linked glycosylation sites within the HIV-1 subtype B 
V3 loop reference sequence, one appears at the N-terminal cysteine residue at the 
base of the loop (NCT) and the other is found from position 6-8 (NNT) (Figure 
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1.9). However, the N-linked glycosylation site (NCT) is rarely present in HIV-1 
subtype C V3 loop sequences [238-240]. The glycan at position 6-8 of the V3 loop, 
has been implicated in CCR5 usage and decreasing sensitivity to antibody 
neutralization [241, 242]. The loss of this N-linked glycan is associated with less 
frequent use of the CCR5 coreceptor and in some cases, lack of the glycan is 
associated with exclusive CXCR4 usage [243, 244]. 
 
Figure 1.9 Schematic illustration of the 35 amino acid V3 loop (in blue). The GPGQ tetrapeptide 
crown/tip motif is indicated in pink. The 11th and 25th amino acid residues are highlighted in red, 
showing their importance in coreceptor binding. The N-linked glycosylation site at NNT and the 
disulphide linkage between the two cysteine residues are also shown. The V3 loop sequence 
depicted here is based on the Consensus subtype C sequence used in Section 2.4.6. 
The highly conserved crown/tip of the V3 loop (residues 15 – 18) is also a strong 
predictive region of HIV-1 subtype C cellular tropism. The consensus subtype B 
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tetrapeptide crown motif is generally GPGR/K, irrespective of coreceptor usage 
[234]. However, in HIV-1 subtype C isolates, the tetramer motif GPGQ has shown 
great conservation in CCR5 utilizing HIV-1 isolates, whereas a more variable 
motif is displayed in CXCR4 utilizing isolates such as GPGR or GRGQ (Figure 
1.9) [245].  
The secondary structure conformation of the V3 loop also plays a crucial role in 
viral biological phenotype/cellular tropism [202, 246]. According to neural 
network modelling, the V3 loop has a predicted secondary structure composed of a 
short carboxyl-terminal α–helix and two antiparallel β–sheets which is formed by 
the disulphide linkage between two conserved cysteine residues at its base [247], 
[201, 248]. 
There is still debate as to whether the V3 loop is directly or indirectly involved in 
the initial gp120-CD4 binding interaction [222]. Whether the V3 loop sequence, or 
its overall conformation, define chemokine coreceptor usage is still uncertain and 
thus further investigations into the specific requirements of the V3 loop that 
influence coreceptor usage are necessary. Studies on the correlation between 
chemokine coreceptor usage/cellular tropism and V3 loop characteristics of HIV-1 
subtype C isolates, remains to be extensively evaluated. To date, only a few 
CXCR4 utilizing HIV-1 subtype C viruses have been identified, and the majority 
of HIV-1 subtype C viruses have shown almost exclusive CCR5 usage [164, 200, 
232, 239, 249-263]. 
Some studies have shown that there is a marked increase in the frequency of 
CXCR4-using HIV-1 viral isolates in HIV-1 infected patients receiving/following 
antiretroviral treatment [264, 265]. A study has shown that host cell availability, 
expressing the various coreceptors used by HIV-1 is unlikely to be the sole driving 
force of this described R5 tropic to X4 tropic switch. This may be due to a delayed 
X4 tropism development associated with higher levels of CXCR4 expression on 
total and naïve CD4+ T cells [266]. 
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Coreceptor usage of HIV-1 isolates is established with 100% accuracy in an MT-2 
phenotypic cell assay [267-269]. However, phenotypic assays do not elucidate 
genotypic changes that are responsible for the change in viral tropism. The advent 
of bioinformatic algorithms as molecular software packages have enabled the 
identification of empirically predetermined sequence motifs in the variable regions 
of HIV-1 coreceptor binding sites. A score is mathematically produced which is 
interpreted by indicating the likelihood of the sequence of interest rendering 
CXCR4 or CCR5 usage [270, 271]. However, the evolutionary pathways, 
sequences of mutations and biological and genotypic selective pressures that are 
required for the switch in viral phenotype from R5 to X4 usage are not fully 
understood, despite being extensively studied.  
Coreceptor switching has become arguably relevant as it may be the reason for 
drug resistance to novel CCR5 antagonists that are currently in advanced stages of 
clinical development [272-275]. 
1.6.5 The HIV-1 Env glycoprotein represents an Antiviral and 
Vaccine Target 
The sequence variability and glycosylation of the gp120 glycoprotein surface may 
vary the immunogenicity and antigenicity of the envelope [276]. The gp120 
glycoprotein is the primary target for neutralizing antibodies elicited by the hosts’ 
immune system during the course of natural infection [177, 276]. Since certain 
conserved residues of gp120 are concealed from the host’s immune system and 
have demonstrated increased sensitivity to neutralizing antibodies, these epitopes 
present as ideal candidates for vaccine studies and or targets of novel antiretroviral 
drugs. Neutralizing antibody determinants can thus be elucidated and used as 
vaccine immunogens to elicit strong memory immune responses within an 
uninfected individual. 
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1.6.5.1 Neutralizing Antibodies  
Broadly neutralizing monoclonal antibodies to HIV-1 infection recognize specific 
epitopes found on the envelope glycoprotein namely, 2G12, 2F5, b12, 4E10 and 
Z13 [178, 277-284]. Both 2G12 and b12 bind the conformationally invariant 
surface of the outer domain of gp120 and have shown efficient neutralization 
against diverse HIV-1 primary isolates [280, 283, 285, 286]. 2G12 contains 
mannose rich glycosylation sites and recognizes glycan residues on the outer 
region on gp120 in positions N295, N332, N339 and N392 (numbering based on 
the HXBc2 viral genome) [277, 281, 287]. 2F5 recognizes a conserved linear 
sequence (ELDKWA) on the C-terminal region of gp41 [278], and 4E10 
recognizes the conserved sequence (NWF(D/N)IT) on gp41 close to the 2F5 
epitope [282]. Recently, a high-affinity variant of Z13, named Z13e1, was isolated 
and found to have 100 times stronger neutralization potency against sensitive HIV-
1 and stronger binding affinity for the membrane-proximal external region of gp41, 
compared to its parental Z13 [280]. 
Recently, Zhou et al., [178] elucidated the structure of the gp120 glycoprotein in 
complex with the broadly neutralizing antibody b12 at 2.3Å resolution [178]. The 
vulnerable site on gp120 that is functionally required for CD4 binding was 
targeted. This recessed site is located between the glycan-shielded silent face and 
the conformationally flexible inner domain/bridging sheet and is accessible by 
CD4 for functional entry [178]. This crystal structure is of profound importance, as 
it details the accessibility and ability of b12 to bind and disable the highly 
protected HIV-1 Env and this has implications for an HIV-1 vaccine [178]. 
The coreceptor switch from NSI (R5) to SI (X4) results in both biological and 
physical changes within Env. Interestingly, the neutralizing antibodies target 
conserved epitopes in the V3 loop and R5 viruses are considerably more resistant 
to neutralizing antibodies as compared to their X4 counterparts [183, 276, 288-
292]. The increased sensitivity of X4/SI Env to some broadly neutralizing 
antibodies is due to the enhanced binding capacity and accessibility of the antibody 
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for the V3 loop. Therefore, the V3 loop conformational state associated with the 
X4 Env is more accessible and susceptible to neutralizing antibodies [293]. This 
information may have profound implications for vaccine design and drug 
development protecting against SI/X4 variant evolution and/or emergence. 
1.6.5.2 Drug Targeting HIV-1 Entry 
The three main classes of Food and Drug Administration (FDA) approved current 
Antiretroviral Therapies (ARTs) for use in HIV infection are; Reverse 
Transcriptase Inhibitors (RTIs), Protease Inhibitors (PIs) and Entry Inhibitors (EIs) 
[294]. However, viral resistance to current therapies has prompted the emergence 
of four new classes of drug targets for ART; Inhibitors targeting (i) NCp7 Zn 
Finger inhibitors, (ii) integrase, (iii) rev/tat and (iv) viral maturation inhibitors 
[295-299].  
Several novel compounds acting as entry inhibitors have been designed to target 
the three distinct stages of the entry process; namely attachment of gp120 to the 
primary CD4 receptor, interaction of the gp120-CD4 complex with either CCR5 
and/or CXCR4 chemokine coreceptors and finally gp41 mediated membrane 
fusion.  
T-20 (Enfuvirtide/Fuzeon) is a novel entry inhibitor peptide that interferes with the 
formation of the six-helix bundle in gp41 thereby preventing fusion between viral 
and host membranes [300, 301]. T-20 was initially used as a salvage therapy, 
however it is now used in combination with other antiretroviral drugs due to the 
detection of drug resistant mutations and incomplete viral suppression in HIV-1 
positive patients taking T-20 [302]. 
Several drugs have been designed to target the gp120-CD4 interaction. PRO 542 
(CD4-IgG2), is a recombinant tetravalent CD4-immunoglobulin fusion peptide 
which comprises four gp120 binding sites [303]. BMS-378806 is the first small 
indole-based molecular compound that inhibits the gp120-CD4 interaction through 
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binding to the conserved CD4-binding pocket on gp120 [304, 305]. Cyanovirin 
(CV-N) is a protein compound (lectin) that targets virion attachment to host cells 
via blocking the gp120-CD4 interaction by competitively binding to high-mannose 
carbohydrates on the viral glycoproteins [306]. This protein was extracted from the 
cyanobacterium Nostoc ellisporum and may be useful as a therapeutic agent or as a 
topical microbicide [306, 307]. 
Many entry-inhibiting compounds that inhibit gp120 from interacting with 
chemokine coreceptors are in various stages of development. There are two main 
classes within the coreceptor inhibitors, namely those targeting CCR5 and those 
targeting CXCR4. Most HIV-1 strains are sensitive to inhibition by CCR5 
proinflammatory chemokines, CCL5 (RANTES), CCL3 (MIP-1α) and CCL4 
(MIP1β) [77]. RANTES is a β-chemokine that is naturally secreted by cytotoxic T 
cells and binds to CCR5 and inhibits cellular entry of R5 variants [308]. TAK779 
prevents gp120 interactions with the CCR5 coreceptor via binding one of the 
grooves formed by the seven transmembrane helices of CCR5 [309, 310] and TAK 
220 is a small molecule CCR5 antagonist that is orally bioavailable [311].  
There are also CXCR4 inhibitors that are highly cationic and specifically target 
CXCR4. However, CXCR4 plays important biological roles (embryogenesis) and 
immunological roles and thus targeting CXCR4 as a therapy is somewhat 
controversial [312]. Stromal cell-Derived Factor - 1 alpha (SDF-1α) is a natural 
ligand for CXCR4 and highly specific for CXCR4 [313]. Therefore, this is cause 
for concern relating to the undesirable effects of blocking SDF-1α in vivo. 
AMD3100 is a bicyclam cationic compound that binds to the extracellular loops of 
CXCR4 and can prevent both X4 and R5X4 isolates from binding to CXCR4 [314, 
315]. Both T140 (precursor peptide T-22) and ALX40-4C are specific for targeting 
X4 viruses [316, 317]. Other CXCR4 antagonists include AMD 070 and KRH 
2731 [318, 319]. 
Currently, many entry and fusion inhibitors are being investigated in controlled 
clinical trials and some are bioavailable as oral compounds in human clinical trials. 
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Fusion and attachment inhibitors include; AK602 [320], a CCR5 antagonist in 
early human trials, Maraviroc [272], a CCR5 antagonist in Phase III trials, 
AMD070 [321], a CXCR4 antagonist in Phase II trials, BMS-378806 [304, 305], is 
in Phase II trials, HGS004 [322], a monoclonal antibody CCR5 antagonist, 
successfully completed a Phase I trial , PRO 140 [323] and PRO 542, Schering C, 
SP01A, an entry inhibitor in Phase III trials, TAK-652, another CCR5 antagonist 
in Phase I trials, TNX-355 is a monoclonal antibody in Phase II trials and finally 
Vicriviroc (SCH 417690) [47, 324, 325]. However, Phase III trials of vicriviroc, a 
non-protein molecule that binds to the extracellular cavity of CCR5, has been 
halted due to its inferior antiviral efficacy [326]. The study will however be 
repeated with higher doses of vicriviroc [47]. 
1.6.5.3 Development of Drug Resistance 
In an attempt to prevent the inevitable progression to AIDS, HAART has been 
developed. However, despite individuals who respond successfully to HAART, 
treatment failure is common and due to the failure of almost 100% viral 
suppression by the current treatment regimes and the emergence of drug resistant 
HIV-1 strains is inevitable [327]. Thus, the development of effective antiretroviral 
drugs and/or vaccines is vital. Treatment failure on HAART results from a 
combination of different factors.  
Firstly, drug-resistant mutations within the HIV-1 genomic material my pre-exist 
and under the pressure of partially-effective antiretroviral regimens, may be 
selected for [328]. Many factors result in the development of drug-resistant strains 
of HIV-1. The high replication capacity of HIV and its error-prone reverse 
transcriptase are major factors that contribute to viral escape from the immune 
system and the emergence of drug resistant strains [46]. Another significant source 
of genetic variation in HIV-1 is recombination between different HIV-1 variants 
within the host. Simultaneous infection of an individual by two or more distinct 
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HIV-1 strains may occur in vivo and recombination between these viruses may 
lead to highly resistant strains [329, 330].  
Secondly, sub-inhibitory drug levels allow resistant strains to populate within the 
host. This can arise from a range of events, such as poor patient adherence to the 
drug regime, poor drug absorption, incorrect drug dose or inhibitory interactions 
between drugs within the host [327].  
Lastly, the exposed surfaces of the gp120 molecule contain hypervariable domains 
that are highly glycosylated with carbohydrate moieties that serve as immunologic 
decoys for the humoral immune response [331, 332]. This hypervariability of the 
HIV-1 surface may also lead to drug resistance. 
The phenomenon of HIV-1 drug resistance may either significantly impair viral 
fitness or lead to the emergence of more fit and more pathogenic viral variants. 
The observed genetic diversity of HIV-1 may also be influenced by selective 
pressure such as the host's immune response, cell tropism of the virus and the 
genetic heterogeneity of the host. Resistance to all of the currently availably ARVs 
has been documented [333-343] and thus new classes of drugs directed against 
more conserved target sites is imperative if the resistance to therapy is to be 
curtailed. 
1.7 CD4-independent Entry 
1.7.1 CD4-independence  
HIV entry into a host cell is a dynamic and complex multi-step cascade process 
which is initiated with binding of the viral envelope glycoprotein to the CD4 
receptor [56, 57]. However, some primary HIV-1, HIV-2 and SIV isolates can, to 
some extent, enter cells in vivo without the requirement for CD4 and bind directly 
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to coreceptors to initiate infection [344-347]. These viruses are termed CD4-
independent and this naturally occurring phenomenon in vivo is relatively rare.  
The viral envelopes are ‘partially triggered’, allowing direct binding of the 
coreceptor to initiate host cell infection. Overall, CD4-independent viruses express 
gp120 in a ‘pre-triggered’ conformation in which the coreceptor binding site is 
exposed and can bypass the CD4 receptor and interact directly with the coreceptor 
[345, 346, 348-350]. 
The CD4-independent Envs generally possess multiple amino acid substitutions 
and/or deletions when compared to the CD4-dependent wild type (wt) virus. These 
mutations ultimately lead to the exposure of conserved epitopes that mediate direct 
binding to the CCR5 and/or CXCR4 coreceptor [167, 175, 351-353]. 
Consequently, CD4-independent viruses infect target cells with a much higher 
efficiency compared to wt viruses. However, these CD4-independent viruses 
exhibit heightened sensitivity to neutralizing antibodies that recognize conserved 
epitopes, which are essential for coreceptor engagement [351, 354-357]. 
The CD4-independent phenotype can be a natural consequence of infection of 
some cell types. Some cells express low levels of CD4, or do not possess CD4 in 
their cellular membrane. For example, macaque macrophages have been shown to 
express low levels of CD4 [358, 359]. Additionally, cells such as brain 
macrophages, oligodendrites, brain microvascular endothelial cells, astrocytes and 
microglia do not express CD4 [360]. HIV-1 is capable of infecting human brain 
cells which results in severe cognitive behavioural and motor destruction, termed 
HIV-Associated Dementia Complex (HADC) [361]. However, the mechanism of 
viral entry into astrocytes and neurons is currently unclear and elucidation of this 
entry pathway will aid in HIV-1 disease pathogenesis control.  
Studying the structure and function of CD4-independent HIV-1 viruses, may 
provide insight into the cascade of events that occur during Env-mediated 
membrane fusion with host cells. The specific residues involved in CD4 binding 
and subsequent conformational changes that allow for coreceptor exposure may be 
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genotypically and phenotypically identified. Further information regarding the 
interaction of the CD4-independent structural intermediate envelope and 
coreceptor, will provide a unique opportunity to determine which mutational 
changes in a CD4-independent envelope govern tropism for the primary receptor, 
CD4. Once the conserved coreceptor binding residues are elucidated, there will be 
potential for exploitation of these regions or analogues thereof for potential use as 
novel entry inhibitors or therapeutic vaccines.  
1.7.2 CD4-independence in vivo 
Several CD4-independent SIV, HIV-2 and HIV-1 isolates have been characterized 
in vivo. CD4-independent CCR5 utilization in vivo is relatively common in SIV 
and HIV-2 strains [345, 348, 362, 363] and CD4-independent, CCR5 tropic SIVs 
have a reduced affinity for CD4 and have been previously isolated from rapid 
progressor rhesus macaques [356, 357, 364].  
To date, only the HIV-1 primary isolate, (R2) has been shown to infect CCR5 
positive CD4 negative cells, but not efficiently. This isolate harbours a rare 
mutation in the V3 loop of gp120 [365].  
The CD4-independent phenotype in HIV and SIV can thus be attributed to one of 
two changes within gp120. Firstly, insertions and/or deletions can cause 
repositioning of the variable V1/V2 loop so as to unmask the coreceptor binding 
site. Secondly, an accumulation of successive mutations in V3 and the base of V4 
might increase envelope affinity for coreceptor binding (or pre-folding of the 
gp120 bridging sheet) [344, 366, 367]. Mutational changes in gp41 may also 
trigger conformational rearrangements and fusion to occur after a weaker gp120-
coreceptor interaction [348]. However, the extent to which CD4-independent 
viruses enter cells via a CD4-independent mechanism and have an expanded 
tropism for CD4-negative cells in vivo is currently unclear. 
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1.7.3 CD4-independence in vitro  
There have also been several reports of in vitro studies showing that strains of SIV, 
HIV-2 and laboratory adapted HIV-1 strains can bind either CXCR4 or CCR5 
coreceptors in the absence of CD4 [344-346, 349, 350, 367-371]. Zerhouni et al., 
[367]  hypothesized that these CD4-independent quasispecies would exist at low 
concentrations (in primary culture) compared to the more abundant CD4-
dependent strains, and that they may be enriched through serial propagation. 
However, infection of T cell lines lacking CD4 expression is much less efficient; 
hence, the significance and relevance of such viruses in vivo is relatively unclear. 
CD4-independent HIV-1 and HIV-2 variants that utilize CXCR4 for cell entry 
have been isolated in vitro by passage through cells lacking CD4. Hoffman et al., 
[351] derived an HIV-1 CD4-independent virus, IIIBx that interacted directly with 
the CXCR4 coreceptor and this phenotype was correlated with mutations 
throughout env. The IIIBx exhibited a heightened sensitivity to neutralization by 
HIV-1 positive human sera, as opposed to its CD4-dependent counterpart, IIIB 
[346, 372]. 
The cloned env from HIV-1 IIIBx (8x) and HIV-1/IIIB (HXB2R) variants were 
generated by serially passaging cloned envs through CD4-negative, CXCR4 
positive cells [350, 369]. The 8x carried a gp120 with a stable, constitutively 
exposed coreceptor binding site enabling it to bind directly to CXCR4 and was 
significantly more sensitive to neutralization by human sera from HIV-1 positive 
individuals [346, 351]. High affinity CXCR4 coreceptor usage was shown in CD4-
independent HIV-2 variants ROD/B and VCP [346, 369, 370]. The critical amino 
acid substitutions that were responsible for the CD4-independent phenotype and 
exposure of the coreceptor binding site, were changes in the V3 loop sequence, 
around the base of the V4, and in gp41 [350, 373].  
The CD4-independence in the HIV-1 m7NDK variant correlated with the 
acquisition of two glycosylation sites in V1/V2 and 7 amino acid changes within 
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the C2, V3 and C3 regions of env [344]. Another study was performed on a 
CXCR4 tropic HIV-1 iNDK recombinant clone, derived from the same parental 
virus as the m7NDK variant. The clone showed the acquisition of two N-linked 
glycosylation sites in the V1/V2 region, three amino acid changes in the V3 loop 
and the loss of one N-linked glycan from the C2 region [374].  
Kolchinsky et al., [349] and colleagues have shown that CD4 binding in the entry 
cascade of HIV-1 isolates can be made redundant by alteration and acquisition of 
glycosylation sites in the V2 loop and V1-V2 stem elements [349]. These changes 
allow the envelope glycoproteins to assume a pre-triggered state whereby the 
coreceptor binding site is exposed and CCR5 binding can occur [349]. The HIV-1 
ADA variant infected cells via CCR5 in the absence of CD4, and removal of a 
single glycosylation site at the base of the V2 loop was found to confer the CD4-
independent phenotype [355]. Structural models of gp120 suggest that removal of 
this glycan presumably results in the repositioning of the V1/V2 loops, so as to 
expose the highly conserved coreceptor binding site. The CD4-independent HIV-1 
NDK variant correlated with the acquisition of two glycosylation sites in the 
V1/V2 loops [374]. 
CD4-independent usage of the CCR5 coreceptor by an HIV-2/vcpm variant 
mapped to a positively charged amino acid in the C4 region of env [375]. Other 
CCR5 tropic, CD4-independent infection of host cells, has been shown in SIV 
[345, 357, 376-378]. Puffer et al., [379] determined that two amino acid changes in 
the V1/V2 loop and gp41 are responsible for the CD4-independent phenotypic 
effects on the SIVmac239 Env [379].  
The genotypic determinants for the CD4-independent phenotype in vitro are 
mapped to env, however the underlying mechanisms of this phenomenon are 
largely unknown. The changes acquired by different HIV-1 recombinant clones 
post CD4-independent adaptation vary considerably between isolates. There does 
not seem to be a common, standard motif associated with env that is required for 
CD4-independent env clones. In general, mutations in the coreceptor binding 
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domains and mutations within the trans-membrane region of env as well as an 
alteration of the N-linked glycosylation profile will render an isolate CD4-
independent [344-346, 349, 350, 367-371]. The changes observed in vitro may not 
be a direct reflection of the exact changes that are taking place in vivo, due to the 
lack of immune pressure in vitro. 
1.7.4 Relevance for Neutralizing Antibodies and Drug Targets 
CD4-independent viruses are more susceptible to antibody neutralization, possibly 
explaining the rarity of the occurrence of the CD4-independent phenotype in vivo 
[355]. The relationships between CD4-independence, antibody neutralization 
sensitivity, and exposure of CD4-induced epitopes that are associated with the 
coreceptor binding site of gp120 have been investigated [351, 354]. The conserved 
determinants of the neutralization sensitivity of the CD4-independent phenotype 
have largely been mapped to the gp160 region.   
There is thus broad potential for the exploitation of these highly neutralization 
sensitive CD4-independent envelopes that are partially triggered, exposing their 
coreceptor binding domains. Neutralization may take the form of antibodies and/or 
small molecular inhibitors of the Env-coreceptor interactions. Monoclonal 
antibodies directed at the conserved coreceptor binding regions of the envelope 
may be used as immunological surrogates for inhibition viral entry. 
As mentioned previously, 50% of worldwide HIV-1 infections are caused by 
subtype C and one-third (32%) of the worlds’ HIV-1 infected population lives in 
Southern Africa [16]. These data taken together with the vast and rapid genetic 
variability rate of HIV-1, highlight the urgency and importance for studying 
subtype C in order to elucidate common drug targets and prevention strategies 
between subtypes that may aid in producing broadly cross-reactive antiviral 
treatments and/or vaccines.  
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It is expected that CD4-independent viruses will have an exposed coreceptor 
binding site, providing a number of potential sites for therapeutic intervention by 
compounds such as small molecule inhibitors and/or neutralizing antibodies.  
To date, there are no reports in the literature on HIV-1 subtype C, CD4-
independent viruses. A CD4-independent HIV-1 subtype C viral isolate would be 
extremely valuable for use as a potential vaccine immunogen, and a target to 
identify novel entry inhibitors. In addition, it would provide useful information on 
the viral entry process. Thus, this study focused on the adaptation of primary HIV-
1 subtype C isolates towards CD4-independence. 
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1.8 Objectives and Aims of the Study 
The overall aim of this study was to isolate a CD4-independent HIV-1 subtype C 
isolate. We attempted to generate this isolate using the following two procedures: 
1. Isolation and characterization (genotypic and phenotypic) of primary HIV-
1 subtype C isolates from antiretroviral drug-naïve AIDS patients. 
2.  Adaptation of selected primary isolates to CD4-independence through 
serial in vitro passage in Cf2Th cell lines.  
The significance of this study is that CD4-independent viruses are expected to 
possess exposed coreceptor binding sites, providing potential conserved sites for 
therapeutic intervention by compounds such as small molecule inhibitors, 
neutralizing antibodies and/or therapeutic vaccines. This is a novel study 
performed on HIV-1 subtype C primary isolates. 
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Chapter 2 ISOLATION AND CHARACTERIZATION OF 
HIV-1 PRIMARY ISOLATES FROM 
ANTIRETROVIRAL DRUG-NAÏVE SOUTH 
AFRICAN AIDS PATIENTS  
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2.1 Abstract 
HIV-1 gains entry into host cells through the envelope glycoprotein binding to 
CD4 and a coreceptor, either CCR5 and/or CXCR4. HIV-1 subtype C viruses 
predominantly use CCR5, unlike other group M subtypes that often switch to using 
CXCR4 during disease progression to AIDS. This study investigated the genetic 
and phenotypic properties of 20 antiretroviral drug-naïve advanced AIDS patients 
attending a clinic in Johannesburg, South Africa. Blood was collected over 6 
months between January and June 2005 and primary viral isolates were established 
and propagated using standard co-culture techniques. Coreceptor usage for each 
isolate was determined, elucidating biotype and phenotype, using the U87.CD4 
and MT-2 cell assays respectively. Viral phenotype was shown to be either Non-
syncytium inducing (NSI) or syncytium inducing (SI). Proviral DNA was 
extracted, the full-length env genes were PCR amplified and the V3 loop region 
was sequenced and extensively analyzed. Fourteen isolates utilized CCR5 and 
exhibited the NSI phenotype and the remaining six of the 20 (30%) primary 
isolates utilized CXCR4 for cell entry and exhibited the SI phenotype. 
Phylogenetic analysis of V3 loop sequences from 19/20 isolates confirmed they 
were HIV-1 subtype C and isolate 05ZAFV10 was found to be subtype D in the 
V3 loop region. Predicted amino acid analysis of the V3 loop sequences indicated 
specific residues and motifs relating to coreceptor usage. The SI viruses had 
significant genetic changes in the V3 loop, characteristic of CXCR4 usage, when 
compared to NSI viruses from the same cohort. We report the highest percentage 
of CXCR4 usage amongst primary isolates from HIV-1 subtype C infected AIDS 
patients in South Africa. These results imply that the frequency of HIV-1 subtype 
C CXCR4 utilizing viruses may be increasing with time. This detected 
emergence/evolution of CXCR4 usage amongst HIV-1 subtype C may have 
profound implications for viral pathogenesis, disease progression and future use of 
CCR5 antagonists as antiretroviral agents. 
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2.2 Introduction 
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HIV-1 entry is initiated by the envelope glycoprotein (Env/gp160), located on the 
surface of the virion, binding to host cellular receptors. Env also plays a pivotal 
role in the viral life cycle, and is responsible for transmission, viral tropism and 
viral replication kinetics. HIV-1 gains entry into host cells through the Env binding 
to its primary receptor, CD4 and a coreceptor, either CCR5 and/or CXCR4. Viral 
tropism of HIV-1 can largely be linked to these two coreceptors.  
Several studies have shown that viruses isolated from HIV-1 positive individuals 
early in the time course of disease progression, are non-syncytium inducing (NSI), 
macrophage (M)-tropic, CCR5-utilizing HIV-1 (R5) strains. While T-cell (T)-
tropic, syncytium inducing (SI), CXCR4-utilizing isolates (X4) may emerge during 
the later phases of infection [141, 142]. Some HIV-1 viruses are capable of gaining 
entry into the host cell by binding to CD4 and CCR5 and/or CXCR4, such viruses 
are termed dual-tropic (R5X4). These phenotypic characteristics of HIV-1 have 
been closely associated with the growth characteristics of viral isolates in co-
culture experiments with donor peripheral blood mononuclear cells (PBMCs) [267, 
380, 381] and in cell lines expressing the relevant coreceptors [197, 268, 269, 382].  
During late stage disease, approximately 50% - 60% of the isolates from AIDS 
patients infected with HIV-1 subtype B showed multiple coreceptor usage [73-76, 
193, 194, 196, 200-207]. After the appearance of CXCR4 utilizing viruses, both 
R5 and X4 tropic variants may co-exist within the individual. Changes in cellular 
tropism and the emergence of X4 coreceptor usage by HIV-1 strains in vivo seem 
to be a key event in disease pathogenesis. This promiscuous nature of the HIV-1 
virus may be associated with accelerated CD4+ T cell decline, broader target cell 
range, accelerated disease progression to AIDS and decreased survival time in 
antiretroviral (ARV) treatment-naive patients [73, 194, 196, 206, 207]. Despite 
extensive research regarding the cellular and molecular mechanisms of coreceptor 
switching observed in conjunction with disease progression towards AIDS, the 
mechanisms remain unknown. 
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Several hypotheses have been described that attempt to elucidate the phenomenon 
of coreceptor switching and the late appearance of X4 variants: Firstly, the 
‘transmission-mutation hypothesis’ suggests that CCR5 utilizing viruses are 
preferentially transmitted and mutate to CXCR4 utilizing variants over time [219, 
383]. It has been shown that dual tropism may evolve in CCR5 utilizing strains of 
HIV-1 through the acquisition of the ability to use the first and second extracellular 
loops of the CXCR4 coreceptor. The HIV-1 env may undergo several mutations to 
acquire dual tropism and maintains its use of the CCR5 coreceptor despite these 
changes.  A second ‘target-cell-based hypothesis’ suggests that the availability of 
CCR5 and CXCR4 expressing cells shift in favour of X4 utilizing virus infection, 
enabling a pre-existing pool of CXCR4 utilizing viruses to expand [383]. Ribeiro 
et al., [384] suggested that naïve and memory cell turnover rates throughout 
disease progression are responsible for the observed tropism switch in HIV-1 
[384]. Finally, the ‘immune-system-based hypothesis’ suggests that during the 
early stages of infection, CXCR4 utilizing viruses are easily neutralized by the host 
immune system and thus suppressed [383]. The X4 populations will emerge later 
during infection, because of the deterioration in function of the immune system.  
Recently, Mild et al., [385] suggested that the detected emergence of CXCR4 
utilizing HIV-1 variants in the later stages of disease pathogenesis, may be due to 
intrapatient recombination between different viruses with distinct tropisms [385]. 
This data suggests that the pre-existing circulating R5 and X4 viruses recombine, 
and result in CXCR4 utilizing chimeric viruses with the potential to evade the host 
immune system [385]. This is the first time that intrapatient recombination has 
been demonstrated at such high frequencies. 
Thus, there is still debate as to how these CXCR4 utilizing viruses arise. X4 
emergence may be a primary or secondary pathogenic event i.e. X4 isolates may 
be directly responsible for accelerated disease progression or there may be an 
independent event that promotes pathogenesis and thus X4 isolates emerge later in 
disease progression. These questions relating to coreceptor change and viral 
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phenotypic evolution need further investigation using both phenotypic and 
genotypic molecular tools. 
There are various culture-based and bioinformatic approaches which are used to 
determine HIV-1 viral coreceptor usage and biological phenotype. The use of the 
MT-2 assay and other indicator cell lines (U87.CD4.CCR5 and U87.CD4.CXCR4) 
establish viral coreceptor usage providing qualitative data represented as either 
NSI/CCR5 utilizing or SI/CXCR4 utilizing [69, 70, 77, 80, 164, 227, 228, 268, 
269].  
The MT-2 cell line has been traditionally used as a experimental surrogate 
phenotypic assay for the prediction of viral tropism in vivo [267-269]. This cell 
line expresses high levels of CXCR4 exclusively and does not express CCR5. 
Therefore, growth of CCR5 utilizing viruses is prohibited and only the CXCR4 
variants will cause a phenotypic cytopathic effect (CPE) in the form of syncytia in 
the MT-2 cell line.  
The third hypervariable loop (V3 loop) within Env is generally 35 amino acids in 
length, and has been implicated in coreceptor usage, and variations within V3 have 
been associated with changes in cell tropism, syncytium formation in MT-2 cell 
lines and progression to AIDS stage of disease [204, 234, 268, 386]. The specific 
progression of mutation acquisition by an HIV-1 viral isolate enabling a switch 
from CCR5 utilization to CXCR4 utilization is largely unknown. 
Bioinformatic approaches suggest that there are many genotypic changes in the V3 
loop that influence changes in subtype B coreceptor usage. Position Specific 
Scoring Matrices (PSSM’s) are used to detect non-random predetermined 
distributions of amino acids and/or motifs in a particular sequence [271]. If a 
sequence has a high PSSM score, the sequence will closely resemble an X4 
sequence and vice versa for R5 variants. The score will also provide an evaluation 
of an isolate’s transition from R5 to X4 tropism. Recently, sensitive modifications 
have been made to the existing PSSM software, to reliably predict viral phenotype 
for HIV-1 subtype C sequences, C-PSSM [270].  
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The Briggs method is another predictive tool for HIV coreceptor usage based on 
subtype B sequences. This method evaluates the net charge and positions of 
specific amino acids: an R5/NSI variant typically possesses a net V3 loop positive 
charge of < 4 and that of an X4/SI variant is typically > 4 [387]. The prediction of 
CCR5 coreceptor usage from HIV-1 env sequences, is relatively accurately 
determined by the presence of a neutral and negatively charged amino acid at 
positions 11 and 25 respectively, in the V3 loop [201, 202, 229-232]. Conversely, 
if a basic/positive amino acid is found at position 11 and/or 25 the sequence will 
probably represent a SI phenotype [201, 202, 229, 233-235]. Recent data suggests 
that the presence or absence of a predicted N-linked glycosylation site found at 
position 6-8 within the V3 loop is associated with efficient CCR5 usage and 
inefficient CCR5 usage, respectively [243, 244]. Whether or not mutations in env 
gradually accumulate over time, or if the presence of basic amino acids at positions 
11 and 25 are sufficient for R5 to X4 transition, is also still uncertain.  
HIV-1 subtype C viruses now are the most prevalent subtype and cause >50% of 
new HIV-1 group M infections worldwide, and have therefore become a major 
focus of novel drug development and vaccine design [52]. Published research up to 
2007 has shown that the ability of HIV-1 subtype C to switch or expand its 
coreceptor usage during the natural course of infection is relatively low. HIV-1 
subtype C isolates from all disease stages, in different regions of the world 
including South Africa, isolated from a variety of cohorts, utilize the CCR5 
coreceptor almost exclusively and show minimal use of CXCR4 [164, 232, 239, 
249-261, 388-390]. Coreceptor usage and switching has been extensively studied 
in HIV-1 subtype B isolates and to a lesser extent in subtype C isolates. The 
therapeutic implications and monitoring of coreceptor usage of HIV-1 isolates 
from AIDS patients, prior to commencement of ARV treatments that incorporate 
coreceptor antagonists, is thus very important. This study focuses on the isolation 
and characterization of primary HIV-1 viruses isolates during 2005. 
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2.2.1.1 Objectives 
The overall objective of this study was to isolate and investigate the genetic and 
phenotypic properties of South African HIV-1 primary isolates collected over 6 
months in 2005 from randomly selected ARV drug-naïve AIDS patients. This was 
achieved by the following aims: 
1. To isolate PBMCs and plasma from selected ARV drug-naïve AIDS 
patients attending an AIDS clinic at the Johannesburg General Hospital. 
2. To isolate and propagate primary HIV-1 isolates by standard co-culture 
techniques. 
3. To phenotypically and biologically characterize each primary viral isolate 
with respect to coreceptor usage by growth in MT-2 and 
U87.CD4.CCR5/CXCR4 cell lines, respectively. 
4. To determine whether genotypic characterization of the V3 amino acid 
sequence of Env can be correlated to phenotype.  
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2.3 Materials and Methods 
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2.3.1 Patients used in this Study 
Thirty-one antiretroviral drug-naïve advanced AIDS patients presenting at the 
HIV/AIDS clinic in the Johannesburg General Hospital, South Africa participated 
in this study between January and July 2005 (Table 2.1). All the patients were 
admitted to the clinic for purposes of initiating HAART treatment and samples for 
the purposes of this study were obtained prior to onset of therapy. To qualify for 
enlistment onto the government rollout, a patient must be diagnosed with AIDS 
and/or present with a CD4+ T cell count of 200 cells/ml or less. Ethical approval 
was obtained for this study from the University of the Witwatersrand Committee 
for Research on Human Subjects (Protocol No. M060734). All patients within the 
cohort completed informed consent documentation, prior to drawing 5 ml of whole 
blood in ethylenediaminetetraacetic acid (EDTA) tubes from each patient and viral 
samples were designated 05ZAFV01 through 05ZAFV31. The plasma viral load, 
the CD4+ T cell counts and individual clinical status were obtained from the 
hospital patient file (Table 2.1). 
2.3.2 Processing of patient samples 
Patient whole blood was centrifuged at 1 400 rpm for 10 minutes. The patient 
plasma was removed in 1 ml aliquots and stored in liquid nitrogen until used. The 
patient PBMCs were then isolated from the remainder blood as described in 
section 2.3.3.1. Patient HIV-1 PBMCs were stored in 1 ml aliquots in a freezing 
mix (50% FCS, 40% RPMI. 10% DMSO (dimethylsulphoxide)) (Sigma, 
Steinheim, Germany). Initially, the infected PBMCs were stored in a slow-freezing 
stratacooler and after 48 hours, they were relocated into a liquid nitrogen freezer (-
130°C), until further use. A 1 ml aliquot of patient PBMCs was used in subsequent 
viral infections (primary viral isolation). 
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2.3.3 Primary HIV-1 Viral Isolation 
2.3.3.1 PBMC Isolation from HIV negative Blood Donor 
Leukocyte enriched whole HIV-1 negative blood (buffy coats) were received 
weekly from the South African National Blood Service (SANBS). These buffy 
coats were depleted of 80-90% of the red blood cells (RBC) and most of the 
plasma had been removed prior to receiving the packs. Random blood donor’s 
PBMCs from two HIV-1 negative donors were isolated using Ficoll-Hypaque 
(Amersham Pharmacia Biotech, Uppsala, Sweden). Two donors were used to 
culture primary virus so as to exclude for host effects. The buffy coats were 
initially decanted into sterile 50 ml NUNC tubes (AEC Amersham, Freiburg, 
Germany) and centrifuged for 10 minutes at  1 200 rpm in an Eppendorf 
Centrifuge 5810 R (Eppendorf, Hamburg, Germany). Remaining plasma was 
removed from each donor and the buffy coat layer was gently layered onto 15 ml 
Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden) and centrifuged 
for 30 minutes at 1 500 rpm without a brake. The PBMCs were transferred into a 
new sterile 50 ml NUNC tube and washed twice, or until clear, in 45 ml of 1 x 
Phosphate Buffered Saline (PBS) (Sigma, Steinheim, Germany) at 1 200 rpm for 
10 minutes. The washed PBMC cell pellet was resuspended in appropriate growth 
medium (described below) and counted manually in 0.4% trypan blue (Sigma, 
Steinheim, Germany) using a haemocytometer. 
Donor PBMCs were cultured in supplemented RPMI growth medium [Roswell 
Park Memorial Institute (RPMI)-1640 medium (Sigma, Steinheim, Germany) 
supplemented with 10% fetal calf serum (FCS) (Gibco, Grand Island, USA), L-
Glutamine (2 mM) (Gibco, Grand Island, USA) and penicillin (0.5 
U/ml)/streptomycin (0.5 U/ml) antibiotics (Gibco, Grand Island, USA)]. Both 
donor cell isolations were adjusted to a final cell concentration of 2 x 106 cells/ml 
and each donor PBMC suspension was maintained separately in 75 cm2 sterile 
NUNC flasks (AEC Amersham, Freiburg, Germany). A final concentration of 1 
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µg/ml of phytohaemagglutinin (PHA) was added to the isolated PBMCs to induce 
T Cell proliferation by upregulating the host Interleukin-2, human (IL-2) 
membrane receptor [391], and incubated at 37°C with 5% CO2.  Three days post 
stimulation the PHA containing medium was removed, and five percent IL-2 
(Roche Diagnostics, Mannheim, Germany) was added to the supplemented RPMI 
growth medium for stimulation of cell growth during isolation. The two isolated 
donor PBMCs were mixed together and used in subsequent co-culture 
experiments.  
2.3.3.2 Isolation of Primary HIV-1  
The PBMCs from each patient within the cohort were isolated with the same 
technique as described for the HIV-1 negative donor PBMCs (section 2.3.3.1), 
however, starting volumes of whole blood were only 5ml and the subsequent steps 
in the isolation process were adjusted for this decrease in starting volume. Primary 
virus was generated by coculturing 2 x 106 cells/ml isolated patient PBMCs with 2 
x 106 cells/ml PHA-activated donor PBMCs in 5ml RPMI growth medium, 
supplemented with 5% IL-2 (described in section 2.3.3.1) in 25 cm2 sterile tissue 
culture flasks (AEC Amersham, Freiburg, Germany). All virus-containing 
supernatants were centrifuged to remove any contaminating cellular debris, 
aliquoted into 1 ml volumes in 2 ml NUNC storage vials (AEC Amersham, 
Freiburg, Germany). Vials were initially stored at -70°C for 24 hours and then 
stored in liquid nitrogen until further use in subsequent studies. 
The T25 flasks containing the first passage (P1) of primary virus co-culture with 
patient and donor PBMCs, were incubated at 37°C with 5% CO2 for up to 28 days. 
The viral isolates were maintained by replacing 50% of the total volume of culture 
medium with fresh medium containing IL-2 (Roche Diagnostics, Mannheim, 
Germany) on days 4, 10, 17 and 24 and with PHA-stimulated donor PBMCs on 
days 7, 14, 21 and 28. The primary viral cultures were monitored weekly (days 7, 
14, 21 and 28) for viral growth indicated by the rise in p24 antigen. The Murex p24 
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enzyme-linked immunosorbent assay (ELISA) kit (Abbot Murex, Dartford, UK) 
was used to monitor the p24 Antigen (Ag) level of the infections (see section 
2.3.4). When cultures yielded negative p24 Ag readings by day 28, they were 
discarded. However, when cultures reached high levels of p24 Ag, they were 
expanded into 10 ml of RPMI growth medium. Once the expanded cultures yielded 
high viral titer, they were centrifuged at 1 400 rpm, and the infected primary 
PBMCs and infected supernatants were stored as above for patient PBMCs and 
viral supernatant.    
A working virus stock (second passage; P2) of the primary virus was performed by 
adding 500 µl of high viral titer P1 supernatant to 20 ml of 2 x106 cell/ml mixed 
donor PHA-stimulated PBMCs. The expanded P2 cultures were also incubated at 
37°C with 5% CO2 for a maximum of 28 days, and monitored for viral growth as 
described for the P1 culture propagation. The infected PBMCs and culture 
supernatant were harvested in the manner mentioned above and stored at -130°C 
and -70°C, respectively. 
2.3.4  Murex p24 HIV-1 Antigen ELISA 
The Murex p24 ELISA kit (Abbot Murex, Dartford, UK) was used to monitor the 
p24 level as an indicator of viral growth in all PBMCs co-culture experiments and 
in cell line supernatants as per manufacturers’ instructions. 
2.3.4.1 Primary antibody 
The 20 x concentrated biotinylated murine anti-p24 monoclonal antibody 
(conjugate 1 – primary antibody) was diluted twenty times by adding aggregated 
human IgG in phosphate buffer (conjugate diluent 1). The diluted conjugate one 
was mixed in a 1:1 ratio with NP40, containing a bovine aprotinin protease 
inhibitor and casein stabilizer, to form the conjugate working solution. One 
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hundred µl of the conjugate working solution was added to each of the test wells 
used and 100 µl of each viral supernatant and the controls were added to each well. 
The working solution was mixed with the viral supernatant/control by gently 
pipetting up and down 5 times with the multi-channel pipette. The strips were 
covered with an adhesive plastic plate sealer for prevention of sample evaporation 
and cross-over contamination between wells. The plate was placed in the 5% C02 
incubator for 1 hour at 37°C. 
2.3.4.2 Secondary Antibody 
After the first 1 hour incubation period, the adhesive plastic seal was removed and 
the strips were washed 5 times with the 1 x phosphate buffer wash fluid using the 
plate washer (ELX 50 Autostrip washer, Bio-tek Instruments, South Africa). The 
secondary antibody (conjugate 2 – peroxidase conjugated streptavidin) was diluted 
100 x with phosphate buffer (conjugate diluent 2). Two hundred microlitres of 1 x 
peroxidase conjugated to streptavidin was added to each well and a new adhesive 
plastic plate sealer was applied to the strips. The plate was again placed in the 
37°C 5% C02 incubator for 30 minutes. 
2.3.4.3 Adding the substrate 
After the second incubation period the plate was washed 5 times in the phosphate 
wash buffer. Two hundred µl of 1 x tetramethylbenzidine (TMB) dissolved in 
dimethyl sulphoxide (DMSO) was then added to each well and allowed to incubate 
for 30 minutes at room temperature (15 – 30°C). 
2.3.4.4 Absorbance Reading 
The ELISA was stopped by adding 50 µl of 1M Sulphuric acid (H2SO4) to each 
well after the last room temperature incubation period. H2SO4 (1M) was added to 
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each well in the same order and the same time intervals as was used when the 
substrate was added. The reaction was allowed between 5 and 10 minutes to stop 
and the strip holder was gently tapped to ensure thorough mixing of the solutions. 
The absorbance of the solutions is each well was read at 450 nm referenced against 
690 nm using the plate reader (ELX 808, Bio-tek Instruments, South Africa). The 
instrument was blanked against air. A positive and negative control was included 
into every p24 ELISA that was performed. The positive and negative control 
solutions were standard solutions provided within the kit, containing recombinant 
p24 Ag in solution and human serum negative for HIV-1 antigens, respectively.  
2.3.5 MT-2 Phenotypic Assay 
The NSI/SI phenotypes of all patient primary isolates (P2), were determined by 
growth in MT-2 cell lines (obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Douglas Richman 
[392, 393]). The cells were maintained in supplemented RPMI growth medium, 
and infections were performed with 5 x 104 cells/ml that had been pre-seeded 
overnight in 24 well NUNC culture plates (AEC Amersham, Freiburg, Germany). 
Infections were performed by adding 50 µl P2 cell-free supernatant of each HIV-1 
isolate to the cells to a final volume of 2 ml supplemented RPMI growth medium. 
The cultures were monitored daily for cytopathic effects (CPEs) (e.g. syncytia) for 
up to 2 weeks in a 37°C, 5% C02 incubator. Syncytia are defined and presented as 
“balloon-like” large cells that form when T-tropic viruses infect host cells. Viruses 
were termed syncytium inducing (SI) if they successfully infected the cells and 
formed syncytia (T-Tropic) and termed non-syncytium inducing (NSI) 
(Macrophage tropic) if no cellular infection/cytopathic effects were observed. Both 
R5 (HIV-1 96ZM651, negative control) and R5X4 (HIV-1 96USNG31, positive 
control) viruses were included in the MT-2 assay. Viruses were obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH HIV-1 96ZM651 (Subtype C) from Dr. Feng Gao and Dr. Beatrice Hahn and 
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a dual tropic HIV-1 96USNG31 (Subtype C) from Drs. D. Ellenberger, P. Sullivan, 
and R.B. Lal [394];.  
2.3.6 U87.CD4 Coreceptor Assay 
Viral coreceptor usage biotype was determined for each isolate by measuring viral 
replication in U87.CD4 cells transfected with either CCR5 or CXCR4 coreceptors 
independently. The U87.CD4.CCR5 and U87.CD4.CXCR4 cell lines were 
obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH, from Dr. Hong Kui Deng and Dr. Dan R. Littman [227]. 
These cells were maintained in supplemented DMEM growth medium [Dulbecco’s 
Modified Eagle’s medium (DMEM) (Sigma, Steinheim, Germany), 10% fetal calf 
serum (FCS) (Gibco, Grand Island, USA), L-Glutamine (2 mM) (Gibco, Grand 
Island, USA) and penicillin (0.5 U/ml)/streptomycin (0.5 U/ml) antibiotics (Gibco, 
Grand Island, USA) additionally supplemented with G418 (500 µg/ml) and 
puromycin (1 µg/ml) (Sigma, Steinheim, Germany)] in a 37°C, 5% C02 incubator.  
When the cells reached 100% confluency (a monolayer of cells within the flask), a 
1% solution of 0.5 M EDTA (SIGMA, Steinheim, Germany) in 1 X Phosphate 
Buffered Saline (PBS) (SIGMA, Steinheim, Germany) solution was used to disrupt 
the adherent cells for cell splitting purposes. The cells were split in a 1:8 ratio 
twice per week and were only maintained for a maximum of 20 passages. 
Thereafter, a fresh vial of cells from the liquid nitrogen storage freezer (-130°C) 
was used to establish a new cell line. Cell lines were stored in a freezing mix at -
130°C (see section 2.3.2). 
The same positive controls used in the MT-2 assay were also used in the U87 
assay. The cells were seeded at 5 x 104 cells/ml in 24 well NUNC culture plates 
(AEC Amersham, Freiburg, Germany), and left to adhere overnight. Coreceptor 
utilization was determined by adding 100 µl of each of the P2 infectious primary 
viral stocks to corresponding wells the following day and left to infect the cells 
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overnight for 16-18 hours. The infected cells were then washed four times with 1 x 
PBS (Sigma, Steinheim, Germany) and 1 ml of the supplemented DMEM growth 
medium was added to each well. Infections were incubated at 37°C in a 5% C02 
incubator.  Each infected well was visually monitored daily for CPEs and viral 
supernatant samples were harvested on days 3, 5, 7, 9, 11, 13, 15 and 17 post-
infection and stored at -70°C for subsequent p24 antigen determinations. Isolates 
that induced syncytia formation and yielded an increase in p24 Ag concentration 
were considered positive for viral growth.   
2.3.7 Proviral DNA Extraction from PBMCs 
DNA was extracted from the HIV-1 infected primary co-cultured PBMCs (P2) 
using a High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) 
according to manufacturer’s instructions. Firstly, 200 µl of primary cultured 
PBMCs were added to 200 µl of binding buffer and 40 µl of Proteinase K to induce 
lysis of the cultures cells and the sample mixture was incubated at 72ºC for 10 
minutes. One hundred microlitres of isopropanol (Merck, Merck Chemicals and 
Laboratory Supplies, South Africa) was then added to the samples post incubation, 
samples were mixed well and the entire mixture transferred to the High Pure Filter 
Tubes and centrifuged for 1 minute at 8000 rpm in an Eppendorf Centrifuge 5810 
R (Eppendorf, Hamburg, Germany). The nucleic acids bind to the glass fibers 
packed into the High Pure Filter Tubes. After centrifugation, the flow through 
solution was discarded, a new collection tube was attached and 500 µl of inhibitor 
removal buffer was added and centrifuged under the same conditions. The inhibitor 
removal buffer eliminates any Polymerase Chain Reaction (PCR) inhibitory 
contaminants. After centrifugation the flow through solution was again discarded 
and a new tube attached. The nucleic acids bound to the glass fibers were washed 
and purified from any cellular impurities as 500 µl wash buffer was added, and 
centrifuged under the same conditions. The wash step was repeated twice to ensure 
complete removal of all residual wash buffer, the tube was further centrifuged at 
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13000 rpm for 10 seconds. After each centrifugation step the flow through tube 
was discarded and replaced with a clean collection tube. Lastly, the column was 
inserted into a sterile 1.5ml reaction tube and 200 µl of the pre-warmed (70°C) low 
salt elution buffer was added to recover the nucleic acids from the column and 
centrifuged at 8000 rpm for 1 minute. The isolated proviral DNA was stored at -
20ºC until required. 
2.3.8 Nested Conventional PCR 
The extracted proviral DNA from Section 2.3.7 was amplified by a nested PCR 
reaction to obtain the full-length viral gp160 gene using the Expand High 
FidelityPLUS PCR System (Roche Diagnostics, Mannheim, Germany). Subtype C 
env specific primers were designed using env primers previously described in Gao 
et al., [395] by comparing them to 52 complete HIV-1 Subtype C genomic 
sequences (K. Michler, pers. comm.). The sequences were obtained from the NLM 
nucleotide database [396]. The primer concentrations were adjusted to final 
concentrations of 0.4 µM (10 ρmol/µl) and the deoxy Nucleotide Triphosphate 
(dNTP) final concentrations were 200 µM. Each 50 µl PCR Reaction contained 5 
µl of 100 fold diluted proviral DNA template, 2.5 U Expand High FidelityPLUS Taq 
DNA Polymerase with appropriate 5 X Expand High FidelityPLUS Reaction Buffer, 
1.5 mM MgCl2, DNase-free and RNase-free water up to the final volume. Twenty 
full-length env genes were successfully amplified by nested PCR performed on 
proviral DNA, using outer (env A-1 and env N-1) and inner primer sets (env B-1 
and env M-1). The first round of outer primers, env A-1 (5’- GGC TTA GGC ATT 
TCC TAT GGC AGG AAG AA -3’) and env N-1 (5’- TTG CCA ATC AGG GAA 
GAA GCC TTG TGT -3’) were used to amplify a 3.2 kb fragment. Amplification 
for the first round had the following cycling conditions; 94°C for 3 minutes, 30 
cycles of 94°C for 15 seconds, 61°C for 30 seconds and 72°C for 3 minutes. A 
final extension was performed at 72°C for 10 minutes followed by a final storage 
at 4°C.  
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The same concentration of primers were used for the second round, as in the first 
round of the nested amplification, using inner primer sequences env B-1 (5’- GGA 
AAG AGC AGA AGA CAG TGG CAA TGA -3’) env M-1 (5’- TAA CCC ATC 
CAG TCC CCC CTT TTC TTT TA –3’) to amplify an approximately 2.7 kb 
fragment. The thermal cycling conditions for the second round were the same as 
for the first round except the denaturation time was increased to 30 seconds and the 
annealing temperature was decreased to 55°C for 45 seconds. All PCR reactions 
were performed on a Bio-Rad MyCyclerTM (Bio-Rad, CA). PCR products were 
pooled and purified using a High Pure PCR Product Purification Kit (Roche 
Diagnostics, Penzberg, Germany) as per manufacturers’ instructions (see section 
2.3.10). 
2.3.9 Agarose Gel Electrophoresis 
The PCR products were resolved on a low density 0,8 % TAE agarose (Sigma, St 
Louis, MO) gel (Appendix D). The solution was heated until the agarose beads 
were fully dissolved and allowed to cool before 5 µl/100 ml solution (EtBr – 0.5 
µg/mL– Promega, WI, USA) was added. Five - 10 µl of each sample was mixed 
with loading dye (see Appendix D) and was loaded into wells in an agarose gel and 
the DNA fragments were separated using electrophoresis for approximately 45 
minutes – 1 hour at 60-80 V and then subjected to UV transillumination to 
visualize the DNA bands. The band size yielded approximately 2.7 - 3 kilobases 
(kb) in length, when compared to the Quick-LoadTM 1kb DNA ladder (New 
England Biolabs, Ipswitch, MA) and samples were subsequently used for 
sequencing. 
2.3.10 PCR Product Purification 
Successfully amplified gp160 templates were cleaned using the HighPure PCR 
Product Purification Kit, according to the manufacture’s recommended protocol 
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(Roche Diagnostics, Mannheim, Germany). Firstly, 500 µl of Binding Buffer was 
added to each 100 µl PCR reaction tube containing the gp160 PCR product from 
all 20 samples, and mixed well. This product was gently added into the upper 
reservoir of a HighPure filter tube resting within a collection tube and centrifuged 
for 1 minute at 13 000 rpm at room temperature. The flow through solution was 
discarded and the same collection tube was re-connected. Five hundred microlitres 
of the Wash Solution was added into the HighPure upper reservoir and centrifuged 
under the same conditions. The flow through solution was again discarded and the 
tube was re-attached to the High Pure filter tube. A further 200 µl of the wash 
buffer was added to the upper reservoir and centrifuged under the same conditions 
so as to ensure that all impurities and wash buffer have been removed from the 
glass fibers in the filter. The collection tube was finally discarded with the flow 
through solution and a new collection tube was attached onto the High Pure filter 
tube. Elution Buffer (100 µl) was added to the empty upper reservoir and 
centrifuged under the same conditions, which yielded 100 µl of purified DNA, 
stored at -20°C until further use. 
2.3.11 Sequencing  
2.3.11.1 Thermal Cycle Sequencing of the gp160 region 
V3 loop specific population based sequencing of the purified second round gp160 
amplicons of 20 HIV-1 viral isolates was performed using 5 primers in order to 
obtain double-stranded sequence in both forward and reverse directions for all 
amplicons. The following sequencing primers spanning the V3 loop region (~700 
bp) were: AA1570 (5’-GGA GCA GCA GGA AGC ACT ATG GGC-3’), AES6 
(5’-GGA CAA GCA TTC TAT GCA ACA GGT G-3’), Env 1f (5’-CCA TAA 
CAC AAG CCT GTC CAA AGG-5’), Env f (5’-CTG TAG AAA TTG TGT GTA 
CAAGAC CC-3’), and E16 (5’-CCA ATT CCC ATA CAT TAT TGT G-3’). 
Sequencing reactions were set up in 21 µl and each reaction contained 20-50 ng of 
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DNA, 4 µl Big Dye ® Terminator Version 3.1 Cycle Sequencing kit, 1x BigDye 
Sequencing Buffer, 1 µl of sequencing primer (3.2 ρmol/µl) and the reaction was 
made up with dH2O to the final volume (Applied BioSystems, Foster City, CA). 
The sequencing reactions were amplified in the Bio-Rad MyCyclerTM 
thermocycler machine (Bio-Rad, Hercules, CA), cycling for 25 cycles for 10 
seconds at 96°C , 5 seconds at 50°C and 4 minutes at 60°C. The final incubation 
was set at 4°C. Sequencing reactions were cleaned immediately.  
2.3.11.2 Isopropanol Purification 
All sequencing reaction extension products were purified after the cycle 
sequencing reaction using Isopropanol precipitation (Merck, Merck Chemicals and 
Laboratory Supplies, South Africa). Each sample was carefully transferred to a 96 
well optical sequencing reaction plate and unincorporated ddNTPs were removed 
by adding 80 µl of 80% Isopropanol to each well in preparation for capillary 
electrophoresis. The sequencing plate was incubated in the dark for 15 minutes 
prior to centrifugation at 3 200 rpm at 4°C for 45 minutes to pellet the sequence 
amplicon. Immediately after centrifugation, the sequencing plate was carefully 
inverted onto a sterile pad of paper towelling and centrifuged in the inverted 
position for 1 minute at 1 900 rpm, so as to remove residual isopropanol. The plate 
was allowed to air dry for two minutes, after which the pellet was re-suspended in 
10 µl of Hi-DiTM Formamide (Applied Biosystems, Warrington, UK). 
2.3.11.3 Sequencing Electrophoresis 
Capillary Electrophoresis was performed on all the 20 amplicons on the ABI 
PRISM 3100 automated Genetic Analyzer (Applied BioSystems, Foster City, CA) 
in MicroAmp 96 well optical reaction plates. The sequence data was edited using 
the Sequence Analysis V3.3 program (Applied Biosystems) and the V3 sequences 
were assembled using Sequencher V4.5 (Genecodes, Ann Arbor, MI).  
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2.3.12 Subtyping and amino acid sequence analysis 
A phylogenetic tree was constructed by performing a Clustal X multiple alignment 
of the nucleotide V3 loop regions with several subtype C reference sequences and 
sequences from HIV-1 subtype A-K from the Los Alamos HIV Sequence database 
[46]. Phylogenetic reconstruction of the nucleotide sequences was also performed 
by Neighbour-Joining using the Kimura two-parameter distance matrix. Data was 
converted to the MEGA V3.0 format, compatible for phylogenetic and molecular 
evolutionary relationship analyses. The reliability of the branching order was 
estimated from 100 bootstrap replicates with values > 70% considered significant 
[397]. 
The predicted amino acid sequences were aligned with a consensus C sequence   
and extensively analyzed. The C-PSSM bioinformatic phenotype prediction 
software was used to analyze all novel 20 HIV-1 Subtype C V3 sequences to 
determine the accuracy of the prediction method to determine viral phenotype. The 
algorithm was created by Mark Jenson [270] and the software is available online 
[398]. Finally, the N-linked glycosylation sites within the V3 loop of the dual 
tropic primary isolates were compared to dual tropic reference sequences from the 
Los Alamos sequence database of varying clades [46].  
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2.4 Results              
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2.4.1 Clinical baseline profiles of South African ARV drug-
naïve AIDS patients 
Epidemiological data of all ARV drug-naïve AIDS patients recruited over six 
months for the purposes of this study are shown in (Table 2.1). Due to poorly 
documented original patient files, not all of the clinical data from these patients 
was available. 
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Table 2.1 Epidemiological data of 31 AIDS patients attending a clinic in Johannesburg, South 
Africa. 
Isolate ID Age 
(years) 
Gender CD4 count 
(cells/ µl) 
Viral Load 
(RNA copies/ 
ml) 
Clinical status Primary 
Isolate 
(Y/N)  
05ZAFV01 34 F 464 NA NA N 
05ZAFV02 46 M 159 22 999 Asymptomatic Y 
05ZAFV03 28 F 101 NA Oral Candidiasis; 
HSV; retinal necrosis 
Y 
05ZAFV04 26 F 274 75 000 NA N 
05ZAFV05 43 M 133 >750 000 Syphilis (Previously 
TB) 
Y 
05ZAFV06 28 M 187 179 000 Asymptomatic Y 
05ZAFV07 41 F 144 598 000 Asymptomatic Y 
05ZAFV08 44 F 130 660 000 Asymptomatic Y 
05ZAFV09 34 M NA 736 000 NA Y 
05ZAFV10 32 M 6 >750 000 On TB Treatment Y 
05ZAFV11 38 M 124 >750 000 Previously TB Y 
05ZAFV12 45 M 141 92 400 Previously TB Y 
05ZAFV13 32 F 85 378 000 Asymptomatic Y 
05ZAFV14 24 F 16 NA NA Y 
05ZAFV15 33 F 122 343 000 Vaginal Candidiasis; 
Previously TB 
Y 
05ZAFV16 33 M 295 >750 000 NA N 
05ZAFV17 43 M 183 16 400 NA N 
05ZAFV18 31 F 119 551 000 NA N 
05ZAFV19 62 F 153 133 000 NA N 
05ZAFV20 29 M 110 >750 000 NA Y 
05ZAFV21 42 F NA 19 500 NA N 
05ZAFV22 34 F NA NA Asymptomatic; 
Previously TB 
Y 
05ZAFV23 33 F 158 37 000 Asymptomatic Y 
05ZAFV24 31 F 219 52 300 NA N 
05ZAFV25 50 F 31 >750 000 Syphilis; Previously 
TB 
Y 
05ZAFV26 49 F NA NA Asymptomatic Y 
05ZAFV27 29 F 11 158 000 NA Y 
05ZAFV28 39 M 45 >750 000 On TB Treatment; 
PCP 
Y 
05ZAFV29 32 M 110 110 000 NA N 
05ZAFV30 31 F 145 NA NA N 
05ZAFV31 60 M 138 >750 000 NA N 
 
Abbreviations: TB, Tuberculosis; PCP, Pneumocytis carinii pneumonia; NA, Not available (due to 
poorly documented original patient files); M, male; F, female, Y, yes; N, no 
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2.4.2 HIV-1 primary virus Isolation 
HIV-1 was successfully isolated from the infected patient PBMCs using standard 
co-culture techniques with two different PHA-stimulated, HIV-1 negative donor 
PBMCs. Of the 31 patients analyzed within the cohort, 24 yielded successful 
primary viral isolates (isolation rate of 80%). Primary cultures were obtained for 
all 24 isolates within 28 days of infection. All the isolates, except 05ZAFV16 and 
05ZAFV18, reached the log growth phase within 14 days of co-culture, these two 
isolates were only considered positive for successful viral growth after four weeks 
of co-culture. Twenty isolates were randomly selected for further studies.  
2.4.3 Phenotyping of HIV-1 primary virus isolates  
The phenotype of each of the 20 selected viral isolates was determined using the 
MT-2 phenotypic assay. Of the 20 isolates, 14 isolates utilized CCR5 and exhibited 
the NSI phenotype in the MT-2 cell line. Six (30%) primary isolates were able to 
successfully grow in the MT-2 cells and formed syncytia, displaying the SI 
phenotype within 5 days post infection (Figure 2.1, Table 2.2).  
 
Figure 2.1 Cytopathic effects of the 05ZAFV03 isolate in MT-2 cells lines; (A) uninfected and 
(B) infected showing extensive formation of syncytia (see arrow), with marked ballooning at the 
edge of the clumps (200 X).  
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Table 2.2 Phenotype and biotype of the 20 HIV-1 ARV drug-naïve primary isolates. 
Isolate ID MT-2 Assay/Phenotype U87.CD4 Assay/Bio-type 
05ZAFV02 NSI R5 
05ZAFV03 SI X4 
05ZAFV05 NSI R5 
05ZAFV06 NSI R5 
05ZAFV07 NSI R5 
05ZAFV08 NSI R5 
05ZAFV09 NSI R5 
05ZAFV10 SI X4 
05ZAFV11 NSI R5 
05ZAFV12 NSI R5 
05ZAFV13 NSI R5 
05ZAFV14 SI X4 
05ZAFV15 SI R5X4 
05ZAFV20 NSI R5 
05ZAFV22 NSI R5 
05ZAFV23 NSI R5 
05ZAFV25 NSI R5 
05ZAFV26 SI X4 
05ZAFV27 SI R5X4 
05ZAFV28 NSI R5 
 
Abbreviations: SI – Syncytium Inducing; NSI – Non-syncytium inducing; R5 – CCR5 utilizing 
isolate; X4 – CXCR4 utilizing isolate 
2.4.4 Coreceptor Usage of HIV-1 primary virus isolates 
The results from the MT-2 assay were further confirmed with the 
U87.CD4.CCR5/CXCR4 assay. There was an absolute correlation between the 
NSI and SI phenotype of the isolates and their ability to grow in U87.CD4.CCR5 
or U87.CD4.CXCR4 cells, respectively (Table 2.2). The 14 NSI isolates replicated 
in the U87.CD4.CCR5 expressing cells and showed zero viral p24 antigen levels in 
the U87.CD4.CXCR4 cells; hence, they were designated as R5 viruses. All six SI 
isolates managed to successfully replicate in the U87.CD4.CXCR4 expressing 
cells (designated as X4 viruses). Interestingly, two (ZA05FV15 and ZA05FV27) 
SI isolates also successfully infected the U87.CD4.CCR5 cell line, and therefore 
were designated as R5X4/dual tropic viruses.  
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2.4.5 Full Length gp160 Amplification 
Proviral DNA from all 20 HIV-1 infected PBMCs from the co-culture experiments 
was successfully isolated and used to PCR amplify the gp160 region (~2.7 kb; 
Figure 2.2).  
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Figure 2.2 Representative electrophoresis gel of the PCR amplification of the envelope region 
(~2.7kb) from the HIV-1 subtype C isolates. Ten µl of second round PCR product was loaded onto 
a 0.8% Agarose gel. The sizes of the molecular weight marker (MW; 1kb Ladder, New England 
Biolabs) are indicated on the left. 
 
Initially, some samples failed to amplify the full gp160 fragment due to primers 
annealing at incorrect positions and sub-stringent PCR annealing temperatures etc. 
However, after subsequent repeated amplification, all the full-length gp160 2.7 kb 
fragments were obtained (results not shown). 
2.4.6 Genotypic characterization of primary virus isolates 
The V3 loop regions were successfully sequenced for all 20 isolates, and the 
nucleotide and amino acid sequences were extensively analyzed. Phylogenetic tree 
analysis confirmed that 19/20 of the newly characterized isolates clustered within 
HIV-1 subtype C (K. Michler, pers. comm.) (Figure 2.3). However, one isolate 
(ZA05FV10) clustered with subtype D reference sequences.   
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Figure 2.3 Phylogenetic relationships of the V3 loop regions (~100 bp) of Env from the 20 newly 
characterized HIV-1 primary viral isolates. Subtype reference sequences from the Los Alamos 
database are shown. Nineteen out of 20 of the isolates clustered distinctly with the subtype C 
reference sequences and one isolate, 05ZAFV10, was confirmed subtype D within the V3 loop.  
The phylogenetic tree was constructed from nucleotide sequences, using the neighbour-joining 
method and bootstrap values were used to estimate the stability of the nodes. Only bootstrap values 
of 70% or higher are shown. The phylogenetic analysis does not show all significant associations 
due to the relatively small fragment size. 
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The predicted V3 amino acid sequences were extensively analyzed and compared 
to determine differences between CCR5 and CXCR4 (Figure 2.4). The 20 env 
sequences (K. Michler, pers. comm.) were submitted to GenBank using Sequin 
V5.35 [396] and are available under the accession numbers DQ382361 – 
DQ382380 (see Appendix D).  
Isolate V3 loop sequence # aa Charge Phenotype Biotype 
Cons_C 
           11              25 
CTRPNNNTRKSIRI--GPGQTFYATGDIIGDIRQAHC 35 +5 NSI R5 
05ZAFV2 CTRPNNNTRKSVRI--GPGQTFYATGDIIGDIRQAYC 35 +1 NSI R5 
05ZAFV5 CTRPNNNTRKSVRI--GPGQTFYATGEIIGNIRQAHC 35 +4.5 NSI R5 
05ZAFV6 CARPGNNTRKSVRI--GPGQAFFATGDIIGNIRKAHC 35 +5.5 NSI R5 
05ZAFV7 CTRPGNNTRKSVRL--GPGQAFFATGDILGNIRQAHC 35 +4.5 NSI R5 
05ZAFV8 CTRHNNNTRKSVRI--GPGQTFYATGEIIGNIRQAHF 35 +5 NSI R5 
05ZAFV9 CTRPNNNTRKSMRI--GPGQTFFATGEIIGNIRQAHC 35 +4.5 NSI R5 
05ZAFV11 CIRPGNNTRKSIRI--GPGQAFYATGDIIGDIRQAHC 35 +3.5 NSI R5 
05ZAFV12 CTRPNNNTRKSVRI--GPGQTFYATGDIIGNIRQAHC 35 +4.5 NSI R5 
05ZAFV13 CARPGNNTRPSVRI--GPGQAFYATGEIIGNIRKAHC 35 +5.5 NSI R5 
05ZAFV20 CTRPNNNTRKSMRI--GPGQAFYAVGDIIGNIRQAHC 35 +4.5 NSI R5 
05ZAFV22 CTRPNNNTRRSIRI--GPGQTFYTN-DIIGNIRQAYC 34 +4 NSI R5 
05ZAFV23 CTRPGNNTRKSVRI--GPGQAFYATGDIIGNIREAHC 35 +3.5 NSI R5 
05ZAFV25 CTRPNNNTRKSVKI--GPGQTFYATGDIIGNIRQAHC 35 +4.5 NSI R5 
05ZAFV28 CTRPNNNTRTSVRI--GPGQAFYATNGIIGDIRQAHC 35 +3.5 NSI R5 
      
05ZAFV03 CPRPGNNTRKSVRIGIGPGLSFYATGKVLGNIRQARC 37 +8 SI X4 
05ZAFV10 CTRPYKSSRRRTHI--GTGQAWYTT-NIEGDIRKAHC 34 +6 SI X4 
05ZAFV14 CTRPANTKIKTLGI--GPGQTFRTVKKIIGNIRQSHC 35 +6.5 SI X4 
05ZAFV15 CARPNNNTRIHVRIGIGPGQTFYATGAIIGNIRQSHC 37 +5 SI R5/X4 
05ZAFV26 CTRPGKGKRTGVKI--GPGRTFYATGAVTGNIRKAHC 35 +8.5 SI X4 
05ZAFV27 CTRPSNNTRKRIRV--GPGQTVYATDAIIGDIRQAHC 35 +4.5 SI R5/X4 
 
Figure 2.4 Alignment of the predicted V3 amino acid sequences of 20 newly characterized South 
African HIV-1 subtype C and D (05ZAFV10) isolates (14 R5 and 6 R5X4/X4). The sequences are 
compared to a HIV-1 subtype C consensus sequence. The overall positive charge, number of amino 
acids and phenotype of each isolate is shown on the right. Dashes (-) indicate deletions/insertions, 
and positions 11 and 25 and the V3 crown/tip are highlighted. 
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Figure 2.5 Comparison of the (A) V3 loop net amino acid length and (B) net amino acid charge 
of the 20 HIV-1 subtype C CCR5 and CXCR4 utilizing isolates from this study. 
The predicted N-linked glycosylation sites (at position 6-8 within the V3 loop) 
were conserved for all 14 CCR5 utilizing HIV-1 subtype C primary isolates, and in 
three of the six CXCR4 utilizing isolates (05ZAFV03, 05ZAFV15 and 
05ZAFV27). 
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Isolate name/Reference 
sequence name 
V3 loop sequence Subtype Isolation 
Year 
Area 
05ZAFV15 
      6-8                  25 
CARPNNNTRIHVRIGIGPGQTFYATGAIIGNIRQSHC C 2005 ZA 
05ZAFV27 CTRPSNNTRKRIRV--GPGQTVYATDAIIGDIRQAHC C 2005 ZA 
     
ACH16810_P23 CTRPNNNIRKRIHI--GPGRAFYTTGQIIGNIRQAHC B NA NL 
ACH168_10P5 CTRPNNNIRKRIHI--GPGRAFYTTGQIIGNIRQAHC B NA NL 
DH12_3 CTRPNNNTRKGITL--GPGRVFYTTGEIVGDIRKAHC B 1991 US 
SC24_QH1520c_2 CTRPNNNTRKSIRM--GIRRAFYTREIIGDIRQAHC B NA TT 
SF2 CTRPNNNTRKSIYI--GPGRAFHTTGRIIGDIRKAHC B 1983 US 
RF CTRPNNNTRKSITK--GPGRVIYATGQIIGDIRKAHC B 1983 US 
P896 CTRPNNNTRRRLSI--GPGRAFYARRNIIGDIRQAHC B 1983 US 
99ZACM9 CARPGNNTIKRIRI--GPRYAFYAKETIIGDIRQAHC C 1999 ZA 
DU179 CTRPGNNTRKSIRI--GPGQAFYTNH-IIGDIRQAYC C 1999 ZA 
99ZASW20 CTRPNNNTRKSIRTGIGRGQTFYVTGQIIGDVRQAHC C 1999 ZA 
99ZASW30_b CTRPNNNTRKSVRIGIGRGHAFYTTGKVIGNIRQAHC C 1999 ZA 
99ZASW30_cl CTRPNNNTRKSVRIGIGRGLSFYTTGKVLGNIRQAHC C 1999 ZA 
92UG001 CTRPYYNQIRQ-RTSIGQGQALYTTRVTGDIRKAYC 
 
D 1992 UG 
 
(-) Indicates amino acids not present, NA – Not available; ZA – South Africa; NL – Netherland; TT – 
Trinidad and Tobago; US – United States; UG - Uganda 
 
Figure 2.6 Alignment of the predicted amino acid sequences of the V3 loop region of the two 
dual tropic primary isolates from this study and dual tropic reference sequences obtained from the 
Los Alamos database [47]. 
The length and charge of the V3 loops of all isolates in the study were compared 
(Figure 2.5) and CXCR4 usage was found to associate an increased overall 
positive charge as well as an increased length. The two dual tropic primary isolates 
showed similar motifs within their V3 loop regions when compared to some dual 
tropic reference sequences (Figure 2.6). 
2.4.7 Prediction of phenotype using C-PSSM 
The V3 loop sequences of all 20 isolates were analyzed using the C-PSSM 
algorithm scores [270] to predict the viral phenotype, and confirm the data 
obtained from the MT-2 and U87.CD4 biological assays. The C-PSSM 
bioinformatic algorithm predicted all of the six SI HIV-1 isolates with 100% 
accuracy. Only 12 of 14 (85.71%) NSI isolates were correctly predicted.
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Table 2.3 Raw data generated from the 20 HIV-1 subtype C isolates in this study 
from the C-PSSM phenotype prediction algorithm web site. 
Name Score
a
 Pred
b
 Geno
c
 
Pos 
Charge
d
 
Net 
Charge
e
 Percentile
f
 
Consensus -29.93 0 S/D 6 4 0.48 
       
05ZAFV02 -27.84 0 S/D 5 3 0.79 
05ZAFV05 -28.06 0 S/E 6 5 0.53 
05ZAFV06 -23.54 0 S/D 7 6 0.84 
05ZAFV07 § -20.03 1 S/D 6 5 0.85 
05ZAFV08 -23.29 0 S/E 7 6 0.76 
05ZAFV09 -27.96 0 SE 6 5 0.63 
05ZAFV11 -26.17 0 S/D 6 4 0.6 
05ZAFV12 -28.94 0 S/D 6 5 0.061 
05ZAFV13 § -20.97 1 S/E 6 5 0.81 
05ZAFV20 -25.28 0 S/D 6 5 0.67 
05ZAFV22 -26.78 0 S/D 5 4 0.94 
05ZAFV23 -27.07 0 S/D 6 4 0.74 
05ZAFV25 -25.77 0 S/D 6 5 0.62 
05ZAFV28 -25.11 0 S/G 5 5 0.68 
       
05ZAFV03 -7.51 1 S/K 7 7 1 
05ZAFV10 8.61 1 R/N 9 7 1 
05ZAFV14 10.18 1 T/K 8 8 1 
05ZAFV15 -13.6 1 R/A 6 6 0.97 
05ZAFV26 -2.1 1 G/A 9 9 0.96 
05ZAFV27 -19.19 1 R/A 7 5 0.83 
 
aC-PSSM score, b1 = CXCR4 use predicted; 0 = CCR5 use only predicted, cAmino acid residues at 
V3 sites 11 and 25, dTotal number of positively charged (R/K/H) amino acid residues, eNumber of 
positively charged (R/K/H) amino acid residues, minus number of negatively charged (D/E) 
residues, fIf this number is over 0.95 this sequence is most likely not a V3. 
§ Incorrect tropism predicted by the PSSM-C bioinformatic scoring system 
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2.5 Discussion 
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HIV-1 subtype C viruses circulating worldwide have previously been shown to 
almost exclusively utilize CCR5 as a coreceptor for cellular entry throughout all 
stages of disease progression, including early and late stage AIDS. Collectively, 
studies reporting these data were performed in a wide range of geographical areas 
predominantly driven by the HIV-1 subtype C epidemic, namely Malawi, Ethiopia, 
Zambia, Botswana, South Africa, Brazil, China, India, Israel and Thailand and 
Ghana which experience lower scale subtype C epidemics [200, 232, 239, 249-
261, 388, 389, 399]. This study reports the highest reported proportion and 
potential emergence/evolution of CXCR4 utilizing HIV-1 subtype C isolates in a 
South African ARV drug-naïve AIDS patient cohort.  
Primary virus was successfully isolated from 24 of 31 patient samples using 
standard co-culture techniques, yielding a viral isolation success rate of 80% 
(Table 2.1). This is a significantly high viral isolation rate of HIV-1 subtype C and 
greater isolation efficiency compared to other studies [251, 400]. This may be due 
to the fact that freshly isolated patient PBMCs were immediately used in 
infections. Possible reasons as to why seven isolates did not grow may be due to 
intrinsic characteristics of the patient virus, or an artefact of the randomly selected 
donor PBMCs; for instance, CD4+ and CD8+ T cell percentages within the donor 
PBMCs were not normalized, high CD8+ T cell counts may have inhibited 
isolation or suppressed viral replication kinetics [401]. Inhibitory cytokines and/or 
chemokines may have also contributed to the 20% of viral isolates that were not 
successfully isolated. Possible contribution of these factors was beyond the scope 
of our study. 
The 20 isolates selected for the purposes of this study were obtained from an AIDS 
patient cohort with nine male and eleven females, ranging from 24 to 50 years of 
age (Table 2.1). The CD4 counts ranged from six to 187 cells/µl, and viral loads 
from 22900 to >750 000 RNA copies/ml. When analyzing the opportunistic 
infections (OIs) found within our cohort, eight of the patients either currently had 
tuberculosis (TB) or had previously experienced TB infection, two patients 
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presented with oral and vaginal candiditis, one patient presented with syphilis and 
one with Pneumocytis carinii pneumonia (PCP). These data confirm that all the 
patients had AIDS, qualifying for the South African government ARV rollout 
program [16].    
Determination of the phenotype and coreceptor usage of the 20 primary virus 
isolates yielded unexpected findings in light of previously published data [164, 
232, 239, 249-261, 388-390]. Interestingly, 30% (6/20) of the isolates utilized 
CXCR4 for cell entry, while two of the six isolates were confirmed dual tropic, 
showing efficient replication in both the U87.CD4.CCR5 and U87.CD4.CXCR4 
cell lines. The remaining 14 (70%) isolates utilized the CCR5 coreceptor, as was 
expected from previously published data [232, 249-260, 388, 389]. This is the 
highest percentage of X4 usage in any described HIV-1 subtype C cohort 
worldwide.  
Since the primary isolates in this study were obtained from patient samples 
collected over a relatively short time period of 6 months, these data may suggest an 
on-going dynamic evolution of the env gene and the maturing of the HIV -1 
subtype C epidemic in South Africa. A striking contrast emerges as other studies 
have reported on HIV-1 subtype C coreceptor usage from samples collected over 
longer periods of time, decreasing the impact and relevance of their findings.  
McCormack et al., [239] reported that in the rural Karonga district of Malawi in 
Central Africa, 100% of the 152 HIV-1 positive subtype C samples, were 
identified as NSI, carrying the characteristic GPGQ crown motif in the V3 region. 
This study was performed over a period of 9 years (1981–1989), where the earliest 
subtype C sequence came from a sample collected in 1983 in the area [239]. Only 
5/29 (17%) of late stage AIDS patients yielded SI phenotypes in a recent study 
performed in South Africa [258]. This percentage of CXCR4 usage in this cohort is 
higher than other similar studies to date, however samples were collected over a 
period of two years (1998-2000) [258]. Another study performed on a cohort of 40 
perinatally infected children in South Africa found only 10% (4/40) of the isolates 
to be SI in the paediatric cohort, observed over four years (1998-2002) [252].  
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Contrary to other studies that have observed a high frequency of HIV-1 CXCR4 
variants, this study population had not received ARV drugs. Interestingly Johnston 
et al., [264] observed a high frequency [50% (10/20)] of SI CXCR4-utilizing HIV-
1 subtype C isolates in patients receiving ARV therapy [264].  
This novel and significant finding prompted further comparative analysis of the 
baseline patient profiles. To establish whether or not the increased CXCR4 usage 
was due to patient disease status, the CD4+ T cell counts and viral loads 
corresponding to the different viral tropisms, were compared. The six patients that 
displayed the SI phenotype in the MT-2 cell line, had low CD4+ T cell counts 
(ranging from 6 – 122 cells/µl; mean of 51.2 cells/µl). However these values were 
not significantly lower than the patients CD4+ T cell counts displaying NSI 
phenotypes (ranging from 31 – 187 cells/ µl; mean of 131.5 cells/µl).  
Similarly, viral loads among the patients with SI viruses (ranged from 158 000 – 
750 000 RNA copies/ml; mean of 417 000 RNA copies/ml) were not particularly 
higher in comparison to the patients with NSI viruses (ranged from 22 900 – 750 
000 RNA copies/ml; mean of 496 407 RNA copies/ml). Three of the patients 
harbouring SI viruses presented with clinical symptoms of HIV infection (AIDS), 
and one patient presented as an asymptomatic AIDS patient with no recorded OIs 
recorded at the time (Table 2.1). These findings are consistent with late stage HIV-
1 disease, and comparable to the clinical profiles of patients from which X4 
variants were isolated in previous studies. Thus, the detected X4 
emergence/evolution is not an artefact of the relatively low CD4+ T cell counts 
harboured by these patients. 
Overall, there does not seem to be any significant clinical differences between 
patients harbouring NSI or SI viruses, since no significant difference could be 
noted in patient age, gender, clinical presentation, CD4+ T cell count or viral load. 
Similar patient clinical baseline profiles were described in various studies 
investigating coreceptor utilization and disease progression, [249-256]. However, 
data from these studies on HIV-1 subtype C infected individuals, yielded almost 
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exclusive usage of CCR5 (under representation of CXCR4 usage) by the isolates, 
irrespective of HIV-1 disease status, CD4+ T cell count and viral load. Cecilia et 
al., [249] demonstrated that there was an exclusive prevalence of CCR5 usage by 
all the viral isolates at both ends of the disease spectrum, namely symptomatic 
(~33 CD4+ T cells/ml) and asymptomatic (~905 CD4+ T cells/ml). These findings 
support the argument that the evolution/emergence of CXCR4 utilizing HIV-1 
subtype C isolates and expansion of coreceptor usage, is neither associated with 
nor a prerequisite for progression of disease pathogenesis to AIDS. 
Phylogenetic analysis of the 20 HIV-1 V3 loop sequences revealed that 19 of the 
20 isolates clustered within HIV-1 subtype C reference, while 05ZAFV10 
clustered within subtype D (Figure 2.3). Further analysis of 05ZAFV10 in the vif, 
vpr and vpu [402] and pol and full-length gp160 (K. Michler, pers. comm.) 
revealed that 05ZAFV10 is a unique CD recombinant. There are two 
recombination breakpoints in the env region at nucleotide positions of 160 and 
1850 (results not shown). The nucleotide segments from 1 – 160 and 1850 – 2559 
were identified as subtype C and the middle segment from nucleotides 160 – 1850 
was classified as subtype D. Therefore, 05ZAFV10 appears to be an interesting 
recombinant strain, combining segments of subtype D that is typically found in 
West/West Central Africa, and subtype C, which is more common in Southern 
Africa [403]. Thus, this strain could have originated in West Central Africa, or it 
could represent a recombination event between a West Central African and South 
African strain.  
To establish whether we could distinguish between CCR5 and CXCR4 usage at the 
amino acid level, the tetramer crown motifs, positions 11 and 25 and N-linked 
glycosylation sites for each V3 loop of each isolate were extensively analyzed 
(Figure 2.4) and length and charge were compared (Figure 2.5). CXCR4 usage is 
associated with nucleotide sequence changes within the V3 loop region of env 
resulting in an increased overall positive charge as well as an increased length 
[201, 202, 229, 234, 404].  
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The majority of the CCR5 utilizing variants contained V3 loops of 35 amino acids 
in length, with the exception of 05ZAFV22 which had a single amino acid deletion 
at position 24 (Figure 2.5 (A)). However, the CXCR4 utilizing sequences consisted 
of 34-37 amino acids in length due to insertions and deletions (Figure 2.5 (A)). 
Two of the X4 isolates had extended V3 loop regions of 37 amino acids in length 
(05ZAFV03 and 05ZAFV15) and one had a shortened V3 loop of 34 amino acids 
(05ZAFV10). Interestingly, variations in the length of the V3 loop are generally 
considered to be associated with CXCR4 usage [236, 405].  
The V3 net charge for the CCR5 and CXCR4 utilizing isolates within this study 
were distinct with slight overlap (Figure 2.5 (B)). The six CXCR4 tropic viral 
isolates contained V3 loop sequences with a higher overall positive charge (≥ 4.5) 
and all of the X4 utilizing isolates had positively charged amino acids at position 
11 of the V3 loop, except for 05ZAFV03, possessing a serine (S). Basic/positively 
or neutral charged amino acid residue substitutions were detected at position 25 of 
all the X4 utilizing isolates, except 05ZAFV10 which had an asparagine (N).  
A comparison of the amino acids at position 25 of subtypes C and D in the 
databases confirm that N is rarely present at this site [51]. The CCR5 variants 
harboured amino acid charges ranging from +1  +5.5, with the majority of the 
isolates having a charge between +3.5 and +4.5. The CXCR4 variants harboured 
charges ranging from +4.5  +8.5, with an equal distribution over the range of 
charges (Figure 2.5 (B)). Interestingly, most of the R5X4 and X4 isolates had 
either a neutral or a positively charged amino acid residue at position 25. 
The amino acid position 11 and/or 25 within the V3 loop of gp120 are of particular 
importance in the coreceptor usage determination [201, 202, 229, 231, 234]. All 12 
R5 isolates possessed the characteristic GPGQ crown/tip motif and all R5 viruses 
had a neutral serine residue present at position 11, and amino acid residues with a 
negatively charged side chains (D or E) were present at position 25, except for 
05ZAFV28. Interestingly, four out of six X4 isolates exhibited changes in the V3 
tip tetramer motif, and two of the six varied from the consensus sequence due to 
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two amino acid insertions. One X4 isolate had a GRGL crown (05ZAFV03), one 
had GTGQ (05ZAFV10), one had GRGQ (05ZAFV15) and one had a GPGR motif 
(05ZAFV26).  
The N-linked glycosylation epitope (NNT) at positions 6 - 8 (corresponding to 
positions 300 to 303 in the prototypic HXBc2 gp120) within the V3 loop of Env in 
R5 HIV-1 variants is highly conserved, and shown to result in a decreased 
sensitivity of the virus to neutralizing antibodies [241, 242]. Many CCR5 utilizing 
viruses detected early in infection, contain this N-linked glycan, suggesting that it 
may be a pre-requisite for CCR5 usage [243]. During disease progression, the 
immune pressure against the HIV-1 virus decreases and CXCR4 variants have 
been shown to emerge, lacking this N-linked glycan [243, 406]. Mutational 
changes within this epitope are detected with a high frequency in SI variants, 
especially among the CXCR4-only utilizing variants. Thus, lack of a glycan at the 
N-terminal of the SI V3 loop, may alter the conformation of the envelope, 
increasing efficiency of the CXCR4 coreceptor usage and contribute to coreceptor 
switching from CXCR4 to dual/R5X4 usage [243, 279].  
All the R5 isolates from this study contained the highly conserved N-linked 
glycosylation motif, NNT, at positions 6 – 8 within the V3 loop. Polzer et al., 
[243] suggested that the presence of this NNT glycan in the V3 loop of R5 HIV-1 
isolates is involved with the interaction with the CCR5 coreceptor [243]. This is 
consistent with recent findings, which highlight the functional importance of this 
site for CCR5 usage, through masking the surrounding positively charged amino 
acids at the N-terminus of the V3 region  [222, 245, 407]. However, 50% of the 
subtype C CXCR4 utilizing isolates in this study did not contain the consensus V3 
N-liked glycan. The loss of this glycan in the V3 loop of the SI/X4 utilizing 
viruses may cause conformational changes that may further expose the V3 loop 
and therefore increase sensitivity of the isolate to neutralizing antibodies. Similar 
results were obtained in a previous report showing altered N-linked glycosylation 
sites in SI subtype C isolates [245, 257]. However, contrasting findings were made 
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by van Rensburg et al., [408] who found intact N-linked glycosylation sites within 
the V3 loops of their subtype C SI isolates [408].  
The mutational changes required for the loss of this N-linked glycan may further 
expose the coreceptor binding, expanding and increasing viral tropism and viral 
neutralizing sensitivity, respectively. Thus, as an infected individual experiences 
HIV-1 disease progression, immune pressure may subsequently decrease and allow 
for the emergence of isolates lacking the N-linked glycan and therefore able to 
utilize the CXCR4 coreceptor. A viral isolate lacking this V3 loop glycan may 
conformationally assist the steric binding of CXCR4 and thus contribute to the 
tropism switch from R5 to X4 virus [243, 279, 406].  
The fact that the two dual tropic isolates, ZA05FV15 and ZA05FV26, retained the 
N-linked glycan in the V3 loop structure may reinforce the hypothesis that the 
presence of the glycan constrains the envelope protein, promoting CCR5 binding. 
When comparing the two dual tropic isolate’s predicted V3 loop amino acid 
sequences from this study, to various V3 loop sequences of dual tropic isolates 
from the Los Alamos database, a striking similarity was found [47]. Ten out of 
thirteen (77%) of the subtype B, C and D dual tropic sequences retained the NNT 
N-linked glycosylation site within their V3 loop sequences (Figure 2.6).  
In summary, the HIV-1 subtype C CXCR4 utilizing variants showed an increased 
number of positively charged amino acids in their V3 loop and hypervariable V3 
loop length and a different tetrapeptide motif at the tip of the V3 loop, as has been 
described previously [236]. Interestingly, there were no striking sequence motifs 
within the V3 loop that could distinguish between dualtropic and CXCR4 utilizing 
viruses. 
The phenotypic coreceptor utilization assays (MT-2 and U87 cell line assays) 
initially flagged the CXCR4 using isolates from the cohort. Subsequent sequence 
analysis of the sequence data confirmed that the X4 isolates were both 
genotypically and phenotypically CXCR4 utilizing. One of the software-based 
phenotypic predictor packages (C-PSSM) was used to confirm the phenotypic 
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classification of the isolates [271]. To test the predictability and accuracy of a 
bioinformatic algorithm C-PSSM, the 20 HIV-1 V3 sequences were analyzed with 
the software. All the SI utilizing isolates were identified correctly; however, two 
R5 utilizing isolates were incorrectly identified as SI isolates (05ZAFV07 and 
05ZAFV13). A possible reason for the incorrect phenotype prediction of these two 
CCR5 utilizing isolates may be due to the insufficient data set available at the time 
of the development of this bioinformatic tool. It is possible that once more subtype 
C sequences and their corresponding tropisms are available in the C-PSSM 
analysis software, the prediction capability of this bioinformatics tool will 
improve. This implies that there is no current, infallible, suitable substitute for 
coreceptor determination, other than in vitro phenotypic determination assays. 
There was an incongruity between the overall charges of the V3 loop regions 
calculated in Figure 2.4 and Table 2.3. The C-PSSM software calculates the 
overall charge by minusing the number of positively charged (R/K/H) amino acid 
residues (each +1 in charge) from the number of negatively charged (D/E) residues 
(each –1 in charge) (Table 2.3). However, in Figure 2.4, the overall V3 loop charge 
was calculated as follows; D and E were each assigned a -1 charge, R and K were 
each assigned a +1 charge and H was assigned a +½ charge. Thus, the different V3 
loop charge outputs have different values yet reflect the same overall 
output/predicted phenotype. 
These data prompt many speculative rationales as to why this detected 
evolution/emergence of HIV-1 subtype C is noticeable in South Africa. The 
driving force for this emergence/evolution may be host or virus-dependent, or a 
complex interplay between the two. The genotypic and consequently phenotypic 
changes that are necessary for HIV-1 subtype C viruses to “switch” from CCR5 to 
CXCR4 tropic may only be a few amino acid changes within the V3 loop, as seen 
in HIV-1 and 2 [405, 409]. Considering the high mutation rate along the entire 
length of the genome being 3 x 10-5/base/replication cycle and the high replication 
rate [17, 21, 22, 26, 410], it is surprising that CXCR4 coreceptor binding 
preference is not detected earlier. Thus, the role of neutralizing antibodies and 
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other cellular host factors in preventing the emergence/evolution of X4 variants 
requires further investigation.  
Overall, these results imply that the frequency of HIV-1 subtype C CXCR4 
utilizing viruses may be increasing with time, as was previously documented in the 
CRF01_AE epidemic [411]. CXCR4 utilizing viruses began to appear with 
increased frequency within the HIV-1 subtype E (CRF01_AE) epidemic in 
Thailand that was initially defined by NSI/R5 isolates. Since the current study was 
cross-sectional, no conclusions about whether HIV-1 subtype C viruses can evolve 
from CCR5 to CXCR4 usage can be made. Future work should focus on 
longitudinal follow-up studies to determine whether env is capable of 
mutating/evolving from CCR5 usage to CXCR4 usage within the same drug-naïve 
patient over time, or whether CXCR4 utilizing viruses are inherently present from 
early infection. Furthermore, findings from this study need to be confirmed in a 
larger cohort. These results emphasize the importance for ongoing investigation of 
coreceptor usage of HIV-1 subtype C isolates particularly since it is likely that the 
next FDA approved antiviral drug will be the CCR5 antagonist, Maraviroc [265, 
272, 412, 413].   
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Chapter 3 IN VITRO ADAPTATION OF AN HIV-1 
SUBTYPE C CXCR4-UTILIZING ISOLATE 
TO CD4-INDEPENDENCE 
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3.1 Abstract 
The HIV-1 subtype C is the most prevalent subtype in the world and there is currently 
no preventative vaccine or curative drug against it. The HIV-1 envelope glycoprotein 
(Env) exists as a trimer on the viral surface and upon binding to CD4 on the host cell, a 
cascade of conformational changes occur within Env, exposing the conserved, 
vulnerable coreceptor binding site. These sites are the main targets for host induced 
neutralizing antibodies and are constitutively exposed in CD4-independent HIV-1 
isolates. A CXCR4 utilizing HIV-1 subtype C primary isolate was obtained from co-
culture of Peripheral Blood Mononuclear Cells (PBMCs) from an HIV-1 infected 
treatment-naïve AIDS patient. The isolate (05ZAFV03) was serially passaged 12 times 
in the Cf2Th cell line with an aim to gradually decrease numbers of CD4 expressing 
cells over time until the virus was fully adapted to CD4-independence. The virus 
successfully adapted and grew in Cf2Th cell cultures where only 10% of the cells co-
expressed CD4 and CXCR4. However, despite several attempts, growth in Cf2Th cells 
lacking CD4 was not achieved. Nucleotide and predicted amino acid sequence analysis 
was performed on the full-length env (gp160) from viruses for each of the serial 
passages selected for analysis. The sequences were compared with each other and to the 
parental primary sequence using phylogenetic methods. After serial in vitro viral 
passage, a bottleneck occurs and the env region remains relatively conserved, contrary 
to what was expected due to the high mutation and replication rate of HIV-1. A single 
non-synonymous nucleotide mutation was detected in the V1 loop region (E152K 
according to Consensus_C numbering) at 50% CD4 expression after four viral passages. 
All subsequent viral passages down to 10% CD4 expression retained the mutation. The 
E152K mutation may have conformational and steric implications for CD4 binding. 
Further adaptation towards 100% CD4-independence may depend on this mutation and 
possibly others that may expose the conserved coreceptor binding domain. Elucidating 
these conserved coreceptor binding domains may have profound implications for 
vaccine and novel drug target design. 
  
 
87 
3.2 Introduction 
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HIV entry into the host cell requires the initial interaction of viral gp120 with the 
host cellular primary receptor, CD4, and successive binding to the coreceptors 
CCR5 and/or CXCR4, respectively [56, 57, 66, 69-71, 77, 80, 164, 227, 228]. CD4 
binding is the first step in the entry process, and is necessary for HIV systemic 
infection in the peripheral cells of the host. Once gp120 interacts with the host 
CD4 receptor, a series of conformational changes within the heavily glycosylated 
gp120 are induced, exposing the conserved, high-affinity coreceptor binding sites 
thereby allowing CCR5 and/or CXCR4 coreceptor engagement [56, 71, 167, 175].  
Crystallographic structures of the gp120 core, the two amino-terminal domains 
(D1D2) of the CD4 and the antigen-binding fragment of the human neutralizing 
antibody 17b, have elucidated the interaction between gp120 and CD4 [66, 176]. 
The gp120 core consists of three major units, the inner and outer domains and the 
intervening bridging sheet, a four stranded β sheet comprised of conserved 
residues that links the two domains (Figure 3.1) [66]. CD4 is bound into a 
depression formed by all three of these units, particularly the V1 and V2 loops 
which contribute two loops of the bridging sheet upon direct interaction with CD4 
(Figure 1.5) [64, 66, 171, 414].  
Recently, the crystal structure of an unliganded, pre-CD4 fusion SIV gp120 core 
has been described (Figure 3.1) [82]. The inner domain of the heavily glycosylated 
gp120 undergoes extensive conformational rearrangements upon CD4 receptor 
binding. Extensive structural characterization and comparison between the 
unliganded pre-CD4 fusion SIV gp120 and the CD4-bound HIV-1 gp120 structure 
revealed four conserved inner-domain disulphide bonds that are critical in 
positioning structural elements involved in CD4 binding [82]. Despite the 
conserved coreceptor binding epitopes being hidden in the unliganded gp120 state, 
there are distinct antigenic surfaces on the gp120 that may also be targeted with 
entry inhibitors. 
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Figure 3.1 Unliganded SIV gp120 core structure. All carbohydrates are depicted as stick models 
and polypeptides as ribbons. The outer domain (in blue) and inner domain is coloured according to 
substructure (N terminus is orange; α1 is yellow; three-strand sheet is cyan; outer/inner domain 
transition is purple; α5 is green). The four strands that form the bridging sheet in the CD4-bound 
conformation are depicted (in red). Disordered residues are shown as dashed lines and the stumps 
of truncated variable loops V1, V2 and V3 are indicated and the intact variable loops V4 and V5 
are also labelled. Figure adapted from [82]. 
Within Env there are three distinct changes that take place during gp120-CD4 
binding; initially, the conserved bridging sheet pre-folds to expose/create the 
conserved coreceptor binding site [64, 66]. Next, the inner and outer domains are 
pulled towards each other. Finally the V1-V2 loops conformationally adjust to 
uncover the coreceptor binding site residues, increasing the affinity of the viral 
gp120 for the downstream binding of the CCR5/CXCR4 coreceptor [64, 66, 67, 
171, 414]. This conformational shift is fundamental in the determination and 
specificity of coreceptor utilization [163, 164, 167, 175, 415-419]. 
Crystallographic modelling of the gp120-CD4 interaction shows that only a small 
number of residues are actually involved in direct interatomic binding between the 
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two proteins [66]. The CD4 binding site in this model, is devoid of carbohydrate 
residues and consists of 26 specific residues within HIV-1 subtype B (HXBc2) 
Env, contacting 22 CD4 residues [66]. Six segments of gp120 are integrally 
involved in the interaction with the CD4 binding pocket. The representative 
contact residues are L125 (from the V1/V2 stem), N280 (from the LD), D368 
(from β15 to α3), W427 (from β20 – β21), D457 (from β23) and G473 (from β24 – 
α5) [66].  
While the CD4 and coreceptor binding sites within gp120 are not accessible and 
only exposed for very brief moments during viral entry, they are highly sensitive to 
neutralization by monoclonal antibodies [68, 283, 354, 414, 420, 421]. The 
envelope escapes this immune pressure through acquiring mutations, due to its 
highly error prone reverse transcriptase and high replication rate [22, 27]. The 
genetic diversity within the HIV Env allows adaptation to evade the immune 
system through changes in the variable loops, changes in tropism and acquisition 
of N-linked glycosylation sites. The glycans conceal the conserved CD4 binding 
and coreceptor binding epitopes, also contributing to the decreased viral 
susceptibility to host neutralizing antibodies [167, 169, 171, 176, 177, 422]. Thus, 
the neutralization-resistant state in wild type (wt) HIV-1 is maintained by CD4 
engagement prior to coreceptor utilization [355]. 
The 35 amino acid V3 loop also plays an important role in chemokine receptor 
binding and viral tropism; coreceptor specificity is largely determined by its 
sequence [164, 167, 414, 415, 417]. Huang et al., [174] recently revealed the 
crystal structure of gp120 with an intact V3 loop extending out from the envelope 
like a “molecular hook” towards the N-terminus of the CCR5 coreceptor. These 
crystallographic structures of gp120 also suggests that the CD4 and coreceptor 
binding domains are strategically hidden and poorly accessible within the Env 
trimer [66, 174]. 
Few primary HIV-2, SIV and some HIV-1 isolates naturally infect a variety of 
different cell types with little to no CD4 expression by interacting directly with the 
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coreceptor (Figure 3.2) [344-347]. These viruses are termed CD4-independent. 
This naturally occurring phenomenon is rare, however arises due to viral envelopes 
being “partially triggered”, allowing direct binding of the coreceptor to initiate host 
cell infection. Thus, the normal need for CD4 binding to induce the conformational 
changes in Env is avoided (Figure 3.2) [345, 346, 348-350]. 
 
Figure 3.2 Schematic illustration of the molecular arrangement of the gp120 proteins on the 
surface of the HIV-1 virion during CD dependent virus infection (A) and CD4-independent Viral 
infection (B). Figure adapted from [423].  
There are low/negligible levels of CD4 expression on cell types such as macaque 
and primate macrophages, microglia, oligodendrites, brain microvascular 
endothelial cells and perivascular macrophages found in the brain. Despite 
decreased CD4 expression, these cells are all permissive to SIV/HIV infection 
[308, 358-360, 424-429]. HIV-1 naturally enters the Central Nervous System 
(CNS) early after systemic infection, via crossing the blood-brain barrier, where 
antibodies are excluded, and infects cells in this immune privileged area. This 
results in neurological disease, ranging from minor cognitive/motor function 
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disorder, to severe HIV dementia (HIVD) and HIV-1 Associated Dementia 
Complex (HADC) [430, 431].  
Consequently, these CD4-independent viruses infect target cells with a much 
higher efficiency compared to wt viruses [363]. This is due to expression of gp120 
in a ‘pre-triggered’ state that results in a conformation where the coreceptor 
binding site is exposed, allowing a high affinity and direct interaction between the 
gp120 and the coreceptor. However, CD4-independent viruses with exposed, 
conserved coreceptor binding sites, exhibit heightened sensitivity to neutralizing 
antibodies and neutralization by HIV-1 positive sera, that recognize conserved 
epitopes which are essential for coreceptor engagement [351, 354-357, 432]. This 
occurrence suggests that the immune system may place a powerful selective 
pressure against the emergence/evolution of such viruses, which may be an 
explanation for the rarity of the CD4-independent phenotype in vivo, in the 
periphery [354]. 
CD4-independent Envs are thought to possess multiple amino acid substitutions 
and/or deletions compared to the CD4-dependent wt viruses. These mutations map 
over broad regions in env, encompassing areas required for coreceptor specificity. 
These changes ultimately lead to the exposure of conserved epitopes that mediate 
direct binding to the CCR5 and/or CXCR4 coreceptors [351]. However, the extent 
to which CD4-independent viruses enter cells via a CD4-independent mechanism 
and have an expanded tropism for CD4-negative cells in vivo is currently unclear. 
Several CD4-independent SIV, HIV-2 and HIV-1 isolates have been characterized 
in vivo. CD4-independent SIVs have a reduced affinity for CD4 and have been 
previously isolated from rapid progressor rhesus macaques [364]. Macrophages 
from these macaques express relatively low levels of CD4, and thus CD4-
independent SIV isolates have an increased capacity to infect CD4-negative, 
CCR5-positive macrophages [356, 357]. CD4-independent CCR5 chemokine 
utilization in vivo is relatively common in SIV and HIV-2 strains [345, 362, 363]. 
This has led to the speculation that CCR5 usage may have been the initial 
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prehistoric coreceptor used by primate lentiviruses [354] and the expanded tropism 
for CXCR4 usage may have evolved later, in humans.  
To date, the only HIV-1 primary isolate which has been shown to inefficiently 
infect CD4-negative, CCR5-positive cells, is R2, which exhibits a single rare 
mutation in the V3 loop of gp120 [365]. The CD4-independent phenotype was 
mapped to a single proline (P) substitution in the proximal limb of the V3 loop, 
(313-4 PM) [365]. Studies concerning CD4-independent HIV-2 confirm that there 
is also a direct interaction between CXCR4 and gp120, which allows for 
subsequent membrane fusion; this phenotype is correlated with mutations 
throughout env [346, 372].  
There have also been several reports of in vitro studies showing that strains of SIV, 
HIV-2 and laboratory adapted HIV-1 strains can bind either CXCR4 or CCR5 
coreceptors in the absence of CD4 [344-346, 349, 350, 367-371]. Zerhouni et al., 
[367] hypothesized that these CD4-independent quasispecies would exist at low 
concentrations (in primary culture) compared to the more abundant CD4-
dependent strains, and that they may be enriched through serial propagation [367]. 
However, infection of T cell lines lacking CD4 expression is much less efficient.  
CD4-independent HIV-1 (subtype B) and HIV-2 variants that utilize CXCR4 for 
cell entry have been previously derived in vitro by serial passage through T cells 
lacking CD4 [344, 350, 351]. The HIV-1 HXBc2 env clone (8x) variant was 
serially passaged and shown to successfully infect CD4-negative, CXCR4-positive 
BC7 cells [350, 351]. Sequence analysis of 8x revealed that gp120 was lacking 5 
glycosylation sites and harboured 18 mutations, resulting in a stably exposed 
coreceptor binding site [346, 350].  
Another CD4-independent HIV-1/IIIB variant was selected through repeated in 
vitro passage in CD4 negative T cell lines and utilized the CXCR4 coreceptor 
[369]. In general, few changes in the V3 loop sequence of gp120, around the base 
of the V4 and in the transmembrane gp41 were required to expose the coreceptor 
binding site [350, 373]. The literature reports that high affinity CXCR4 coreceptor 
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usage was also shown in CD4-independent HIV-2 variants, ROD/B and VCP [346, 
347, 369, 370, 372]. 
In contrast, CD4-independence in the HIV-1 m7NDK variant correlated with the 
crucial acquisition of two glycosylation sites in V1/V2 and 7 amino acid changes 
within the C2, V3 and C3 regions of env [344]. These changes are likely to be 
responsible for the spontaneous exposure and increased flexibility of the V3 loop 
that allows for direct interaction with CXCR4. A study was performed on a 
CXCR4 tropic HIV-1 iNDK recombinant clone in intestinal cells, derived from the 
same parental virus as the m7NDK variant. The clone showed the acquisition of 
two N-linked glycosylation sites in the V1/V2 region, 3 amino acid changes 
(296KYT  296NNI) in the V3 loop and the loss of one N-linked glycan from the 
C2 region [374]. The loss of the positive charge (K296N) within the V3 loop might 
have increased the Env hydrophobicity, and contributed to the direct binding of 
gp120 to the coreceptor. In all these cases, CD4-independence has been associated 
with the alteration of the N-linked glycosylation profile.  
CCR5 tropic, CD4-independent HIV-1, HIV-2 and SIV have also been reported. 
Kolchinsky et al., [349] found two sets of genotypic changes within env upon 
CD4-independent adaptation. The intact whole virus was not used for infections, 
rather the HIV-1 env was cloned into a pNL4-3 plasmid, to produce an infectious 
provirus [349]. The first change detected was a 10 residue sequence from the C-
terminal of the V2 loop into the V1/V2 stem (positions 188 – 197 in the HXBc2 
strain) and the second change was a conserved pair of adjacent residues (positions 
539 – 540 in the HXBc2 strain) in the gp41 ectodomain [349]. Here, the 
repositioning of the V2 loop is largely responsible for the major gp120 
conformational change in response to CD4 binding, and unmasking of the 
coreceptor binding site.  
An HIV-1 ADA variant, also described by Kolchinsky et al., [366], could infect 
cells via CCR5 in the absence of CD4 [366]. Removal of a single N-linked 
glycosylation site (N197) at the base of the V1/V2 region was found to be 
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responsible for this CD4-independent phenotype [366]. Structural models of gp120 
suggest that removal of this glycan probably results in the repositioning of the 
V1/V2 loops so as to expose the highly conserved coreceptor binding site [366]. 
This was supported by studies which showed that HIV-1 ADA and SIV variants 
with deleted V1/V2 loops, could infect CD4-negative CCR5 positive cells, and 
bind CCR5 directly [366].  
CD4-independent usage of the CCR5 coreceptor by an HIV-2/vcpm variant 
mapped to a positively charged amino acid in the C4 region of env [375]. There 
may be an electrostatic interaction between the negatively charged CCR5 amino 
acid and the positive residue within the C4 region [375]. The critical amino acid 
substitutions in env that were responsible for the CD4-independent phenotype in 
HIV-2 were shown to partially expose the coreceptor binding domains. 
CD4-independent infection of host cells, and infection with a reduced requirement 
for CD4 have been shown in SIV, and the most common utilized coreceptor is 
CCR5 [345, 357, 376-378]. Puffer et al., [379] determined that two amino acid 
changes are responsible for the CD4-independent phenotypic effects on the 
SIVmac239 Env [379]. These two changes include substitutions at M165I within 
the V1/V2 loop and K573T of gp41 that supposedly enhance coreceptor binding 
[379].  
The determinants for the CD4-independent phenotype are mapped to env, however 
the underlying mechanisms of this phenomenon are largely unknown. Taken 
together, the changes acquired by different HIV-1 env clones post CD4-
independent adaptation vary considerably between isolates. There does not seem to 
be a common, standard motif associated with env that is required for CD4-
independence. The changes observed in vitro may not be a direct reflection of the 
exact changes that are taking place in vivo, due to the lack of immune pressure in 
vitro. 
In general, mutations acquired by CD4-independent isolates in vitro can be divided 
into two distinct groups: those that harbor mutations (deletions/changes) in/around 
  
 
96 
the V1/V2 region causing downstream unmasking of the of the coreceptor binding 
site, and isolates which harbor mutations elsewhere in the envelope (gp41, V3, V4 
etc). The elucidation of this complex process and the many determinants for CD4-
independence may provide useful information pertaining to the exact step-wise 
process of CD4 binding, viral tropism and fusion. However, the clinical and 
pathogenic significance of HIV-1 CD4-independent infection is largely unknown 
due to their rarity and difficulty of isolating such viruses from primary culture. 
Many biochemical and crystallographic studies over the past few decades have 
provided detailed descriptions of the multifactorial complexity of viral entry into 
host cells. However, there are still many unanswered questions relating to the 
structural moieties and details of the dynamic conformational changes involved in 
the viral entry process into the host cell. An in depth understanding of the 
mechanism and specific resides involved in HIV-1 entry into host cells is 
paramount in developing immunological and pharmacological strategies to prevent 
infection.  
The evolution and occurrence of CD4-independent HIV-1 variants within infected 
individuals, ultimately expands viral tropism and target cell range in vivo. The 
mutations within the gp160 of the CD4-independent envelope allow exposure of 
the conserved coreceptor binding domains, and enhance fusogenicity with the host 
cell membrane. It is expected that the exposed conserved coreceptor binding sites 
of CD4-independent viruses may allow targeting of these immunogenically 
enhanced conserved neutralization epitopes. 
The CD4-independent, CCR5/CXCR4 dependent phenotype in HIV and SIV can 
thus be attributed to one of two changes in gp120; Firstly, insertions and/or 
deletions can cause repositioning of the variable V1/V2 loops so as to unmask the 
coreceptor binding site. Secondly, an accumulation of successive mutations in V3 
and the base of V4 might increase envelope affinity for coreceptor binding (or pre-
folding of the gp120 bridging sheet). Mutational changes in gp41 may also trigger 
conformational rearrangements and fusion to occur after a weaker gp120-
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coreceptor interaction [348]. In general, HIV-1 envelopes with decreased 
dependence on the primary CD4 receptor harbour altered glycosylation patterns. 
Thus, such viruses have partially triggered envelopes as a result of their adaptation 
to growth in cells of the CNS environment with decreased CD4 expression 
profiles. 
A number of potential sites may be identified/determined from neutralization-
sensitive Envs that can be used to generate effective immunogens. These 
prospective immunogens may be used for future vaccination studies and 
therapeutic intervention strategies that elicit broadly neutralizing antibodies. Small 
molecule inhibitors/compounds may also be designed to potently block the 
conserved coreceptor binding domains. To this end, the purpose of this study was 
to adapt an HIV-1 subtype C primary isolate/s to CD4-independence and to 
elucidate the residues that are responsible for this phenotype in the envelope 
glycoprotein/s.  
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3.2.1 Objectives  
The overall aim of this study was to adapt HIV-1 subtype C primary isolates to 
CD4-independence in vitro.  
This was attempted by the following three procedures:  
1. Adaptation of CCR5 and CXCR4 utilizing primary HIV-1 subtype C to the 
Cf2Th.CD4.CCR5 or Cf2Th.CD4.CXCR4 expressing cell lines 
respectively, as measured by p24 antigen ELISA. 
2. Adaptation of cell-line adapted viruses to decreasing concentrations of 
cellular expressed CD4 by serial passaging in cell cultures containing 
mixtures of Cf2Th.CD4.CCR5/CXCR4 and Cf2Th.CCR5/CXCR4, as 
determined by p24 antigen ELISA.  
3. Proviral DNA sequencing and extensive analysis of full-length Env 
nucleotide and amino acid sequences, from each successful serial passage 
to determine the changes associated with decreased dependence of CD4 
and/or CD4-independence. 
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3.3 Materials and Methods 
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3.3.1 Primary virus Selection 
Five CCR5 utilizing and five CXCR4 utilizing primary isolates were randomly 
selected for the purposes of this study (see Table 2.3) from the cohort (described in 
Section 2.3.1). These included 05ZAFV02, 05ZAFV03, 05ZAFV06, 05ZAFV10, 
05ZAFV11, 05ZAFV14, 05ZAFV15, 05ZAFV20, 05ZAFV22, 05ZAFV26, 
05ZAFV27 and 05ZAFV28. The passage 2 (P2) primary viral isolates were used in 
all experiments and each viral supernatant (1.5 ml) was added to 1.5 ml of sterile 
supplemented DMEM (Sigma, Steinheim, Germany) growth medium (described 
below) and filter sterilized through a 0.2 µm filter (Acrodisc PF Syringe Filter, Pall 
Corporation, UK) before infection. 
3.3.2 Thymocyte Cell Lines and Growth Conditions 
The Canine Thymocyte cell lines [433] (Cf2Th.CD4.CCR5 ; Cf2Th.CD4.CXCR4; 
Cf2Th.CCR5 and Cf2Th.CXCR4) were generous gifts from Joseph G. Sodroski, 
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts). 
These cells were maintained in supplemented DMEM growth medium [DMEM 
(Sigma, Steinheim, Germany) supplemented with 10% FCS, L-Glutamine (2 mM) 
(Gibco, Grand Island, USA) and penicillin (0.5 U/ml)/streptomycin (0.5 U/ml) 
antibiotics (Gibco, Grand Island, USA)]. The supplemented DMEM growth 
medium for the Cf2Th.CD4.CCR5 expressing cell lines, was additionally 
supplemented with G418 (500 µg/ml) (Calbiochem, Canada) and Hygromycin 
(150 µg/ml) (Calbiochem, Canada). The Cf2Th.CD4.CXCR4 expressing cell lines, 
were also grown in supplemented DMEM growth medium, additionally 
supplemented with Zeocin (300 µg/ml) (Invitrogen) and Hygromycin (150 µg/ml) 
(Calbiochem, Canada). The Cf2Th.CCR5 and Cf2Th.CXCR4 cell lines, were 
grown in supplemented DMEM growth medium and additionally supplemented 
with only G418 (500 µg/ml) (Calbiochem, Canada). 
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3.3.2.1 Basic Cell Growth and Storage 
All the cell lines were maintained in the supplemented DMEM growth medium 
with appropriate antibiotic supplements in T25 NUNC culture flasks (AEC 
Amersham, Denmark) in a 37°C, 5% C02 incubator. When the cells reached 100% 
confluency, they were split as described for the U87.CD4 cell line in section 2.3.6. 
A 1% solution of 0.5 M EDTA (SIGMA, Steinheim, Germany) in 1 X Phosphate 
Buffered Saline (PBS) (SIGMA, Steinheim, Germany) was also used to disrupt 
cell line adherent properties and cells were split in a 1:8 ratio twice per week, and 
where only maintained for a maximum of 20 passages. Cell lines were stored in a 
freezing mix in liquid nitrogen (see 2.3.3.2 in Chapter 2). 
3.3.3 Viral Infection of Thymocyte Cells 
Cf2Th cells were seeded either in T25 NUNC culture flasks (AEC Amersham, 
Denmark), or in 24 well flat-bottomed NUNC culture plates (AEC Amersham, 
Denmark). Cells for all infection experiments were plated at 5 x 104 cells/ml in 2 
ml of supplemented DMEM growth medium. The supplemented DMEM growth 
medium was additionally supplemented with the appropriate antibiotics. The 
following day, the supplemented DMEM growth medium was removed and 
between 70 - 500 µl of P2 viral supernatant, was added to the adherent cells with 
500 µl of supplemented DMEM growth medium, to prevent the cells from drying 
out, during infection. A maximum of ten wells were seeded and infected in the 
same way as in the T25 culture flasks, so as to allow for sampling each day post 
infection. The number of wells that were infected was limited by the volume of 
infectious viral supernatant that was available from the previous round of 
infections. Viral infections were incubated in a 37°C, in a 5% C02 incubator 
between 12-18 hours (overnight). The input virus was subsequently washed off 
gently four times with 1 x PBS (SIGMA, Steinheim, Germany) to remove unbound 
virus. Both the input virus and the 4th wash with 1 x PBS (SIGMA, Steinheim, 
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Germany) were stored at -80°C for further analysis by p24 Ag ELISA (Abbot 
Murex, Dartford, UK). Infections in the T25 culture flasks were split as required or 
when cells were confluent. 
Fresh supplemented DMEM growth medium (2 ml) was added to each well post 
washing with PBS. The wells were visually monitored for Cytopathic Effects 
(CPEs) daily. Viral supernatant (2 ml) and adherent cells were harvested from 
different wells on days 0, 3, 5, 7, 10, 11, 13, 15 and 17 post-infection and were 
stored at -80°C for subsequent p24 Antigen (Ag) ELISA analysis (Abbot Murex, 
Dartford, UK). However, for certain infections viral supernatant was sampled on 
different days.  
3.3.4 Murex p24 HIV-1 Antigen ELISA 
All culture supernatants (including input virus and the 4th PBS wash (controls)) 
were monitored by p24 Ag ELISA (Abbot Murex, Dartford, UK) measured by the 
plate reader (ELX 808, Bio-tek Instruments, South Africa) as described in Chapter 
2, section 2.3.4. Negative control wells were not infected with virus and performed 
for each separate infection. A positive control from the kit was also performed for 
every p24 ELISA.  
3.3.5 Adaptation to CD4-independence 
The experimental design described here was based on a previously published 
protocol [349] and initially a pilot study was performed to establish the most 
effective protocol for infection of the Canine Thymocyte (Cf2Th) cell lines. 
Initially 30 µl, 50 µl, 70 µl, 100 µl and 200 µl of filter sterilized infectious P2 viral 
supernatant was used to infect the cell lines in T25 NUNC culture flasks (AEC 
Amersham, Denmark). Each day post infection, 200 µl of supernatant was 
harvested for p24 Ag ELISA from the same flask. This method did not yield an 
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accurate reflection of the viral growth curve, because infectious virus was 
constantly being removed from the total viral population in the T25 flask. Thus, 24 
well NUNC culture plates (AEC Amersham, Denmark) were used for infections 
and viral supernatant and infected cells were removed from a separate well for 
each harvest on separate days. An infectious viral input volume of 70 - 200 µl was 
sufficient for successful infection.   
Infection of a particular cell line (e.g. Cf2Th.CD4.CXCR4) was repeated between 
2 and 4 passages to achieve stable infection in that cell line before infecting the 
next lowest concentration of CD4 expressing cells. Viral supernatants from 
infected wells, yielding absorbances reading “out of detection range” of the 
instrument (A450/630), were considered to be replication positive and capable of 
successfully infecting the next passage of the same cell line or the next cell line. 
Once stable infection within a certain cell line had been reached, viral supernatant 
yielding a high p24 Ag absorbance reading was then used to infect another passage 
of the same cell population as well as a population of cells expressing decreased 
levels of CD4, in parallel. Throughout the adaptation process, the concentration of 
cellular expressed CD4 was incrementally decreased within each different cell line 
i.e. ratios of Cf2Th.CD4.CXCR4 : Cf2Th.CXCR4 expression decreased from 
100:0 to 50:50 to 25:75 to 10:90 to 1:99 and finally down to 0:100.  
3.3.6 Proviral DNA Isolation 
Proviral DNA isolation was performed on all infected cell culture samples from 
each of the sequential adaptation stages, i.e. P2 100% Cf2Th.CD4.CXCR4, P2 
50% Cf2Th.CD4.CXCR4 : 50% Cf2Th.CXCR4 (50%:50%), P3 and P4 from 25% 
Cf2Th.CD4.CXCR4 : 75% Cf2Th.CXCR4 (25%:75%) and P1 and P4 from 10% 
Cf2Th.CD4.CXCR4 : 90% Cf2Th.CXCR4 (10%:90%). The High Pure PCR 
Template Kit (Roche, Mannheim, Germany) was used as per manufacturer’s 
instructions (see Chapter 2, section 2.3.7). All the samples were eluted in 200 µl 
pre-warmed (70°C) elution buffer and stored at -20°C until further use. 
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3.3.7 Amplification and Sequencing of Full-length gp160  
The gp160 coding region was successfully amplified from all the extracted proviral 
DNA samples, using the same PCR primers and protocol as described in Chapter 
2, section 2.3.8. The PCR products were resolved on a 0.8% agarose gel (Sigma, St 
Louis, MO) to confirm the amplicon size, as described previously (Chapter 2, 
section 2.3.9). All the successfully amplified p160 amplicons from each cultured 
sample were immediately purified using the High Pure PCR Product Purification 
Kit (Roche Diagnostics, Penzberg, Germany) as per manufacturer’s instructions 
(see Chapter 2, section 2.3.10).  
Sequencing reactions were performed in MicroAmp 96 well optical reaction plates 
using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit 
(V3.1), according to manufacturer’s instructions (Applied Biosystems, Foster City, 
CA). Sixteen primers encompassing both forward and reverse strands were used to 
sequence the ~2.7 kb fragment in both directions (Table 3.1). Sequences were 
resolved on the ABI 3100-Avant Automated Genetic Analyzer (Applied 
Biosystems, Foster City, CA) as previously described (Chapter 2, section 2.3.11). 
Sequence data editing was performed using the Sequencing Analysis V3.3 
programs (Applied Biosystems) and assembled using Sequencher V4.5 
(Genecodes, Ann Arbor, MI). A nucleotide and amino acid alignment with the 
primary proviral 05ZAFV03 gp160 sequence was performed using CLUSTAL X 
V1.81 and analyzed in Genedoc and for any amino acid sequence changes acquired 
during adaptation. 
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Table 3.1 Primers used for gp160 cycle sequencing. 
Primer Primer Sequence 
5R(3)Cφ 5’-CAT TGC TCG TCC TAC CCC CTG CCA C-3’ 
A590* 5’-AAT CGC GAA ACC AGC CGG CGC ACA AT-3’ 
AA1570 §  5’-GGA GCA GCA GGA AGC ACT ATG GGC-3’ 
AES6§ 5’-GGA CAA GCA TTC TAT GCA ACA GGT G-3’ 
DR7Cφ 5’-TCA ACT CAA CTA CTG TTA AAT GGT AGC CTA GC-3’   
E16* 5’-CCA ATT CCC ATA CAT TAT TGT G-3’ 
Env1f * 5’-CCA TAA CAC AAG CCT GTC CAA AGG-5’ 
Env3f * 5’-GGA AGC ACT ATG GGC GCG GC-3’ 
Env4f * 5’-GAG TTA GGC AGG GAT ACT CAC C-3’ 
ES21 § 5’-ACA CAT GCC TGT GTA CCC ACA G-3’ 
Gp120 5’ § 5’-AGA GCA GAA GAC AGT GGC AAT GA-3’ 
JL103 § 5’-TAA CAA ATT GGC TGT GGT ATA TAA-3’ 
JL74 § 5’-ACA TGT GGA AAA ATA ACA TGG TAG AAC AG-3’ 
SQ15FCφ 5’-GAG AGC GGT GGA ACT TCT GG-3’   
TU-J § 5’-GTT AGG CAG GGA TAC TCA CC-3’ 
ZM184D § 5’-CCA CTC AGC TAC TGC TAT TGC TAT GGT-3’ 
 
§ F. McCutchan 
* Personal communication with Dr. Maria Papathanasopolous 
φ  Taken from Rousseau et al., [390]   
  
 
106 
3.4 Results 
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3.4.1 Adaptation of Primary CCR5 and CXCR4 utilizing 
 viruses to Cf2Th.CD4.CXCR4/CCR5 cell lines 
Despite repeated attempts, stable, sustainable infection with 05ZAFV22 (and four 
other R5 primary isolates; 05ZAFV02, 05ZAFV06, 05ZAFV11 and 05ZAFV20) 
was not successful in the Cff2Th.CD4.CCR5 cell line. A very slight increase in 
p24 antigen was detected on day 7 for the 05ZAFV22 infection (Figure 3.3 (A) 
Blue curve), however, this result may be background absorbance and/or very 
low/slow inefficient replication of the R5 virus in this particular cell line. The R5 
viruses were thus no longer incorporated in any of the cell line adaptation 
experiments. 
Stable infection of the 100% Cf2Th.CD4.CXCR4 cell line was achieved with one 
out of the five selected CXCR4 utilizing primary isolates, 05ZAFV03. By day 7 
post P1 of the 100% Cf2Th.CD4.CXCR4 infection, the cells in the 24 well NUNC 
culture plates were fully confluent and required a larger surface area in which to 
grow. Thus, the infections (viral supernatant and cells of the controls and 
infections) were carefully transferred into the larger wells of the 6 well NUNC 
culture plates, to allow for further cell growth and to prevent over-growing and 
premature cell death caused by cell crowding. The viral growth curve over 13 days 
is shown with the viral growth peak detectable by day 10 (Figure 3.3 (A) red 
curve).  
To strengthen the viral growth of 05ZAFV03 in the Cf2Th.CD4.CXCR4 cell line, 
high titer virus was taken from the P1 generation, into a second generation of 
Cf2Th.CD4.CXCR4 expressing cells (P2). Here, 70 µl of viral supernatant from 
day 10 of the P1 generation was used to infect each of the 14 wells of pre-seeded 
Cf2Th.CD4.CXCR4 cells. The 05ZAFV03 virus had reached the log phase of viral 
infectivity for the P2 by day 3 and had reached out of range p24 Ag by day 5 
(Figure 3.3 (B)). 
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Figure 3.3 Graphical representation of successful infection of the P1 Cf2Th.CD4.CXCR4 cell 
line with 05ZAFV03 by day 9 post infection (red graph) and unsuccessful infection of the 
Cf2Th.CD4.CCR5 cell line with 05ZAFV22 (blue graph) (A). Graph representing successful 
infection of the second generation (P2) of Cf2Th.CD4.CXCR4 cells with 05ZAFV03 by day 3. 
Infection had reached a plateau by day 4-5 (B). 
3.4.2 Adaptation of 05ZAFV03 towards CD4-Independence 
The aim to achieve CD4-independent infection of the Cf2Th cell line by 
05ZAFV03 was executed using the following methodical process (Figure 3.4). 
  
 
109 
 
Figure 3.4 Schematic overview of the serial Cf2Th cell line passages of 05ZAFV03 grown in 
decreasing amounts of CD4 cell surface expression. As described in the Section 3.3, there were 
sequential passages were performed with a volume of infectious cell-free viral supernatant from the 
preceding passage.  
Infections performed with viral supernatant were either in duplicate, triplicate or 
quadruplicate, with most of the infections performed once, due to limiting volumes 
of infectious supernatant (Table 3.2). For all the infections performed, p24 Ag 
levels were over the detectable range between 5 - 12 days post infection. A total of 
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12 serial viral passages were performed in this experiment, towards viral growth in 
cells only expressing 10% cellular CD4 (Table 3.2).  
In parallel with each viral passage, the same starting volume of input virus was 
used to directly infect the Cf2Th.CXCR4 (CD4 negative) cell line, however, this 
approach of achieving CD4-independent infection was not successful. 
Table 3.2 Cell culture data for 05ZAFV03 growth as the CD4 cell surface concentration 
decreased towards CD4-independence. 
Cell Culture Composition 
(CD4 percentage 
Expression %) 
Number of Cell line 
passages 
Number of 
culture 
replicates 
c
 
Culture time in days 
until OUT of range 
viral p24 detection 
d
 
 Sequential 
a
 Total 
b
   
100 1 1 1 10 
100 2 2 1 5 
50 1 3 1 6 
50 2 4 1 12 
25 1 5 2 7 
25 2 6 3 10 
25 3 7 3 10 
25 4 8 4 5 
10 1 9 1 9 
10 2 10 1 10 
10 3 11 1 11 
10 4 12 1 12 
 
a p24 positive sequential passages that were transferred to the same CD4 percentage expression 
uninfected fresh Cf2Th cells (see figure 3.3) 
b Cumulative number of passages from first infectious viral supernatant. 
c Most of the cell culture infections were performed in single wells. Only the 25%:75% 
CD4.CXCR4 infections were performed in replicates. 
d All cell cultures reached log phase viral growth before two weeks. 
 
3.4.3 Passage 1 (P1) an P2 50% Cf2Th.CD4.CXCR4 : 50% 
Cf2Th.CXCR4 
One hundred and fifty microlitres of the highest viral titer supernatant obtained 
from Day 5 in the P2 100% Cf2Th.CD4.CXCR4 infection, was used to infect the 
next generation of cells in the CD4-independent adaptation process; 50%:50% 
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expressing cells. As in the P1 100% Cf2Th.CD4.CXCR4 infection, the cells 
reached confluency by day 7, and infected cells and supernatants (and negative 
controls), were transferred into the 6 well NUNC culture plates.  
Similarly, the P2 50%:50% infection was performed. Interestingly, viral 
supernatant from day 6 of the P1 50%:50% cell infection passage, yielded a higher 
infectious viral titer compared to viral supernatant from day 8, when used to infect 
the P2, despite the lower absorbance reading detected on day 6 (Figure 3.5).The 
two passages within the 50% CD4 expressing cell line population were successful. 
Two distinct peaks in infectious virus are visible, on days 6 and 8 in P1 and days 9 
and 10 in P2. 
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Figure 3.5 Graphical representation of successful P1 infection within the cell population 
comprising 50% Cf2Th.CD4.CXCR4 expressing cells and 50% Cf2Th.CXCR4 expressing cells 
(A). Graphical representation of the successful P2 50% Cf2Th.CD4.CXCR4 : 50% Cf2Th.CXCR4 
infection (B). 
3.4.4 P1, P2 and P3 25% Cf2Th.CD4.CXCR4 : 75% 
Cf2Th.CXCR4 
The highest viral titer supernatant from P2 50%:50% day 12, was diluted two fold 
with supplemented DMEM growth medium and 200 µl viral supernatant was used 
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to infect each pre-seeded well of P1 25%:75% expressing cells. The highest viral 
titer supernatant from P1 (day 7) and P2 (day 10), were used to infect the second 
and third passages, respectively (Figure 3.6). Three passages of 05ZAFV03 within 
this ratio of cell lines, was performed to reinforce the evolving/adapting population 
of CD4-independent isolates. Each successive passage depicts a different viral 
growth curve from the previous passage.  
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Figure 3.6 Successful infection by day 7 of the first passage of 25% Cf2Th.CD4.CXCR4 : 75% 
Cf2Th.CXCR4 (A). The viral supernatant was then used to infect the second passage, in parallel 
(B) and to further strengthen the viral infectivity of this percentage cell line, the viral supernatant  
was  taken through a passage 3, again in parallel (C). 
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3.4.5 Cell-Cell Infection 
Fifty thousand infected cells from Day 10 of the P3 25%:75% were successfully 
co-cultured with 7 x 105 uninfected Cf2Th.CXCR4 expressing cells in T25 flasks 
(AEC Amersham, Denmark), in a total culture volume of 8 ml supplemented 
DMEM growth medium. Two separate infections were performed from the two 
separate successful P3 25%:75% adaptations (Figure 3.7).  
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Figure 3.7 Co-culture of infected cells from P3 25% Cf2Th.CD4.CXCR4 : 75% Cf2Th.CXCR4 
with uninfected CXCR4 expressing cell in a ratio of 1:1400.  
3.4.6 P1, P2, P3 and P4 10% Cf2Th.CD4.CXC4 : 90% 
Cf2Th.CXCR4 
The P1 10%:90% was infected with 410 µl of the day 6 viral supernatant from the 
highest viral titer obtained in the co-cultured infection. The viral supernatant was 
harvested on day 7 and 500 µl of P1 was used to infect P2. Similarly, 400 µl of the 
highest viral titer from day 7 of P2 was used to infect P3 and finally, 300 µl from 
the peak of the viral growth curve on day 7, was used to infect P4 (Figure 3.8). 
Infection of all four passages was successful. 
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Figure 3.8 Graphical representations of the P1 – P4 of 10% Cf2Th.CD4.CXCR4 : 90% 
Cf2Th.CXCR4 viral growth over 7 – 8 days represented by graphs A – D respectively.  
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3.4.7 P1 1% Cf2Th.CD4.CXC4 : 99% Cf2Th.CXCR4 and P1 
100% Cf2Th.CXCR4 
From day 8 of the P4 10%:90%, 300 µl viral supernatant was used to infect the 
final passage containing only 1% of the Cf2Th.CD4.CXCR4 expressing cells 
(1%:99%). The viral growth curve peaked at day 6 and the culture was 
subsequently expanded into a larger volume, to accommodate the rapid cell 
growth. The numbering of the days was re-started from 1 after the culture was 
expanded. However, the infectious viral titer was diluted after expansion and the 
p24 Ag levels in the culture were unrecoverable (Figure 3.9 (A)). This experiment 
was not repeated due to insufficient starting volume of infectious virus and 
insufficient volume of virus from day 6. 
Seven hundred microlitres of viral supernatant from the expanded P1 1% 
Cf2Th.CD4.CXCR4 : 99% Cf2Th.CXCR4 day 4 culture was used to infect the P1 
100% Cf2Th.CXCR4 expressing cells. No growth was detected here (Figure 3.9 
(B)). 
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Figure 3.9 (A) Graphical representation of the P1 1% Cf2Th.CD4.CXCR4 : 99% Cf2Th.CXCR4 
viral growth curve over almost 2 weeks. The viral culture was expanded on day 6 and the days were 
continually number from one, one day post expansion. (B) Graphical representation of the minimal 
05ZAFV03 viral growth in the 100% Cf2Th.CXCR4 expressing cell line by day 5. 
3.4.8 Uninfected and Infected Cf2Th cells  
No CPEs were ever detected when viral replication in these cell lines was present. 
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Figure 3.10 Uninfected Cf2Th cells (A) Cf2Th.CD4.CXCR4 expressing and (B) Cf2Th.CXCR4 
expressing, respectively, and infected Cf2Th cells with 05ZAFV03 (C) Cf2Th.CD4.CXCR4 
expressing and (D) Cf2Th.CXCR4 expressing, respectively. Cytopathic effects and cell death can 
be seen in Cf2Th.CD4.CXCR4 expressing cells, panel C. However, there are negligible, if any, 
cytopathic effects in infected Cf2Th.CXCR4 expressing cells, panel D. All images were acquired at 
10 X magnification on the Zeiss Axiovert 100 M microscope (Zeiss, Göttingen, Germany). 
3.4.9 Amplification and Sequencing of Full-Length gp160 
The amino acid changes arising within env responsible for the adaptation of 
05ZAFV03 to cell culture conditions of low CD4 expression were identified by 
sequencing the gp160 regions. Cleaned PCR amplified gp160 regions are shown 
(Figure 3.11). 
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Figure 3.11 Cleaned gp160 PCR Products (~ 2.7 kb) of all the isolates chosen for sequence 
analysis for the adaptation towards CD4-independence. The DNA Molecular Weight Marker (MW) 
X (Roche, Mannheim, Germany) was used and 10 µl of each PCR product was electrophoresed in a 
0.8% Agarose gel (Sigma, St Louis, MO).     
The following cultured passages were used to amplify proviral gp160 sequences; 
P2 from 100% Cf2Th.CD4.CXCR4, P2 from 50%:50%, P3 and P4 from 25%:75% 
and finally P1 and P4 from 10%:90%.  
To reveal molecular changes within the gp160 region that associated with cell line 
adaptation and growth in low levels of CD4 expression, detailed analysis of the 
sequences electropherograms was performed. Overall, there were 3 nucleotide 
differences between all the cultured gp160 sequences and the primary gp160 
parental sequence. These differences resulted in two synonymous mutations and 
one non-synonymous mutation (Figure 3.12). PCR amplification of the P2 100% 
Cf2Th.CD4.CXCR4 and the P4 10%:90% was repeated twice on different days, to 
confirm the results and prove the absence of contamination.   
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Figure 3.12 Alignment of the predicted amino acid sequences of the parental (primary) sequence 
with the sequences obtained from the Cf2Th cell line serial passage variants with decreasing 
amounts of CD4 expression. Variable (V), constant (C) and other regions of the gp160 region are 
indicated. Synonymous mutations are indicated at amino acids 295 (in green) and at 454 (in pink). 
The non-synonymous mutation within the V1 loop (in yellow) is indicated by the E to K mutation 
(in red) shown at position 152. Primary refers to the primary 05ZAFV03 gp160 sequence (section 
2.4.5); P2 100% refers to gp160 sequence from the P2 100% Cf2Th.CD4.CXCR4; P2 rep refers to 
the repeated P2 100% sequence; P2 50%50% refers to gp160 sequence from the P2 50% 
Cf2Th.CD4.CXCR4 : 50% Cf2Th.CXCR4;  P3 25%:75% refers to gp160 sequence P3 25% 
Cf2Th.CD4.CXCR4 : 75% Cf2Th.CXCR4; P4 25%:75% refers to gp160 sequence from the co-
culture; P1 10:90% refers to gp160 sequence from the P1 10% Cf2Th.CD4.CXCR4 : 90% 
Cf2Th.CXCR4; P4 refers to gp160 sequence from the P4 10% Cf2Th.CD4.CXCR4 : 90% 
Cf2Th.CXCR4 and P4 rep refers to the repeated P4 10%:90% sequence. The dots represent 
identical amino acids. 
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3.5 Discussion 
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HIV-1 is currently the most thoroughly researched human pathogen and there is a 
wealth of knowledge pertaining to its in vivo evolution, however, in vitro HIV-1 
evolution is less widely researched. To date, HIV-1 Subtype C isolates have never 
been adapted to CD4-independence. The present study aimed to adapt an HIV-1 
isolate towards CD4-independence and analyze the genetic changes that 
accompanied serial passage of a CXCR4 utilizing HIV-1 isolate in the Cf2Th cell 
line with decreasing concentration of CD4 expressing cells over time. The gp160 
sequence analysis showed that env is relatively conserved throughout serial in vitro 
passage with decreasing cellular CD4 expression, and a single non-synonymous 
nucleotide mutation (E152K) was detected within the V1 loop compared to the 
parental sequence.  
Here, a CXCR4 utilizing HIV-1 subtype C isolate, 05ZAFV03, was adapted and 
passaged 12 times through the Cf2Th cell line. An attempt was made to adapt the 
isolate towards CD4-independence and the isolate was adapted to grow in cell 
cultures where only 10% of the cells expressed CD4. All the viral infections 
throughout this study were either performed in duplicate, triplicate or 
quadruplicate to increase sample volume and to ensure reproducibility of each 
passage. The 05ZAFV03 isolate did require serial in vitro passages within cell 
populations of gradually decreasing amounts of CD4 expression, as the primary 
isolate was unable to directly infect cell populations with no CD4 expression (data 
not shown). The rapid detection of viral p24 Ag post infection in vitro may be a 
reflection of the aggressive and highly pathogenic nature of the 05ZAFV03 isolate. 
Despite several attempts to adapt CCR5 utilizing HIV-1 subtype C isolates to in 
vitro growth in the Cf2Th cell lines, successful T cell line infection for this viral 
tropic variant was not established. Reasons for this are speculative at this stage. 
There may be some subtype C specific inhibitory mechanism that resists HIV-1 
CCR5 utilizing variants from adapting to the Cf2Th cell line.  
The first passage (P1) of the CXCR4 utilizing HIV-1 05ZAFV03 isolate, adapted 
relatively rapidly to in vitro growth in the Cf2Th.CD4.CXCR4 cell line. By day 10 
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of P1, the viral titer had reached the log phase and the absorbance was out of the 
detection range of the spectrophotometer (Figure 3.3 (A)). Two stable rounds of 
infection were performed for the 05ZAFV03 isolate within the 100% 
Cf2Th.CD4.CXCR4 cell line.  
Similarly, two successful rounds of viral passage were achieved in the 50%:50% 
cell line population. The repeated passage (P2) was necessary for the 
reinforcement of any mutational derived genotypic and phenotypic adaptive 
changes that may have occurred within the env (Figure 3.5 (B)). There are two 
distinct viral infectious peaks at days 6 and 8 in P1 and days 9 and 12 in P2, with a 
drastic decrease in infection on day 7 and 10, respectively (Figure 3.5). There may 
be two explanations for such a phenomenon.  
Firstly, due to the fact that infections were performed in 24 NUNC culture plates, 
for each successive day post infection a single well was harvested each day, 
achieving the effect of following the infection day by day, all wells were treated 
equally. Here, there may have been well-to-well variation of viral p24 Ag titer and 
this may have contributed to the perceived “dip” in infectivity. It is unlikely that 
such well-to-well variation would occur twice in such a similar pattern.  
Another explanation might be that each peak in viral infectivity may be a 
consequence of two separate phenotypic viral populations within the viral 
supernatant (Figure 3.5). One population of viruses may have budded from the 
Cf2Th.CD4.CXCR4 expressing cell population and another viral population may 
have emerged from the Cf2Th.CXCR4 expressing cells. Both populations of target 
cells (CD4 positive and CD4 negative) were present in equal proportions in this 
infection and it is reasonable to assume that the first peak in viral growth may have 
come from the Cf2Th.CD4.CXCR4 cell population due to the viral selective 
advantage and preference for this cell line. However, there is more 
“conformational stress” on the Env to enter CD4 negative cells. This may be the 
reason for a second peak being observed two days later - CD4-independent viral 
production emerging from Cf2Th.CXCR4 expressing cells. Thus two different 
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homogenous viral populations may have existed one after the other. However, this 
hypothesis is unlikely as the virus harvested from either peaks, was incapable of 
growth in 100% CD4 negative Cf2Th cells. 
Each viral growth curve differs from the previous curve in the 25%:75% cell line 
infections. The first passage, (Figure 3.6 (A)), shows a relatively rapid adaptation 
to the cell line with the virus reaching log growth phase growth levels by day 5. 
However, in P2 and P3, (Figure 3.6 (B) and (C), respectively), the virus had 
established stable infection within culture in a slightly longer time period. This 
might be due to the decrease in actively replicating CD4.CXCR4 tropic virions due 
to their overall reduced target cell count. This may then lead to the gradual 
increase in the population of viruses that are evolving/adapting towards the CD4-
independent phenotype. 
Relatively rapid viral growth was detected in co-culture, as within 6 days of 
infection, the viral p24 Ag levels were out of range of detection. This high viral 
growth rate may indicate the viral adaptation to the changing target cell range. All 
four passages of the 10%:90% cell line ratio, were successful. Here, the minority 
(10%) of cells in culture expressed cellular CD4, thus increasing the probability of 
viruses infecting the 90% of the remaining CD4 negative cells. In theory, the 
experimental process was forcing/favouring the adapted, pre-triggered Env 
conformational state. A population of the virions in culture may have been under 
selective pressure to enter the Cf2Th cells via CXCR4 coreceptor binding alone.  
A single round of infection within the P1 1%:99% cell line was successful. Viral 
titer reached a peak by day 6 and the cells had over-grown and reached confluency 
within the culture well. The infection was expanded into a larger volume and the 
expansion was not successful. This passage was the final viral passage reached due 
to time being a limiting factor as well as the depletion of stored viral supernatant in 
repeated infections and sequencing. The P1 100% CXCR4 cell line infection was 
unsuccessful and yielded low viral titers that were detected day 5. Due to an 
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insufficient volume of stored viral supernatant this experiment was not able to be 
repeated.  
At each stage of the viral adaptation process, viral supernatant was used in parallel 
to directly infect CD4 negative Cf2Th cells, which did not result in infection. This 
implies that the necessary changes in the Env of 05ZAFV03 required to achieve 
CD4-independence have not been achieved in this study, and supports continued 
passage of the virus with sequential decreases in the proportion of CD4 expressing 
Cf2Th cells in cell culture. 
Overall, the CXCR4-utilizing HIV-1 subtype C 05ZAFV03 isolate grew in cell 
cultures where 10% of the cells expressed CD4 however, adaptation towards CD4-
independence was unsuccessful. Since this strategy was previously successful in 
adapting a CCR5 utilizing HIV isolate to CD4-independence [349], it raises the 
possibility that it is more difficult/not possible to adapt CXCR4 utilizing isolates to 
CD4-independence or the 05ZAFV03 isolate needs to be passaged for longer to 
achieve CD4-independence. 
The full-length gp160 sequence data from all six stages of the serial in vitro 
passage adaptation experiments towards decreased CD4 expression levels, were 
analyzed and compared to the parental primary gp160 sequence (see section 2.4.5). 
The HIV-1 virus that was passaged in the 100% Cf2Th.CD4.CXCR4 expressing 
cell line showed no mutations compared to the parental strain. Upon genotypic 
analysis, three mutations were detected within the env region in all the passages 
from the P2 50%:50% through till the final P4 1%:99% adapted isolate.   
A single non-synonymous nucleotide mutation was detected at nucleotide position 
454 (G to A) between the primary sequence, P2 100% Cf2Th.CD4.CXCR4, and 
the rest of the cultured sequences. This translated to an amino acid change at 
position 152 (according to the numbering of Consensus_C), between the N 
(position 125) and C (position 194) termini within the V1/V2 loop region, 
specifically at the mid-point of the V1 loop. The E152K mutation was detected in 
every env gene obtained from the samples that were grown in Cf2Th cell 
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concentrations with less than 100% CD4 expression (Figure 3.12). The single 
amino acid change that was detected in 5 out of 6 env sequences resulted from a 
negatively charged Glutamate (G) to a highly positive Lysine (K) at position 152 
within the V1 region of gp160 (Figure 3.12), altering the size and charge of the the 
residue within the V1 loop.  
The other two mutations were synonymous nucleotide differences detected at 
position 885 (C to T) between the primary sequence and all the sequences derived 
from culture and at position 1362 (A to T) between the primary, P2 100% 
Cf2Th.CD4.CXCR4, P2 50%:50% and the remaining sequences derived from 
culture. These synonymous mutations did not result in amino acid changes at 
positions 295 and 454, within the C2 and C4 regions of gp160 respectively 
(according to the numbering of Consensus_C) (Figure 3.12).  
The acquisition of a single highly positive Lysine within the V1/V2 loop, may also 
increase the overall electrostatic attraction of the Env for the highly negatively 
charged CXCR4 chemokine coreceptor [434]. 
The CD4 epitope that sterically interacts with HIV-1 Env harbours a highly 
positive residue [66] which is supposedly electrostatically attracted to the 
negatively charged CD4 binding pocket within the V1/V2 loops. The non-
synonymous E152K mutation detected in this study may electrostatically repel the 
positive epitope of the CD4 molecule, therefore decreasing frequency of the initial 
binding of CD4 by the 05ZAFV03 HIV-1 Env. A sequence alignment was 
performed in GeneDoc (V2.6.003) between the gp160 gene obtained in this study 
harbouring the E152K mutation, and the full spectrum of HIV-1 env sequences in 
the Los Alamos database [46]. About 0.6% (6/1000) of the HIV-1 env sequences 
from the database that were aligned to the gp160 region of interest, harboured 
positive amino acid residues at this position (152 according to Consensus_C 
numbering) within the V1 loop, however, the positive lysine was not a rare amino 
acid within the V1 loops compared.  
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The V1/V2 loop structure is in direct contact with the CD4 receptor and this loop 
contributes two strands to the bridging sheet of gp120, which is intimately 
involved in coreceptor binding [66, 414]. Therefore, mutational changes in this 
region may disrupt the normal binding process that takes place between CD4 and 
gp120, leading to the CD4-independent conformational state. There are eight 
potential N-linked glycosylation sites within the primary 05ZAFV03 V1 region 
and an extension of the V1 region by 15 amino acids was noted, when compared to 
the HXBc2 gp160 reference sequence. Changes in the length and N-linked 
glycosylation profile of the V1/V2 loops in gp120 are generally necessary for the 
CD4-independent phenotype in some HIV and SIV isolates. Further studies are 
necessary to determine exactly which changes mediate the decreased CD4-
dependent phenotype in HIV-1 subtype C. 
Of the CD4-independent HIV and SIV isolates characterized thus far, five research 
groups have also detected amino acid substitutions in the V1/V2 region of gp160 
[350, 355, 374, 379, 435]. La Branche et al., [350] characterized an HIV-1 IIIBx 
CXCR4 tropic CD4-independent isolate which harboured mutations in the trans 
membrane domain, V1/V2, V3 and C4 regions of gp160. Of the mutations within 
the V1/V2 loop, I165K and Q170K substitutions, conferred two positive lysine 
residues in the V1 region that were previously absent in the CD4-dependent HIV-1 
IIIB variant. Kolchinsky et al., [355] also reported on the acquisition of a lysine 
residue within the V1/V2 region (N197K) of the CD4-independent HIV-1 ADA 
variant. Gorry et al., [435] and Chenine et al., [374] showed extensions of the 
V1/V2 regions by 12 and 5 amino acids, respectively, in the CD4-independent 
isolates they derived. 
The single non-synonymous nucleotide mutation, resulting after four serial in vitro 
passages obtained in this study, was not expected and it is in contrast to the large 
number of mutations observed in HIV-1 populations in vivo [76, 230, 231, 436-
438]. Many mutations after serial passages in vitro with decreasing concentrations 
of CD4 expression were expected, due to the rapid replication rate of HIV-1 and 
the low fidelity of the reverse transcriptase enzyme [22, 27]. The gp160 gene is the 
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most variable and highly diverse gene within the HIV-1 virion and sequence 
variation within this gene increases at a rate of about 1-2% per year [15, 439-441]. 
This phenomenon is utilized by HIV-1 to adapt and avoid many selective pressures 
such as host neutralizing antibodies, cytotoxic T lymphocytes and antiretroviral 
drugs in vivo [176, 177, 442-444]. However, these selective pressures are not 
present in vitro and the HIV-1 env experiences less pressure to adapt and escape.  
Due to the low fidelity of the HIV-1 genome replication system, a population of 
related, yet genetically heterogeneous circulating HIV-1 viral variants exist within 
an infected individual [445-447]. The population of related, yet distinct genomes, 
is referred to as the quasispecies of circulating HIV-1 [446, 448]. During in vitro 
culture, pre-existing quasispecies may emerge from the background parental 
population and reach lower levels of genetic diversity. The adaptation of primary 
HIV-1 to growth in T cell lines generally selects for and encourages the emergence 
of pre-existing variants from the quasispecies which have a heightened sensitivity 
to neutralization [449-452]. 
The chromatograms obtained in this study underwent extensive sequence analysis 
and assembly in Sequencher V4.5 and no quasispecies were detected in 
proportions >10%. This is an unusual result when analyzing population based env 
sequences and may suggest that each population was almost 100% homogeneous 
and that the predominating quasispecies in vivo may have been selected for in 
vitro. These data imply that it may be valuable to further investigate and compare 
the quasispecies present within the patient at the time of viral isolation. 
To exclude the possibility of PCR cross-contamination, the proviral DNA 
extraction (using a brand new High Pure PCR Template Preparation Kit (Roche, 
Penzberg, Germany)), PCR experiments and sequencing reactions were performed 
(and repeated) on separate days. The same sequencing results were obtained each 
time and all the negative controls for all experiments were confirmed negative. 
In general, when RNA viruses undergo repeated bottleneck passages or 
multiplication of their genetic material from a small/one viral genome in vitro the 
  
 
133 
average fitness of the viral population decreases [78, 453, 454]. The phenomenon 
of an observed decrease in fitness caused by repeated bottlenecks is known as the 
Muller’s ratchet effect [454]. According to this model, small asexual populations 
will incorporate deleterious mutations, unless recombination events can restore the 
functionality of their genome [454]. This effect has been seen in many viruses such 
as the bacteriophage φ6 [78], vesicular stomatitis virus [453], foot-and-mouth 
disease virus [455] and was first detected for HIV-1 in MT-4 plaque-to-plaque 
passages [456].  
Yuste et al., [456] and colleagues performed full-length HIV-1 genome sequencing 
and revealed that gag had a three-fold higher mutation frequency compared to env, 
and the V3 loop remained conserved, after fifteen passages. The amino acid 
changes that had accumulated throughout the passages were uncharacteristic and 
several had not been previously recorded in natural occurring HIV-1 isolates [456].  
Yuste et al., [457] also detected few mutations throughout the HIV-1 viral genome 
which were associated with serial bottleneck passages in vitro. Fifteen clones from 
four different HIV-1 viruses underwent serial (15) viral passages in the MT-4 T 
cell line. The env was found to be the most conserved genomic region in all the 
clones examined in the assay, yet this phenomenon was unexplained [457]. Fifty 
percent of the acquired mutations were detected within the V1/V2 region (between 
positions 130 – 232 according to the numbering of HIV-1 HXBc2).  
Another study by Yuste et al., [458] compared the HIV-1 genomic nucleotide 
parental strain sequences to those of viruses that had been passaged between 5 and 
10 times in an MT-4 T cell line [458]. Most of the identified mutations that had 
accumulated along the genomic length were synonymous mutations and 
predominantly found in the 5’ un-translated leader region [458]. Only a quarter of 
the HIV-1 clones acquired a single amino acid mutation in the env region, the 
others were 100% conserved from the parental strain [458].  
A study by Kusumi et al., [459] commented on the loss of HIV diversity that 
results from co-culture. They showed that the mean diversity between individual 
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gp120 coding regions in PBMCs was five-fold greater (3.24%) than the diversity 
after co-culture (0.65%) [459]. 
Zhang et al., [450] performed multiple passages of HIV-1 clones on different T 
cell lines (MT-2, H9 and CEM) and showed that two out of three viruses did not 
accumulate any mutations within the V3 region of gp120 after three passages 
[450]. Similar findings were also shown when multiple passages of a primary 
CXCR4 utilizing HIV-1 virus was performed in H9 cells and the resulting viruses 
all retained the genotypic characteristics of the parental strain [460].  
Quakkelaar et al., [449] showed that a pre-existing neutralization sensitive HIV-1 
variant may emerge from a quasispecies during T cell line adaptation. After two 
serial passages within the H9 T cell line, 50% of the H9 T cell passaged variants 
showed only one and/or two amino acid changes within the V1-V5 regions [449]. 
These studies are strongly supportive of the data in this study. A single non-
synonymous mutation within env detected in this study, does concur with 
previously published data on serial in vitro passages of HIV-1 primary virus in T 
cell lines and the low genetic diversity that is observed, especially in env [456-
458]. The selective pressure in vitro on the HIV-1 isolate in this study was 
relatively low, thus the 05ZAFV03 isolate underwent minimal mutational changes 
when adapting to the altered, low CD4 expression environment. However the 
current literature reporting on mutational changes in cloned envs that are 
responsible for the phenotypic conversion from CD4 dependence to CD4-
independence, are contrary to the findings in this study. Generally, more than a 
single non-synonymous mutation within gp160 is responsible for CD4-
independent phenotypes [344, 349, 350, 364, 366, 367, 374, 379, 461-463].  
The 05ZAFV03 viral isolate may have been isolated from a highly 
immunocompromised HIV-1 infected AIDS patient. If so, at the time of viral 
isolation, this relatively ‘fit’ pre-selected virus within the patient would display 
rapid growth in vitro and its sequence would not change drastically through serial 
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in vitro passage. The high pathogenicity and conserved nature of the 05ZAFV03 
env may support this theory. 
The study of CD4-independent envelopes provides valuable insights into the 
different conformational states of gp120 during the host entry process. CD4-
independent virus are detected in vivo in the immune privileged sites of the body, 
where antibodies are excluded by the blood-brain barrier, or in individuals with 
severely compromised immune systems. However, the precise mechanisms as to 
how and why CD4-independent envelopes display an increased sensitivity to 
humoral neutralizing antibodies in vivo, is still unclear. The genotypic and 
structural determinants of CD4-independence vary considerably among CD4-
independent HIV and SIV isolates, and therefore the structure/function 
relationships may also differ. The relevance of these changes and their impact on 
pathogenesis and neuropathogenesis is also not yet clear.  
This is the first study that has successfully passaged an HIV-1 subtype C CXCR4-
utilizing isolate in the Cf2Th cell line and serially passaged the intact virus towards 
a final concentration of 10% CD4 expressing cells. The isolate adapted towards 
decreased CD4-dependence in this study, originated from a parental CXCR4 
utilizing isolate, similar to other studies [367, 464, 465].  
Future studies aimed at achieving 100% CD4-independence should re-grow the 
virus from the 10%:90% adaptation stage and generate large amounts of viral 
stocks before progressing and infecting the 1%:99% cell mixture and similarly 
with viral growth in the CD4 negative cells. Additionally, future studies should 
determine whether this E152K mutated envelope is intrinsically less dependent 
upon CD4 for cellular entry. This may be achieved by testing the 10%:90% virus 
in a PBMC based inhibition assay to determine the extent of inhibition by soluble 
CD4 verses the 100%:0% virus. Alternatively, the pseudovirion assay [466] can be 
used to test the 10%:90% envelope, where the E152K mutated envelope can be 
cloned and co-transfected with a backbone virus into a CD4-negative cell line. 
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This assay is important because if there is not enough virus stock available from 
the 10%:90% passage, a clone of the envelope can still be used in the system.  
Many studies demonstrate that in some cases, CD4 is dispensable as the primary 
receptor and that CXCR4/CCR5 is essential for cellular entry. The availability of 
modified Env proteins will also be a powerful tool for analyzing gp120-coreceptor 
interactions and possibilities for inhibiting these interactions. As the functionally 
relevant coreceptor binding sites are elucidated and correlated with pathogenicity, 
we can begin to gain comprehensive understandings of the relationship between 
viral phenotype and disease progression and perhaps an evolution thereof. The 
impact of this knowledge extends to the preventative and clinical treatment 
implications for vaccine design and drug development respectively. 
From this study, there is strong evidence for the presence of a highly positive 
lysine residue at position 152 within the V1/V2 loop region that may contribute to 
the evolution and/or adaptation to CD4-independence of a CXCR4 utilizing HIV-1 
subtype C isolate in the Cf2Th cell line. Further experimentation and possibly 
repeats of these experiments with different HIV-1 subtype C isolates (both R5 and 
dual tropic R5X4 variants) and possibly in different T cell lines are required to 
verify these data. As can be seen, the extent of env diversity in vitro is clearly a 
complex multifactorial interplay of HIV-1 isolate- and cell-type-specific factors. 
Overall, the 05ZAFV03 CXCR4-utilizing HIV-1 subtype C isolate was serially 
passaged 12 times through the Cf2Th cell line. After the fourth passage with 50% 
of the cells expressing CD4, a single non-synonymous mutation (E152K) was 
detected in V1 loop region of the gp160 sequence. This change did not support 
CD4-independence and future work should continue to serially passage the virus 
for longer periods while sequentially decreasing numbers of CD4 expressing cells 
in culture until CD4-independence is reached. Once the CD4-independent 
determinants are elucidated, rational drug design techniques can be employed to 
target the vulnerable, exposed and conserved viral binding epitopes on such CD4-
independent isolates. 
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Chapter 4 SUMMARIZING DISCUSSION AND 
CONCLUSION  
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At the end of 2006 there was an estimated 39.5 million people worldwide living 
with HIV-1 and an estimated 2.9 million people lost their lives to AIDS [16]. 
These figures constitute one of the largest medical crises the human race has ever 
experienced. 
Entry of HIV-1 into host CD4+ T lymphocytes is mediated by the HIV-1 envelope 
glycoprotein (env/gp160), which is initially synthesized as a precursor and 
subsequently cleaved to yield gp120 and gp41, the surface and transmembrane 
subunits of the envelope respectively [59, 467-471]. Classical HIV-1 entry requires 
the gp120 to bind both the host surface receptor CD4 [56, 57] and a chemokine 
receptor, either CXCR4 and/or CCR5 [69-71, 77, 80, 164]. Interestingly, many 
primary HIV-2, SIV and some HIV-1 isolates can, to some extent, enter cells in 
vivo without the requirement for CD4, and bind directly to a coreceptor to initiate 
infection. However, these studies have only investigated HIV-1 subtype B isolates 
[344-348].  
CD4-independent viruses are rare, yet are a natural phenomenon and found in 
immune privileged sites within the host. Previous studies have suggested that the 
HIV-1 subtype B Env from such viruses are “partially triggered”, thus invariably 
exposing their conserved coreceptor binding domains [345, 346, 348-350, 472]. 
Therefore, CD4-independent Envs exhibit heightened sensitivity to neutralizing 
antibodies and neutralization by HIV-1 positive sera [351, 354-357, 432]. These 
vulnerable epitopes are usually shielded from the surveillance by the immune 
system in vivo in a CD4-dependent HIV-1 Env, however if this functionally 
important site is targeted, HIV-1 may be effectively neutralized.  
According to the 2006 WHO/UNAIDS statistics [16, 52], Subtype C was the most 
prevalent HIV-1 subtype accounting for 55% of all HIV-1 infections worldwide, 
yet this clade is less widely studied. Thus, this study aimed to successfully adapt 
and genotypically characterize an HIV-1 subtype C isolate/s to CD4-independence 
in vitro.  
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In order to obtain a sample size of primary isolates for the present study, the 
genotypic and phenotypic properties of 20 primary isolates from antiretroviral 
(ARV) naïve advanced AIDS patients attending an HIV/AIDS clinic in 
Johannesburg were investigated. Primary viruses were isolated through standard 
co-culture techniques and subsequent in vitro viral tropism determination assays 
were performed. Phenotype and biotype were elucidated by means of the MT-2 
and U87.CD4 cellular-based assays, respectively. The full-length env and V3 loop 
genes were amplified from proviral DNA, sequenced and extensively analyzed (K. 
Michler, pers. comm.).  
Fourteen primary isolates utilized the CCR5 coreceptor exclusively and exhibited 
the Non-Syncytium Inducing (NSI) phenotype and the remaining six (30%) 
utilized the CXCR4 coreceptor for cell entry and exhibited the Syncytium Inducing 
(SI) phenotype. Phylogenetic analysis of env sequences from 19/20 isolates 
confirmed they were HIV-1 subtype C and one isolate was a CD recombinant. Two 
dual-tropic isolates were identified and they were both X4 utilizing isolates that 
retained the N-Linked glycosylation site within the V3 loop. Overall, the CXCR4 
utilizing amino acid sequences showed a higher positive charge and increased 
variability of V3 loop length, compared to those of the CCR5 utilizing regions.  
HIV-1 variants may emerge during the late phases of disease pathogenesis, which 
correlates with the accelerated loss of naïve and resting CD4+ T cells, broadening 
of viral tropism and rapid progression to AIDS. Disease progression as just 
described is observed in at least 50%-60% of HIV-1 subtype B patients [73, 193, 
194, 196, 199-207]. To date however, only a few CXCR4 utilizing HIV-1 subtype 
C viruses have been identified, and the majority of HIV-1 subtype C viruses have 
shown almost exclusive CCR5 usage, even in late stage disease [164, 249, 251-
253, 257-260, 388, 389]. The present study reports the highest ever-detected 
percentage of CXCR4 utilizing/SI variants within a cohort of similar clinical 
background. Future follow-on studies will investigate HIV-1 subtype C tropism in 
longitudinal follow-up cohorts of larger sample size.  
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To facilitate the adaptation of an HIV-1 subtype C primary isolate towards CD4-
independence, an isolate (05ZAFV03) was subject to serial viral passage in the 
Cf2Th T cell line co-expressing cellular receptors CD4 and CXCR4. Over time, 
the concentration of cellular CD4 expression was incrementally decreased from 
passage to passage. After the in vitro culturing, the proviral gp160 regions from 
isolates at each subsequent adaptation step were sequenced and analyzed. Due to 
serial in vitro bottle-neck passage of 05ZAFV03, the env region remained 
relatively conserved as observed in similar experiments [456-458]. After four 
serial passages, a single non-synonymous mutation, E152K, occurred within the 
V1 loop, in the gp160 sequences obtained from the proviral DNA of cultured cells 
with 50% CD4 expression. Throughout the 12 serial passages in the Cf2Th T cell 
line, with decreasing concentration of cellular CD4 expression, two synonymous 
mutations were detected at positions 295 and 454, respectively (according to the 
numbering of Consensus_C).  
For the first time, an HIV-1 subtype C isolate has been successfully passaged in 
the Cf2Th cell-line and has successfully grown in vitro towards a final 
concentration of 10% CD4 expressing cells. The single non-synonymous mutation 
within the V1 loop of gp160, may contribute to the conformational changes that 
are required to expose the coreceptor binding domain in CD4-independent isolates. 
The repeated infection of a cell line may enhance the selection of the mutations 
throughout the HIV-1 genome acquired during the in vitro adaptation process. 
Additionally, the experimental approach of serial HIV-1 viral passage in T cell 
lines in the absence of host immune pressure, adds to the complexity of studying 
the behaviour of HIV-1 in vitro. Further experimentation on larger sample sizes, 
differing viral tropisms and different T cell lines is required to obtain 
comprehensive understanding of the CD4-independent HIV-1 subtype C genotype 
and phenotype. 
Ultimately, after 12 serial passages the X4 HIV-1 subtype C isolate successfully 
infected Cf2Th cell cultures where only 10% of the cell population expressed CD4. 
The viral adaptation process was performed as described previously [349] and all 
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infections were performed in duplicate, triplicate or quadruplicate to ensure 
reproducibility and increased sample volume for further use. Viral infection was 
achieved with 1% CD4 expression however, due to time constraints and low 
volumes of viral sample, continuation of the assay was not possible. In future work 
continuing towards 100% CD4-independence, larger volumes of viral samples 
should be stored at the 10%:90% stage before progressing to the next stage. 
Overall results from this study imply that the frequency of CXCR4-utilizing HIV-1 
subtype C viruses may be increasing with time. This detected emergence/evolution 
of CXCR4 usage amongst HIV-1 subtype C isolates may have profound 
implications for viral pathogenesis, disease progression and future use of CCR5 
antagonists as ARVs. Hence, the search for targeting conserved/vulnerable sites on 
the HIV-1 envelope as drug targets and vaccine candidates is ever more crucial. 
Adaptation of a primary HIV-1 subtype C isolate towards CD4-independence via 
serial in vitro passage, may expose these vulnerable epitopes that could potentially 
be drug targets/vaccine immunogens. 
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Ethical clearance was granted by the University of the Witwatersrand Medical 
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B 
Appendix B: Amino Acid Abbreviations 
 
Amino Acid Abbreviation 
Alanine A 
Arginine R 
Asparagine N 
Aspartic acid D 
Cysteine C 
Glutamine Q 
Glutamic acid E 
Glycine G 
Histidine H 
Isoleucine I 
Leucine L 
Lysine K 
Methionine M 
Phenylalanine F 
Proline P 
Serine S 
Threonine T 
Tryptophan W 
Tyrosine Y 
Valine V 
  
 
C 
Appendix C: Base Pair Abbreviations 
 
Adenine A 
Cytosine C 
Guanine G 
Thymidine T 
  
 
D 
Appendix D: Media, Buffers and Solutions  
 
B1 Buffers 
 
B 1.1  0.5 M EDTA 
0.5 M EDTA (186.10 g in a final volume of 1 L ) pH 8 
B 1.2  50 X TAE Buffer 
400 mM Tris-acetate base, 50 mM Na2EDTA pH 7.6 Adjust volume to 0.2 L with 
dH2O, sterilize by autoclaving, stored at room temperature (~25°C).   
B 1.3 TE buffer 
10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 7.6 Adjust volume to 1 L with dH2O, 
sterilize by autoclaving, stored at room temperature (~25°C). 
 
B2 Solutions 
B2.1  Loading dye 
4.5 mL glycerol, 10.5 mL deionised sterile distilled water, 0.04 g bromophenol 
blue
  
 
E 
Appendix E: GenBank Accession Numbers for gp160 sequences 
 
DQ382361 (05ZAFV02) DQ382368 (05ZAFV10) DQ382375 (05ZAFV22) 
DQ382362 (05ZAFV03) DQ382369 (05ZAFV11) DQ382376 (05ZAFV23) 
DQ382363 (05ZAFV05) DQ382370 (05ZAFV12) DQ382377 (05ZAFV25) 
DQ382364 (05ZAFV06) DQ382371 (05ZAFV13) DQ382378 (05ZAFV26) 
DQ382365 (05ZAFV07) DQ382372 (05ZAFV14) DQ382379 (05ZAFV27) 
DQ382366 (05ZAFV08) DQ382373 (05ZAFV15) DQ382380 (05ZAFV28) 
DQ382367 (05ZAFV09) DQ382374 (05ZAFV20)  
 
